# 2025年11月23日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. CircleBase V2：一个跨癌症与物种的eccDNA注释平台。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41273082](https://pubmed.ncbi.nlm.nih.gov/41273082)
**期刊：** Nucleic acids research
**PMID：** 41273082
**DOI：** 10.1093/nar/gkaf1266

### 第一部分 原文与翻译

**英文原标题：** CircleBase V2: an eccDNA annotation platform across cancers and species.

**英文摘要原文：**
CircleBase V2 (http://circlebase2.maolab.org) is a comprehensive update of our previously developed database, offering a significantly expanded and functionally enhanced resource for investigating extrachromosomal circular DNA (eccDNA) in human and mouse. This version introduces several key advancements: (i) a 12-fold increase in eccDNA data, comprising over 7.4 million entries from >300 types of cell lines and tissues, providing broader coverage across diverse physiological and disease contexts; (ii) inclusion of mouse eccDNAs, with >3.6 million entries from over 20 tissues, enabling robust cross-species comparative analyses and enhancing translational research with mouse models; (iii) a dedicated motif discovery module that systematically identifies junction-specific sequence patterns, shedding light on molecular mechanisms underlying eccDNA formation; and (iv) an improved functional scoring framework that integrates multi-omic annotations, including chromatin accessibility, regulatory elements, genetic variants, and chromatin interactions, to help prioritize functionally relevant eccDNAs. Additionally, CircleBase V2 features an upgraded user interface with enhanced visualization tools, supporting flexible querying, batch downloads, and integrative analyses. Collectively, these advancements establish CircleBase V2 as an indispensable platform for uncovering the biological roles and regulatory functions of eccDNAs in cancer, development, and other diseases.

**中文摘要译文：**
CircleBase V2 (http://circlebase2.maolab.org) 是我们先前开发的数据库的全面更新版本，为研究人类和小鼠的染色体外环状DNA (eccDNA) 提供了一个显著扩展和功能增强的资源。此版本引入了数项关键进展：(i) eccDNA数据量增加了12倍，包含来自超过300种细胞系和组织的740多万个条目，为多样的生理和疾病背景提供了更广泛的覆盖；(ii) 纳入了小鼠eccDNA，包含来自20多种组织的360多万个条目，从而实现了可靠的跨物种比较分析，并加强了利用小鼠模型的转化研究；(iii) 一个专用的基序发现模块，可系统性地识别连接区域特异的序列模式，为阐明eccDNA形成的分子机制提供了线索；以及 (iv) 一个改进的功能评分框架，该框架整合了多组学注释，包括染色质可及性、调控元件、遗传变异和染色质相互作用，以帮助优先筛选出具有功能相关性的eccDNA。此外，CircleBase V2拥有升级的用户界面和增强的可视化工具，支持灵活查询、批量下载和综合分析。总而言之，这些进展使CircleBase V2成为一个不可或缺的平台，用以揭示eccDNA在癌症、发育及其他疾病中的生物学作用和调控功能。

### 第二部分 AI 大师评价

本研究介绍了全面升级的CircleBase V2数据库，旨在为染色体外环状DNA (eccDNA) 的研究提供一个跨物种、跨癌种的综合性注释平台。该平台通过大幅扩增数据量、整合人与小鼠eccDNA数据，并创新性地加入了基序发现模块与多组学功能评分框架，实现了对eccDNA的深度注释和功能预测。CircleBase V2的建立极大地便利了全球研究者，为揭示eccDNA在癌症、发育等生命过程中的生物学功能与调控机制提供了不可或缺的工具，具有重大的科研价值和转化应用潜力。

---

## 2. 撤稿声明：Runt相关转录因子1在体外和体内促进细胞凋亡并抑制神经母细胞瘤的进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41272903](https://pubmed.ncbi.nlm.nih.gov/41272903)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41272903
**DOI：** 10.1186/s13046-025-03581-7

### 第一部分 原文与翻译

**英文原标题：** Retraction Note: Runt-related transcription factor 1 promotes apoptosis and inhibits neuroblastoma progression in vitro and in vivo.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

这是一篇关于Runt相关转录因子1（RUNX1）在神经母细胞瘤中作用的研究的撤稿声明。原研究旨在探讨RUNX1作为肿瘤抑制因子的功能，声称其能通过在体外和体内诱导细胞凋亡来抑制肿瘤进展。然而，该文章的撤回意味着其研究结果和结论的可靠性已受到严重质疑，不再被认为是有效的。因此，科学界在进行相关研究时应忽略此前的结论，以维护学术记录的准确性和科学的严谨性。

---

## 3. 赖氨酸去甲基化酶6A和6B作为癌症治疗抵抗中的表观遗传调控因子

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41272745](https://pubmed.ncbi.nlm.nih.gov/41272745)
**期刊：** Clinical epigenetics
**PMID：** 41272745
**DOI：** 10.1186/s13148-025-02010-y

### 第一部分 原文与翻译

**英文原标题：** Lysine demethylases 6 A and 6B as epigenetic regulators in therapeutic resistance of cancer.

**英文摘要原文：**
Histone 3 lysine 27 (H3K27) demethylation is a key post-translational modification of chromatin and plays a fundamental role in gene activation. Demethylation of H3K27 is mediated by Jumonji C domain-containing lysine demethylase 6 A (KDM6A) and its paralog, KDM6B, both of which are responsible for homeostasis, autoimmune response, infectious diseases, and cancers. To date, mounting studies dedicate the roles of KDM6A/B on tumor promotion or suppression, and there are many reviews systematically summarize the relevant mechanisms of KDM6A/B in tumor development and therapy. KDM6A and KDM6B also contribute to the regulation of therapeutic insensitivity to chemotherapy, targeted response, radiotherapy and immunotherapy. Herein, we outline the current knowledge of KDM6A/B in regulation of therapeutic resistance, and suggest that KDM6A/B holds immense potential in recovering therapeutic resistance.

**中文摘要译文：**
组蛋白3赖氨酸27（H3K27）的去甲基化是染色质的一种关键翻译后修饰，并在基因激活中扮演着基础性角色。H3K27的去甲基化由含有Jumonji C结构域的赖氨酸去甲基化酶6A（KDM6A）及其旁系同源物KDM6B介导，这两者都与体内稳态、自身免疫反应、感染性疾病及癌症相关。迄今为止，越来越多的研究致力于阐明KDM6A/B在肿瘤促进或抑制中的作用，并且已有许多综述系统性地总结了KDM6A/B在肿瘤发生发展和治疗中的相关机制。KDM6A和KDM6B也参与调控对化疗、靶向治疗、放疗和免疫治疗的治疗不敏感性。本文中，我们概述了当前关于KDM6A/B在调控治疗抵抗方面的知识，并提出KDM6A/B在逆转治疗抵抗方面拥有巨大潜力。

### 第二部分 AI 大师评价

该文献是一篇综述性文章，核心目的在于系统性地阐述赖氨酸去甲基化酶KDM6A/B作为表观遗传调控因子，在癌症治疗抵抗机制中的作用。文章总结了现有研究，指出KDM6A/B参与调控化疗、靶向治疗、放疗及免疫治疗等多种疗法的敏感性。其价值在于整合了该领域的最新进展，明确了KDM6A/B作为克服肿瘤耐药性潜在靶点的重要性，为未来的转化研究和新药开发提供了理论依据和方向。

---

## 4. 基于组蛋白的液体活检可区分骨髓增生异常综合征与实体恶性肿瘤

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41272736](https://pubmed.ncbi.nlm.nih.gov/41272736)
**期刊：** Clinical epigenetics
**PMID：** 41272736
**DOI：** 10.1186/s13148-025-01995-w

### 第一部分 原文与翻译

**英文原标题：** Histone-based liquid biopsy discriminates between myelodysplastic syndrome and solid malignancies.

**英文摘要原文：**
BACKGROUND: Cancers can be hematological or solid, sharing many hallmarks, although their clinical behaviors are distinct. Identifying biomarkers that differentiate hematological from non-hematological malignancies could aid differential diagnosis by providing the basis for developing point-of-care diagnostic devices. In this respect, complex histone populations are secreted and detectable in biological fluids in various disease settings. To our knowledge, studies analyzing the circulating histone profile complexity by comparing healthy individuals, patients with hematological malignancies, and solid cancer patients are currently lacking.

RESULTS: We assessed the plasma histone signature of healthy subjects (n = 30), and of patients with myelodysplastic syndrome (MDS, n = 43), colorectal cancer (CRC, n = 39), lung cancer (non-small cell lung cancer [NSCLC, n = 15]), small cell lung cancer [SCLC, n = 4]), or breast cancer [BC, n = 16]). Principal component analysis (PCA) demonstrated the segregation of circulating histones and histone complexes between oncological and healthy patients. Individual histones (H2A, H2B, H3, H4, macroH2A1.1, and macroH2A1.2), histone dimers and nucleosomes were assayed by ImageStream(X)-advanced flow cytometry. We found general increases in circulating histone abundance in the blood of cancer patients versus healthy controls. MDS and solid cancers could be discriminated among themselves for an increased abundance of histones H2A and macroH2A1.2 (p < 0.01), and a decreased abundance of H2A/H2B/H3/H4 and H3/H4 histone complexes (p < 0.01). Moreover, macroH2A1.2 and H2A/H2B/H3/H4 levels negatively or positively correlated with age in healthy subjects versus MDS patients, respectively.

CONCLUSIONS: Overall, we identified circulating histone signatures able to discriminate between solid and MDS, using a rapid and non-invasive imaging technology, which may improve patient diagnosis.

**中文摘要译文：**
背景：癌症可分为血液系统恶性肿瘤或实体瘤，尽管其临床行为不同，但它们具有许多共同的特征。识别能够区分血液系统与非血液系统恶性肿瘤的生物标志物，可为开发即时诊断设备提供基础，从而辅助鉴别诊断。在这方面，复杂的组蛋白群在多种疾病状态下会分泌并可在生物体液中被检测到。据我们所知，目前缺乏通过比较健康个体、血液系统恶性肿瘤患者和实体癌患者来分析循环组蛋白谱复杂性的研究。

结果：我们评估了健康受试者（n = 30）以及骨髓增生异常综合征（MDS，n = 43）、结直肠癌（CRC，n = 39）、肺癌（非小细胞肺癌[NSCLC, n = 15]、小细胞肺癌[SCLC, n = 4]）或乳腺癌（BC，n = 16）患者的血浆组蛋白特征。主成分分析（PCA）显示，肿瘤患者与健康患者的循环组蛋白及组蛋白复合物存在分离。我们通过ImageStream(X)高级流式细胞术检测了单个组蛋白（H2A, H2B, H3, H4, macroH2A1.1, 和 macroH2A1.2）、组蛋白二聚体和核小体。我们发现，与健康对照组相比，癌症患者血液中的循环组蛋白丰度普遍增加。MDS和实体癌之间可以通过组蛋白H2A和macroH2A1.2的丰度增加（p < 0.01）以及H2A/H2B/H3/H4和H3/H4组蛋白复合物的丰度减少（p < 0.01）来进行区分。此外，在健康受试者与MDS患者中，macroH2A1.2和H2A/H2B/H3/H4的水平分别与年龄呈负相关和正相关。

结论：总的来说，我们利用一种快速、无创的成像技术，确定了能够区分实体瘤和MDS的循环组蛋白特征，这可能会改善患者的诊断。

### 第二部分 AI 大师评价

本研究旨在探索利用循环组蛋白作为液体活检标志物，以区分骨髓增生异常综合征（MDS）与实体恶性肿瘤。研究团队采用先进的成像流式细胞术技术，分析了MDS、多种实体瘤患者及健康人群的血浆组蛋白谱。关键发现是，特定的循环组蛋白（如H2A、macroH2A1.2）及其复合物的丰度变化，能够有效地区分MDS与实体瘤。这项工作提出了一种新颖、快速且无创的鉴别诊断策略，对于临床上区分血液系统与实体肿瘤来源的癌症具有重要潜在价值。

---

## 5. 内分泌回路的统一调控模式

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271754](https://pubmed.ncbi.nlm.nih.gov/41271754)
**期刊：** Nature communications
**PMID：** 41271754
**DOI：** 10.1038/s41467-025-65924-4

### 第一部分 原文与翻译

**英文原标题：** Unifying regulatory motifs in endocrine circuits.

**英文摘要原文：**
Hormone systems, which control diverse physiological functions, have been extensively studied, yet consistent rules underlying these systems remain elusive. Here we identify unifying design principles in human endocrine systems. Available data was found for 43 of 63 systems, and all 43 fall into five classes of circuits. Each class uses distinct regulation circuitry to perform specific dynamical functions: homeostasis, acute input-output response, or adjustable set points. The circuits involve interactions across multiple timescales - minutes to hours for hormone secretion, ultradian and diurnal rhythms, and weeks for changes in endocrine gland mass. The weeks-timescale for gland mass occurs in several circuit classes, including the most complex, which features an intermediate gland, the pituitary. We analyze this circuit in detail and identify tradeoffs between endocrine amplification, buffering of hypersecreting tumors, and response times. These unifying principles reveal how circuit structure maps to function and contribute to the emerging field of systems endocrinology.

**中文摘要译文：**
激素系统控制着多种生理功能，虽已被广泛研究，但其潜在的一致性规律仍不明确。在本研究中，我们识别出了人类内分泌系统的统一设计原则。我们找到了63个内分泌系统中的43个可用数据，且这43个系统均可归为五类回路。每一类回路利用独特的调控电路来执行特定的动态功能：维持稳态、急性输入-输出反应或调节设定点。这些回路涉及多个时间尺度上的相互作用——从分钟到小时的激素分泌、超日节律和昼夜节律，到长达数周的内分泌腺体质量变化。腺体质量在数周时间尺度上的变化发生在几类回路中，包括以垂体这一中间腺体为特征的最复杂回路。我们详细分析了这类回路，并识别了内分泌放大效应、对高分泌性肿瘤的缓冲作用以及反应时间之间的权衡关系。这些统一的原则揭示了回路结构如何映射到功能，并为系统内分泌学这一新兴领域做出了贡献。

### 第二部分 AI 大师评价

该研究旨在揭示人类内分泌系统中潜在的统一设计原则。研究人员通过分析43个内分泌系统的数据，创新性地将其归纳为五种具有不同动态功能的调控回路类型。其核心发现不仅阐明了内分泌回路结构与功能（如稳态维持、急性反应）之间的映射关系，还揭示了多时间尺度下的调控机制与系统性权衡。这项工作为新兴的“系统内分泌学”领域提供了坚实的理论框架，对理解内分泌疾病的病理生理机制及开发新的治疗策略具有重要指导价值。

---

## 6. 通过关联不同细胞类型的游离DNA片段覆盖度与开放染色质位点实现跨数据集泛癌种检测

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271753](https://pubmed.ncbi.nlm.nih.gov/41271753)
**期刊：** Nature communications
**PMID：** 41271753
**DOI：** 10.1038/s41467-025-66503-3

### 第一部分 原文与翻译

**英文原标题：** Cross-dataset pan-cancer detection by correlating cell-free DNA fragment coverage with open chromatin sites across cell types.

**英文摘要原文：**
The fragmentation patterns of whole genome sequenced cell-free DNA are promising features for tumor-agnostic cancer detection. However, systematic biases challenge their cross-cohort generalization. We introduce LIONHEART, an open source cancer detection method specifically optimized to generalize across datasets. The method correlates bias-corrected cfDNA fragment coverage across the genome with the locations of accessible chromatin regions from 898 cell and tissue type features. We use these correlations to detect changes in the cell-free DNA cell type composition caused by cancer. We test LIONHEART on nine datasets and fourteen cancer types (1106 non-cancer controls, 1449 cancers) obtained from different studies and show that it can distinguish cancer samples from non-cancer controls across cohorts with ROC AUC scores ranging from 0.62-0.95 (mean = 0.83, std = 0.12). We further validate the method on an external dataset, achieving a ROC AUC of 0.917.

**中文摘要译文：**
全基因组测序的游离DNA（cell-free DNA）的片段化模式是实现肿瘤不可知（tumor-agnostic）癌症检测的有前景的特征。然而，系统性偏倚对其跨队列的泛化应用构成了挑战。我们介绍一种名为LIONHEART的开源癌症检测方法，该方法经过专门优化以实现跨数据集的泛化。该方法将经过偏倚校正的全基因组cfDNA片段覆盖度与来自898种细胞和组织类型的开放染色质区域的位置进行关联。我们利用这些相关性来检测由癌症引起的游离DNA细胞类型组成的变化。我们在来自不同研究的九个数据集和十四种癌症类型（1106名非癌症对照，1449名癌症患者）上测试了LIONHEART，并证明它能够在不同队列中区分癌症样本与非癌症对照，其ROC AUC得分范围为0.62-0.95（平均值=0.83，标准差=0.12）。我们进一步在一个外部数据集上验证了该方法，实现了0.917的ROC AUC。

### 第二部分 AI 大师评价

本研究旨在开发一种能克服系统性偏倚、实现跨数据集应用的泛癌种检测新方法。研究团队推出了名为LIONHEART的开源算法，其核心创新在于将校正后的cfDNA片段覆盖度信息与庞大的细胞类型特异性开放染色质位点数据库相关联，从而推断cfDNA的组织来源变化以识别癌症信号。该方法在多个独立数据集中展现了稳健的诊断性能，有效解决了液态活检领域中模型泛化能力差的关键难题。这项工作为开发普适性更强的癌症早期筛查血检技术提供了重要方法学和证据支持。

---

## 7. DNA连接酶3α的锌指结构通过精氨酸锚定机制与核小体结合

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271738](https://pubmed.ncbi.nlm.nih.gov/41271738)
**期刊：** Nature communications
**PMID：** 41271738
**DOI：** 10.1038/s41467-025-66320-8

### 第一部分 原文与翻译

**英文原标题：** The zinc finger of DNA ligase 3α binds to nucleosomes via an arginine anchor.

**英文摘要原文：**
Ligation of DNA single strand breaks is critical for maintaining genome integrity during DNA replication and repair. DNA Ligase III (LIG3α) forms an important complex with X-ray cross complementing protein 1 (XRCC1) during single strand break and base excision repair. We utilize a real time single molecule approach to quantify DNA binding kinetics of HaloTag-LIG3α and XRCC1-YFP from nuclear extracts on long DNA substrates containing nicks, nucleosomes or nicks embedded in nucleosomes. LIG3α displays higher affinity for nicks than XRCC1 with the LIG3α catalytic core and N-terminal zinc finger (ZnF) competing for nick engagement. Surprisingly, compared to single strand breaks in naked DNA, LIG3α binds even more avidly to an undamaged nucleosome reconstituted on the 601-sequence, with binding dependent on two arginine residues in the N-terminal ZnF. These studies reveal insights into nick detection and identify an arginine anchor mechanism for LIG3α engagement with nucleosomes.

**中文摘要译文：**
DNA单链断裂的连接对于在DNA复制和修复过程中维持基因组完整性至关重要。在单链断裂修复和碱基切除修复过程中，DNA连接酶IIIα (LIG3α) 与X射线交补蛋白1 (XRCC1) 形成一个重要的复合物。我们利用实时单分子方法，在含有切口、核小体或嵌入核小体的切口的长DNA底物上，定量分析了来自核提取物的HaloTag-LIG3α和XRCC1-YFP的DNA结合动力学。LIG3α对切口的亲和力高于XRCC1，其催化核心和N端锌指（ZnF）会竞争性地与切口结合。令人惊讶的是，与裸露DNA上的单链断裂相比，LIG3α能更紧密地结合到在601序列上重构的未损伤核小体上，且这种结合依赖于其N端锌指中的两个精氨酸残基。这些研究揭示了切口检测的新见解，并确定了LIG3α与核小体结合的一种精氨酸锚定机制。

### 第二部分 AI 大师评价

本研究采用前沿的实时单分子技术，旨在探究DNA连接酶IIIα (LIG3α) 在DNA修复过程中的结合动力学。其核心发现是，LIG3α不仅能识别DNA切口，而且能以更高的亲和力结合到未损伤的核小体上，这一过程依赖其锌指结构中的两个关键精氨酸残基。这项工作创新性地揭示了LIG3α通过“精氨酸锚定”与核小体互作的新机制，加深了我们对染色质环境下DNA修复分子事件的理解，为相关疾病的治疗提供了新的潜在靶点。

---

## 8. 利用可扩展且内存高效的DNA树状计算实现可解释的分子决策

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271734](https://pubmed.ncbi.nlm.nih.gov/41271734)
**期刊：** Nature communications
**PMID：** 41271734
**DOI：** 10.1038/s41467-025-66610-1

### 第一部分 原文与翻译

**英文原标题：** Interpretable molecular decision-making with DNA-based scalable and memory-efficient tree computation.

**英文摘要原文：**
DNA computing has emerged as a transformative paradigm for tackling computational problems at the molecular level, yet existing approaches remain constrained in algorithmic interpretability, efficiency, and scalability. Here we present a DNA-based decision tree system that modularly embeds classification rules into DNA strand displacement reaction cascades for interpretable decision-making across various configurations. It supports cascaded networks exceeding 10 layers, parallel computation of 13 decision trees in a Random Forest involving 333 strands, and multimode operation (linear/nonlinear, binary/multi-class, single/tandem trees), while maintaining low leakage, rapid signal propagation, and minimal computational elements. Coupled with a DNA-methylation sensing module, it translates biomarker profiles into molecular instructions for tree traversal, reproduces in-silico predictions and enables accurate disease subtype classification. The decision tree system represents an interpretable, scalable, and memory-efficient DNA computing approach and will open new avenues for programming intelligent molecular machines with broad applicability.

**中文摘要译文：**
DNA计算已成为在分子水平上解决计算问题的变革性范式，但现有方法在算法可解释性、效率和可扩展性方面仍受限制。在此，我们提出了一种基于DNA的决策树系统，该系统将分类规则模块化地嵌入到DNA链置换反应级联中，以在各种配置下实现可解释的决策。该系统支持超过10层的级联网络，能在随机森林中并行计算13个涉及333条DNA链的决策树，并支持多模式操作（线性/非线性、二元/多类、单/串联树），同时保持低泄漏、快速信号传播和最少的计算元件。结合DNA甲基化传感模块，该系统能将生物标志物谱转化为用于树遍历的分子指令，复现计算机模拟预测，并实现准确的疾病亚型分类。该决策树系统代表了一种可解释、可扩展且内存高效的DNA计算方法，将为编程具有广泛应用前景的智能分子机器开辟新途径。

### 第二部分 AI 大师评价

本研究旨在解决现有DNA计算在可解释性、效率和可扩展性方面的局限。研究团队创新性地构建了一种基于DNA链置换反应的决策树系统，该系统能将复杂的分类规则模块化，并成功实现了多层级、多模式的并行计算。其关键发现是，该系统能与生物传感模块（如DNA甲基化检测）结合，将生物标志物信息直接转化为分子指令，从而精确地进行疾病亚型分类，验证了其在分子诊断和智能分子机器编程中的巨大潜力。这项工作为开发更高级的分子计算和靶向治疗工具开辟了新路径。

---

## 9. 一个用于表征CAR-T细胞对癌抗原应答的酵母表面展示平台

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271729](https://pubmed.ncbi.nlm.nih.gov/41271729)
**期刊：** Nature communications
**PMID：** 41271729
**DOI：** 10.1038/s41467-025-65236-7

### 第一部分 原文与翻译

**英文原标题：** A yeast surface display platform for characterizing CAR T cell responses to cancer antigens.

**英文摘要原文：**
Chimeric antigen receptor (CAR) T cells have become an established immunotherapy with promising results for the treatment of hematological malignancies. However, modulation of the targeted antigen's surface level in cancer cells affects the quality and safety of CAR-T cell therapy. Here we present an engineered yeast-based antigen system for simulation of cancer cells with precise regulation of surface-antigen densities, providing a tool for controlled activation of CAR T cells and systematic assessment of antigen density effects. This Synthetic Cellular Advanced Signal Adapter (SCASA) system uses G protein-coupled receptor signaling to control cancer antigen densities on the yeast surface and provides a customizable platform allowing selectable signal inputs and modular pathway engineering for precise output fine-tuning. In relation to CD19+ cancers, we demonstrate synthetic cellular communication between CD19-displaying yeast and human CAR T cells as well as applications in high-throughput characterization of different CAR designs. We show that yeast is an alternative to conventional technologies (e.g. microbeads) and can provide higher activation control of clinically derived CAR T cells in vitro, relative to cancer cells. In summary, we present a customizable yeast-based platform for high-throughput characterization of CAR-T cell functionality and show potential applications within therapeutic T cells in clinical settings.

**中文摘要译文：**
嵌合抗原受体（CAR）T细胞已成为一种成熟的免疫疗法，在治疗血液系统恶性肿瘤方面取得了令人鼓舞的成果。然而，癌细胞上靶向抗原表面水平的调控会影响CAR-T细胞疗法的质量和安全性。在此，我们提出一种基于工程化酵母的抗原系统，通过精确调控表面抗原密度来模拟癌细胞，为CAR-T细胞的受控激活和抗原密度效应的系统性评估提供了一种工具。该合成细胞高级信号适配器（SCASA）系统利用G蛋白偶联受体信号通路来控制酵母表面的癌抗原密度，并提供一个可定制的平台，允许选择性信号输入和模块化通路工程，以实现精确的输出微调。针对CD19阳性癌症，我们展示了展示CD19的酵母与人CAR-T细胞之间的合成细胞通讯，及其在高通量表征不同CAR设计中的应用。我们证明，相对于癌细胞而言，酵母是传统技术（如微珠）的一种替代方案，并能在体外为临床来源的CAR-T细胞提供更高水平的激活控制。总之，我们提出一个基于酵母的可定制平台，用于高通量表征CAR-T细胞的功能，并展示了其在临床环境中治疗性T细胞中的潜在应用。

### 第二部分 AI 大师评价

本研究的核心在于开发并验证了一个创新的工程化酵母表面展示平台（SCASA），旨在精确模拟肿瘤细胞表面的抗原密度。通过该平台，研究者能够可控地激活CAR-T细胞，并系统性地评估不同抗原密度对T细胞应答的影响。研究关键发现，该酵母系统在体外对CAR-T细胞的激活控制上优于传统方法，可作为高通量筛选和表征不同CAR设计的有力工具。这项技术的创新性在于利用酵母作为一种可定制、可扩展的“人造抗原呈递细胞”，为优化CAR-T细胞疗法的安全性与有效性提供了重要的临床前研究手段，具有显著的转化应用潜力。

---

## 10. 多组学分析揭示肺炎链球菌的非典型糖利用及关键膜组分调节因子

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271728](https://pubmed.ncbi.nlm.nih.gov/41271728)
**期刊：** Nature communications
**PMID：** 41271728
**DOI：** 10.1038/s41467-025-66611-0

### 第一部分 原文与翻译

**英文原标题：** Multi-omics profiling reveals atypical sugar utilization and a key membrane composition regulator in Streptococcus pneumoniae.

**英文摘要原文：**
The human body comprises many different microenvironments, each with their own challenges for microorganisms to overcome in order to survive and possibly cause infection. The human pathogen Streptococcus pneumoniae is notoriously flexible in this regard, and can adapt to a wide range of host niches, including the nasopharynx, lungs, and cerebrospinal fluid. However, the molecular and genetic foundation of this ability remain largely uncharted. In this work, we demonstrate that niche adaptation imposes genome-wide changes on multiple levels, including gene essentiality, expression and membrane lipid composition, by using infection-mimicking growth conditions. In general, we show that gene expression and fitness profiling couple orthogonal sets of genes to environmental stimuli. For instance, import (manLMN) and catabolism (nagAB) genes are required, but not differentially expressed during growth on N-acetylglucosamine (GlcNAc), opposite to the pattern of other amino sugar metabolism pathways. Surprisingly, we find that pneumococci do not necessarily prefer glucose over GlcNAc and that uptake of GlcNAc in absence of subsequent catabolism is toxic. Moreover, we identify a previously overlooked fatty acid saturation regulator, FasR, controlling membrane composition, rendering it important during heat stress. As nutrient availability and temperature fluctuations are distinctive facets of infection environments, these findings may inform anti-infective strategies.

**中文摘要译文：**
人体包含许多不同的微环境，每个微环境都对微生物的生存和可能引发的感染构成了独特的挑战。人类病原体肺炎链球菌在这方面表现出众所周知的灵活性，能够适应广泛的宿主生态位，包括鼻咽、肺部和脑脊液。然而，这种能力的分子和遗传基础在很大程度上仍是未知的。在这项工作中，我们通过使用模拟感染的生长条件，证明了生态位适应在多个层面上引起了全基因组范围的变化，包括基因必需性、表达和膜脂质组成。总的来说，我们证明了基因表达谱和适应性谱分析将相互独立的基因集与环境刺激耦合起来。例如，在N-乙酰葡糖胺（GlcNAc）上生长时，输入（manLMN）和分解代谢（nagAB）基因是必需的，但并未差异性表达，这与其他氨基糖代谢途径的模式相反。令人惊讶的是，我们发现肺炎链球菌并不一定偏好葡萄糖而非GlcNAc，并且在缺乏后续分解代谢的情况下摄取GlcNAc是有毒的。此外，我们鉴定出一个先前被忽视的脂肪酸饱和度调节因子FasR，它控制着膜的组成，使其在热应激期间变得重要。由于营养物质的可用性和温度波动是感染环境的显著特征，这些发现可能为抗感染策略提供信息。

### 第二部分 AI 大师评价

本研究通过创新的多组学分析方法，深入探究了肺炎链球菌在模拟感染条件下的适应性机制。核心发现揭示了该菌株对N-乙酰葡糖胺（GlcNAc）的非典型利用模式，并鉴定出一个新的膜成分调节因子FasR及其在热应激中的关键作用。这项工作不仅加深了我们对细菌如何适应宿主多变环境的分子基础的理解，其发现的独特代谢途径和调控蛋白也为开发新型抗感染策略提供了潜在的靶点，具有重要的科研与临床转化价值。

---

## 11. 黑素体中天然PMEL片层的原子结构与原位可视化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271718](https://pubmed.ncbi.nlm.nih.gov/41271718)
**期刊：** Nature communications
**PMID：** 41271718
**DOI：** 10.1038/s41467-025-65221-0

### 第一部分 原文与翻译

**英文原标题：** Atomic structure and in situ visualization of native PMEL lamellae in melanosomes.

**英文摘要原文：**
Melanin synthesis within melanosomes critically depends on the fibrillar architecture formed by the pigment cell-specific protein PMEL. Although PMEL fibrils have historically been classified as functional amyloids, their native supramolecular organization in situ and detailed molecular architecture have remained unresolved. In this study, we combine in situ cryo-electron tomography (cryo-ET) and cryo-electron microscopy (cryo-EM) to elucidate the native structural organization of PMEL fibrils within human melanosomes from both patient melanoma tissues and melanocyte cell lines. We demonstrate that PMEL does not form conventional isolated amyloid fibrils, but rather assembles into highly organized lamellar sheets consisting of laterally aligned fibrils interconnected by flexible linker regions. Cryo-EM structures reveal a distinctive butterfly-shaped fibril unit composed of multiple structured domains, including both the proteolytically cleaved Mα and Mβ fragments of PMEL, which assemble into a amyloid-like β-sheet arrangement. Notably, we identify intrinsically disordered regions critical for lamellar assembly and curvature and verify key glycosylation modifications in the structure. This architecture distinguishes PMEL fibrils from canonical amyloids and elucidates the molecular basis underlying melanosome integrity and pigmentation. Moreover, our work provides molecular insights relevant for pigmentation disorders and PMEL-associated diseases, including melanoma.

**中文摘要译文：**
黑素体内的黑色素合成关键依赖于色素细胞特异性蛋白PMEL形成的纤维状结构。尽管PMEL纤维在历史上被归类为功能性淀粉样蛋白，但其在体内的天然超分子组织形式及精细的分子结构仍未被解析。本研究结合了原位冷冻电子断层扫描技术（cryo-ET）和冷冻电子显微镜技术（cryo-EM），旨在阐明来自患者黑色素瘤组织和黑素细胞系的人类黑素体内PMEL纤维的天然结构组织。我们证明了PMEL并不形成传统的孤立淀粉样纤维，而是组装成高度有序的层状片层结构，这些片层由横向排列并通过柔性连接区相互连接的纤维组成。冷冻电镜结构揭示了一个独特的蝴蝶状纤维单元，该单元由多个结构域组成，包括PMEL蛋白经蛋白酶裂解产生的Mα和Mβ片段，它们共同组装成一种类似淀粉样蛋白的β-折叠排列。值得注意的是，我们识别出了对层状组装和弯曲至关重要的内在无序区，并验证了结构中的关键糖基化修饰。这种结构将PMEL纤维与典型的淀粉样蛋白区分开来，并阐明了维持黑素体完整性和色素沉着的分子基础。此外，我们的工作为色素沉着障碍和包括黑色素瘤在内的PMEL相关疾病提供了分子层面的见解。

### 第二部分 AI 大师评价

本研究利用尖端的原位冷冻电镜断层扫描与冷冻电镜技术，首次在原子级别上解析了人类黑素体中PMEL蛋白纤维的真实三维结构。研究的关键发现颠覆了传统认知，证明PMEL并非形成孤立的淀粉样纤维，而是构成高度有序的片层网络结构。这项工作不仅揭示了黑色素合成支架的精细分子基础，也为理解色素性疾病及黑色素瘤的发病机制提供了全新的结构生物学视角，具有重大的科研价值。

---

## 12. 积极评价风格可预测长期压力复原力并介导促复原力干预措施的效果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271713](https://pubmed.ncbi.nlm.nih.gov/41271713)
**期刊：** Nature communications
**PMID：** 41271713
**DOI：** 10.1038/s41467-025-65147-7

### 第一部分 原文与翻译

**英文原标题：** Positive appraisal style predicts long-term stress resilience and mediates the effect of a pro-resilience intervention.

**英文摘要原文：**
Stress resilience is the maintenance of mental health despite adversity. Identifying factors that predict and promote good long-term mental health outcomes in stressor-exposed individuals is a first step towards developing more effective prevention programs. In two independent observational samples (N = 132, N = 1034), we find that a tendency to evaluate stressors in a realistic to slightly unrealistically positive fashion (positive appraisal style, PAS) is prospectively associated with resilient outcomes over several years. We also find that PAS is an integrative, proximal resilience factor that mediates the pro-resilience effects of other protective factors (e.g., social support). In an analysis of pre-specified exploratory outcomes of a randomized controlled trial comparing a behavioral intervention targeting a broad set of resilience factors against usual care in a sample of distressed healthcare workers (N = 232; trial registry: NCT04980326), we find that PAS is modifiable, with improvements in PAS mediating intervention-induced improvements in resilience. These results establish PAS as a proximal, plastic, and potentially causal resilience factor.

**中文摘要译文：**
压力复原力是指在逆境中维持心理健康的能力。识别那些能够预测并促进暴露于压力源的个体获得良好长期心理健康结局的因素，是开发更有效预防方案的第一步。在两个独立的观察性样本（N = 132, N = 1034）中，我们发现，以现实乃至略带不切实际的积极方式评估压力源的倾向（即积极评价风格，PAS），与数年间的复原力结局存在前瞻性关联。我们还发现，PAS是一个整合性的、近端的复原力因素，它介导了其他保护性因素（如社会支持）对复原力的促进效应。在一项针对身处困境的医护人员样本（N = 232；试验注册号：NCT04980326）的随机对照试验中，我们对预设的探索性结局进行了分析，该试验比较了一种旨在干预多种复原力因素的行为疗法与常规护理的效果，结果发现PAS是可改变的，并且PAS的改善介导了干预措施所带来的复原力提升。这些结果确立了PAS作为一个近端的、具有可塑性的、且可能具有因果作用的复原力因素。

### 第二部分 AI 大师评价

本研究通过结合大样本观察性研究与随机对照试验，旨在探讨“积极评价风格”（PAS）在长期压力复原力中的预测和中介作用。研究核心发现，倾向于积极评估压力事件的思维模式不仅能预测个体未来数年的心理复原力，还在社会支持等保护因素与复原力之间起到了关键的桥梁作用。更具价值的是，研究证实了PAS是可塑的，通过行为干预能够有效提升，并由此增强个体的抗压能力，这为开发心理健康预防方案提供了新的、可操作的干预靶点。

---

## 13. 人体离体毛囊的细胞动力学图谱揭示其毛发生长的牵拉机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271712](https://pubmed.ncbi.nlm.nih.gov/41271712)
**期刊：** Nature communications
**PMID：** 41271712
**DOI：** 10.1038/s41467-025-65143-x

### 第一部分 原文与翻译

**英文原标题：** Mapping cell dynamics in human ex vivo hair follicles suggests pulling mechanism of hair growth.

**英文摘要原文：**
Homeostasis in continuously renewing organs like the gut, skin, and hair follicles relies on niche architecture and intricately orchestrated cellular dynamics, encompassing proliferation and migration. Here, we develop a 3D live imaging system to map single cell dynamics in micro-dissected human hair follicle segments during anagen phase in ex vivo culture. This approach reveals a spiral-like downward movement of outer root sheath cells entering the lower bulb region. We further mapped upwards flowing cells in the bulb, whose pathways align with differentiation patterns observed for stem cell-derived progenitors in rodent hair follicles. Cell division rates and orientation in the bulb correlate with the velocities of the adjacent upward-moving cell layers, with faster outer layer movement linked to higher mitotic rates. Integrating fluid dynamics simulations and experimental manipulation of mitosis and actin kinetics, we propose a mechanistic model, where a pulling force induced by the outer root sheath contributes to hair fiber extrusion.

**中文摘要译文：**
肠道、皮肤和毛囊等持续更新器官的稳态依赖于微环境结构以及包括增殖和迁移在内的复杂细胞动力学过程。本研究中，我们开发了一套3D活体成像系统，用于在离体培养条件下绘制生长期人毛囊微解剖切段中的单细胞动力学图谱。该方法揭示了外根鞘细胞以螺旋状向下运动并进入毛囊下部毛球区的过程。我们进一步绘制了毛球区内向上流动的细胞图谱，其路径与在啮齿动物毛囊中观察到的干细胞源性祖细胞的分化模式一致。毛球区的细胞分裂速率和方向与相邻向上移动细胞层的速度相关，其中较快的外层细胞运动与更高的有丝分裂率相关联。通过整合流体动力学模拟以及对有丝分裂和肌动蛋白动力学的实验性干预，我们提出了一个机制模型，即由外根鞘产生的牵拉力促成了毛纤维的挤出。

### 第二部分 AI 大师评价

本研究利用先进的3D活体成像技术，首次在离体培养的人类毛囊中实时描绘了单细胞的动态行为。其核心发现是，外根鞘细胞的螺旋式向下运动产生了一种“牵拉力”，与毛球区细胞向上增殖的“推力”协同作用，共同驱动毛干生长。这一“推拉结合”的全新机制模型，颠覆了以往仅强调“推力”的传统认知，为理解毛囊稳态和相关疾病（如脱发）的发病机制提供了崭新的力学视角，具有重要的科研价值和潜在的临床应用前景。

---

## 14. 一种位阻-平面-位阻分子工程策略：构筑用于增强光动力治疗的自组装纳米棒

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271710](https://pubmed.ncbi.nlm.nih.gov/41271710)
**期刊：** Nature communications
**PMID：** 41271710
**DOI：** 10.1038/s41467-025-66470-9

### 第一部分 原文与翻译

**英文原标题：** A hindrance-plane-hindrance molecular engineering strategy towards self-assembled nanorods for enhanced photodynamic therapy.

**英文摘要原文：**
As the vital component of photodynamic therapy, organic photosensitizers face challenges in clinical translation due to their compromised reactive oxygen species generation and limited tumor targeting when aggregated or formulated as nanoparticles. Herein, we overcome this dilemma by proposing a steric hindrance-plane-hindrance molecular design strategy to guide the self-assembly of twisted donor-π-acceptor photosensitizers into rod-shaped nanoparticles, which concurrently enhance reactive oxygen species (ROS) generation and tumor accumulation. Using TPA-S-DCR and other 7 molecules as models, we demonstrate that tuning the donor and acceptor steric hindrances around π-conjugated planar center enables the controllable spherical or rod-shaped supramolecular self-assembly of these twisted donor-π-acceptor photosensitizers under mild sonication condition. The resulting nanorods exhibit 1.31-fold higher ROS production, 5.04-fold higher cancer cell uptake over the nano-spherical counterparts. Moreover, TPA-S-DCR nanorods also show higher tumor accumulation, deeper tumor penetration, and longer tumor retention over its nano-spherical counterpart, which together with its better reactive oxygen species production amplifies photodynamic therapy efficacy in female mice model. This work establishes a simple and universal approach for morphology regulation of twisted donor-π-acceptor type photosensitizers, and also highlights the therapeutic advantages of anisotropic supramolecular self-assemblies, paving the way for next-generation phototheranostic agents.

**中文摘要译文：**
作为光动力疗法的关键组成部分，有机光敏剂在聚集或制备成纳米颗粒时，其活性氧的产生能力会受损且肿瘤靶向性有限，因此在临床转化中面临挑战。在此，我们提出一种空间位阻-平面-位阻的分子设计策略，引导扭曲的给体-π-受体（D-π-A）型光敏剂自组装成棒状纳米颗粒，从而同时增强活性氧（ROS）的产生和肿瘤蓄积，以克服这一困境。以TPA-S-DCR及其他7种分子为模型，我们证明了通过调控π共轭平面中心周围给体和受体的空间位阻，可以在温和的超声条件下，实现这些扭曲的D-π-A型光敏剂可控的球形或棒状超分子自组装。与球形纳米颗粒相比，所得的纳米棒表现出高1.31倍的ROS产量和高5.04倍的癌细胞摄取量。此外，与球形纳米颗粒相比，TPA-S-DCR纳米棒还显示出更高的肿瘤蓄积、更深的肿瘤穿透和更长的肿瘤滞留时间，这些特性与其更优的活性氧生成能力相结合，在雌性小鼠模型中显著增强了光动力疗法的效力。这项工作为调控扭曲的D-π-A型光敏剂的形态建立了一种简单而通用的方法，并凸显了各向异性超分子自组装体的治疗优势，为下一代光疗诊断剂铺平了道路。

### 第二部分 AI 大师评价

本研究旨在解决有机光敏剂在纳米化后因聚集导致活性氧生成效率降低及肿瘤靶向性不佳的核心难题。研究团队创新性地提出了一种“位阻-平面-位阻”分子工程策略，通过精巧调控分子结构，成功引导扭曲的D-π-A型光敏剂自组装成具有优异性能的纳米棒。关键发现表明，与传统的纳米球相比，这种纳米棒在活性氧生成、细胞摄取、肿瘤蓄积及穿透方面均表现出显著优势，从而在动物模型中实现了更强的光动力治疗效果。该策略不仅为高性能光敏剂的形貌可控合成提供了一种通用方法，也凸显了各向异性纳米材料在肿瘤诊疗中的巨大潜力，具有重要的科研价值和临床转化前景。

---

## 15. 舌后部的三潜能Lgr5+干细胞可生成舌上皮、味蕾及唾液腺谱系

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271704](https://pubmed.ncbi.nlm.nih.gov/41271704)
**期刊：** Nature communications
**PMID：** 41271704
**DOI：** 10.1038/s41467-025-65140-0

### 第一部分 原文与翻译

**英文原标题：** Tripotent Lgr5 stem cells in the posterior tongue generate lingual, taste, and salivary gland lineages.

**英文摘要原文：**
The circumvallate papillae and foliate papillae of the posterior tongue contain taste buds in close proximity to specialized salivary glands, known as von Ebner glands. The developmental relationship between taste buds and these salivary glands has been suggested but remains largely unexplored at postnatal and adult stages. Lineage tracing studies in mice have revealed that Lgr5 marks taste bud stem cells. Here, we report single-cell RNA sequencing of the entire circumvallate and foliate papillae of mice, providing a transcriptional atlas of cells from tongue surface epithelium, taste buds, and the associated and non-associated salivary glands. We unveil a developmental trajectory in which taste buds, the associated salivary glands, and the non-taste tongue surface epithelium originate from a common Lgr5 cell. We confirm this tripotency at the clonal level in vitro and with multicolor lineage tracing in vivo. Thus, the circumvallate and foliate papillae harbor chemosensory units composed of taste bud and salivary gland cells derived from the same parental Lgr5-positive stem cell.

**中文摘要译文：**
舌后部的轮廓乳头和叶状乳头含有味蕾，这些味蕾紧邻被称为冯·埃布纳腺的特化唾液腺。味蕾与这些唾液腺之间的发育关系虽早有推测，但在出生后和成年阶段仍基本上未被探索。在小鼠中进行的谱系追踪研究已经揭示，Lgr5是味蕾干细胞的标记物。在本研究中，我们报告了对小鼠整个轮廓乳头和叶状乳头的单细胞RNA测序结果，提供了一个涵盖舌表面上皮、味蕾以及相关和非相关唾液腺细胞的转录图谱。我们揭示了一条发育轨迹，其中味蕾、相关唾液腺以及非味觉舌表面上皮均起源于共同的Lgr5细胞。我们在体外通过克隆水平实验，并在体内通过多色谱系追踪证实了这种三潜能特性。因此，轮廓乳头和叶状乳头包含着由味蕾细胞和唾液腺细胞组成的化学感应单元，而它们均源自同一个亲代Lgr5阳性干细胞。

### 第二部分 AI 大师评价

该研究旨在阐明舌后部味蕾与冯·埃布纳腺的发育关系。研究团队综合运用了单细胞RNA测序、体外克隆分析和体内多色谱系追踪技术，关键性地发现了一群位于舌后部的Lgr5阳性干细胞。这项研究的重大创新在于，首次证实了这些干细胞具有三向分化潜能，能够同时生成味蕾、伴生的唾液腺以及周围的舌上皮细胞。这一发现不仅揭示了舌后部存在一个功能性的“化学感应单元”，也为理解味觉器官的稳态维持、损伤修复及相关疾病的治疗提供了新的理论基础和潜在靶点。

---

## 16. 多重神经退行性蛋白毒性平台揭示DNAJB6促进FUS凝聚体的无毒凝胶化并抑制神经毒性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271702](https://pubmed.ncbi.nlm.nih.gov/41271702)
**期刊：** Nature communications
**PMID：** 41271702
**DOI：** 10.1038/s41467-025-65178-0

### 第一部分 原文与翻译

**英文原标题：** Multiplex neurodegeneration proteotoxicity platform reveals DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity.

**英文摘要原文：**
Neurodegenerative disorders (NDDs) are a family of diseases that remain poorly treated despite their growing global health burden. To gain insight into the mechanisms and modulators of neurodegeneration, we developed a yeast-based multiplex genetic screening platform. Using this platform, 32 NDD-associated proteins are probed against a library of 132 molecular chaperones from both yeast and humans, and an unbiased set of ~900 human proteins. We identify both broadly active and specific modifiers of our various cellular models. To illustrate the translatability of this platform, we extensively characterize a potent hit from our screens, the human chaperone DNAJB6. We show that DNAJB6 modifies the toxicity and solubility of multiple amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD)-linked RNA-binding proteins (RBPs). Biophysical examination of DNAJB6 demonstrated that it co-phase separates with, and alters the behavior of FUS containing condensates by locking them into a loose gel-like state which prevents their fibrilization. Domain mapping and a deep mutational scan of DNAJB6 revealed key residues required for its activity and identified variants with enhanced activity. Finally, we show that overexpression of DNAJB6 prevents motor neuron loss and the associated microglia activation in a mouse model of FUS-ALS.

**中文摘要译文：**
神经退行性疾病（NDDs）是一类尽管全球健康负担日益加重但治疗效果仍然不佳的疾病。为了深入了解神经退行性变的机制和调控因子，我们开发了一个基于酵母的多重基因筛选平台。利用该平台，我们将32种NDD相关蛋白与一个包含132种酵母和人类分子伴侣的文库以及一个约900种人类蛋白的无偏集进行了筛选。我们在各种细胞模型中识别出了具有广泛活性和特异性的修饰因子。为证明该平台的可转化性，我们对筛选出的一个强效命中分子——人类分子伴侣DNAJB6——进行了广泛的表征。我们发现DNAJB6能够调节多种与肌萎缩侧索硬化症和额颞叶痴呆（ALS/FTD）相关的RNA结合蛋白（RBPs）的毒性和溶解度。对DNAJB6的生物物理学检测表明，它能与含FUS的凝聚体共相分离，并通过将其锁定在一种疏松的凝胶状状态来改变其行为，从而防止其纤维化。对DNAJB6的结构域作图和深度突变扫描揭示了其活性所需的关键残基，并鉴定出活性增强的变体。最后，我们证明了在FUS-ALS小鼠模型中，过表达DNAJB6可以防止运动神经元的丢失以及相关的小胶质细胞活化。

### 第二部分 AI 大师评价

本研究旨在开发一个高通量筛选平台以发现神经退行性疾病的调控因子。研究人员创新性地构建了一个基于酵母的多重筛选系统，并成功鉴定出人类分子伴侣DNAJB6是多种ALS/FTD相关蛋白毒性的关键抑制剂。核心发现是，DNAJB6通过促进FUS蛋白凝聚体向无毒的凝胶态转变，从而阻止其纤维化并抑制神经毒性，这一保护效果在FUS-ALS小鼠模型中也得到了验证。该研究不仅提供了一个强大的筛选工具，还揭示了DNAJB6作为ALS/FTD潜在治疗靶点的重要价值，为相关疾病的干预策略开辟了新方向。

---

## 17. 生殖系致病性变异影响儿童中枢神经系统肿瘤的体细胞改变及患者结局

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271695](https://pubmed.ncbi.nlm.nih.gov/41271695)
**期刊：** Nature communications
**PMID：** 41271695
**DOI：** 10.1038/s41467-025-65190-4

### 第一部分 原文与翻译

**英文原标题：** Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric central nervous system tumors.

**英文摘要原文：**
The contribution of rare pathogenic/likely pathogenic (P/LP) germline variants to pediatric central nervous system (CNS) tumor development remains understudied. Here, we characterize the prevalence and biological significance of germline P/LP variants in cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBTA). We identify germline P/LP variants in 23.3% (193/830) of patients and the majority (137/193) lack clinical reporting of genetic tumor syndromes. Among P/LP carriers, 34.6% have putative somatic second hits or loss of function tumor alterations. Finally, we link pathogenic germline variation with somatic events and patient survival to highlight the impact of germline variation on tumorigenesis and patient outcomes.

**中文摘要译文：**
罕见致病性/可能致病性（P/LP）生殖系变异对儿童中枢神经系统（CNS）肿瘤发生发展的贡献仍研究不足。在此，我们描述了来自儿童脑肿瘤图谱（PBTA）的830名CNS肿瘤患者中，癌症易感基因中生殖系P/LP变异的患病率和生物学意义。我们在23.3%（193/830）的患者中发现了生殖系P/LP变异，其中大多数（137/193）缺乏遗传性肿瘤综合征的临床报告。在P/LP变异携带者中，34.6%的患者存在推定的体细胞二次打击或功能丧失性肿瘤改变。最后，我们将致病性生殖系变异与体细胞事件及患者生存相关联，以突显生殖系变异对肿瘤发生和患者结局的影响。

### 第二部分 AI 大师评价

该研究基于儿童脑肿瘤图谱（PBTA）的大样本数据，系统分析了儿童中枢神经系统肿瘤中致病性生殖系变异的普遍性及其生物学意义。其核心发现是，近四分之一的患儿携带此类变异，且多数未被临床诊断为遗传综合征，研究进一步揭示了这些生殖系变异与体细胞“二次打击”及患者生存结局的关联。这项工作不仅强调了对儿童脑肿瘤患者进行生殖系基因检测的重要性，也为理解肿瘤发生机制和指导个体化治疗策略提供了关键证据。

---

## 18. 儿童T细胞急性淋巴细胞白血病中免疫微环境的重塑与不良预后相关

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271691](https://pubmed.ncbi.nlm.nih.gov/41271691)
**期刊：** Nature communications
**PMID：** 41271691
**DOI：** 10.1038/s41467-025-65134-y

### 第一部分 原文与翻译

**英文原标题：** Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia.

**英文摘要原文：**
Changes in the immune microenvironment are frequent in cancers occurring in adult patients, yet our understanding of the pediatric cancer immune microenvironment and its clinical relevance is limited. We investigate the immune microenvironment in pediatric T cell acute lymphoblastic leukemia (T-ALL), using single-cell CITE-seq and immune repertoire analyses. We identify a T-ALL subgroup characterized by a remodeled immune microenvironment, which is associated with adverse clinical outcome in minimal residual disease low patients. This adverse immune landscape is dominated by the presence of a population of non-malignant CD4CD8TCRαβ T cells that interact with CXCL16 expressing non-classical monocytes. Leukemia cell intrinsic transcriptional rewiring in these patients is associated with activation of Rap1 signaling. Inhibiting Rap1 signaling results in increased sensitivity to the BCL2/BCL-XL inhibitor navitoclax. Our study provides insights into the immune microenvironment of pediatric hematologic malignancies, forming the basis for identifying potential (immuno) therapeutic targets and risk stratification for treatment.

**中文摘要译文：**
成人癌症患者中，免疫微环境的改变十分常见，但我们对儿童癌症免疫微环境及其临床相关性的理解却很有限。我们利用单细胞CITE-seq和免疫组库分析技术，对儿童T细胞急性淋巴细胞白血病（T-ALL）的免疫微环境进行了研究。我们识别出一个以免疫微环境重塑为特征的T-ALL亚群，该亚群与微小残留病低风险患者的不良临床结局相关。这种不良免疫景观主要由一群非恶性的CD4+CD8+TCRαβ+ T细胞主导，这些T细胞与表达CXCL16的非经典单核细胞相互作用。这些患者的白血病细胞内源性转录重编程与Rap1信号通路的激活有关。抑制Rap1信号通路可增加细胞对BCL2/BCL-XL抑制剂navitoclax的敏感性。我们的研究为儿童血液系统恶性肿瘤的免疫微环境提供了新的见解，为识别潜在的（免疫）治疗靶点和制定治疗风险分层奠定了基础。

### 第二部分 AI 大师评价

该研究创新性地运用单细胞CITE-seq及免疫组库分析技术，深入揭示了儿童T细胞急性淋巴细胞白血病（T-ALL）中免疫微环境重塑与不良预后的关键联系。其核心发现是识别出一个特定的T-ALL亚群，其特征在于非恶性T细胞与非经典单核细胞的相互作用，并关联到白血病细胞内Rap1信号通路的激活。这项工作不仅为理解儿童血液肿瘤的免疫病理学提供了新视角，更重要的是，它指出了Rap1信号通路可作为潜在治疗靶点，为改善高危患儿的治疗策略和风险分层提供了实验依据和新方向。

---

## 19. 诱导化疗联合卡瑞利珠单抗继以同步放化疗治疗不可切除的局部晚期食管鳞癌：一项单臂II期临床试验。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271680](https://pubmed.ncbi.nlm.nih.gov/41271680)
**期刊：** Nature communications
**PMID：** 41271680
**DOI：** 10.1038/s41467-025-65206-z

### 第一部分 原文与翻译

**英文原标题：** Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial.

**英文摘要原文：**
Concurrent chemoradiotherapy (CCRT) has remained the standard treatment for unresectable locally advanced esophageal squamous cell carcinoma (ESCC), yet survival remains poor. This single-arm, phase II trial aims to evaluate the efficacy and safety of two cycles of induction chemotherapy with camrelizumab followed by CCRT in previously untreated patients with unresectable locally advanced ESCC. The primary endpoint, the 1-year overall survival (OS) rate in the per-protocol population (N = 46), was 87.0% (95% confidence interval [CI]: 77.7%-97.3%), exceeding the pre-specified target. Secondary endpoints included OS in the intention-to-treat (ITT) population, progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), duration of response, safety, and health-related quality of life. In the ITT population (N = 49), the 1-year OS rate was 85.7% (95% CI: 76.5%-96.1%). The 1-year PFS rates in the per-protocol and ITT populations were 71.7% (95% CI: 59.8%-86.0%) and 71.4% (95% CI: 59.8%-85.3%), respectively. The median OS, PFS, and duration of response were not reached. Following CCRT, the ORR was 93.5%, with a DCR of 95.7%. Lymphopenia was the most frequent Grade ≥3 adverse event (100%). One patient died from treatment-related myelosuppression. Health-related quality of life generally improved after induction therapy, with significant improvements in global health status, emotional functioning, and some symptom relief, despite a slight decline in physical functioning. Here, we show that induction chemoimmunotherapy followed by CCRT exhibits promising efficacy and manageable safety in patients with unresectable locally advanced ESCC, thus warranting further randomized controlled trials. Trial number: ChiCTR2000034304.

**中文摘要译文：**
同步放化疗（CCRT）一直是不可切除的局部晚期食管鳞状细胞癌（ESCC）的标准治疗方案，但患者生存状况依然不佳。这项单臂II期试验旨在评估两周期卡瑞利珠单抗联合诱导化疗，继以同步放化疗，在初治的不可切除局部晚期ESCC患者中的疗效与安全性。主要终点是符合方案人群（N=46）的1年总生存（OS）率，结果为87.0%（95%置信区间[CI]: 77.7%-97.3%），超过了预设目标。次要终点包括意向性治疗（ITT）人群的OS、无进展生存期（PFS）、总缓解率（ORR）、疾病控制率（DCR）、缓解持续时间、安全性以及健康相关生活质量。在ITT人群（N=49）中，1年OS率为85.7%（95% CI: 76.5%-96.1%）。在符合方案人群和ITT人群中，1年PFS率分别为71.7%（95% CI: 59.8%-86.0%）和71.4%（95% CI: 59.8%-85.3%）。中位OS、PFS和缓解持续时间均未达到。同步放化疗后，ORR为93.5%，DCR为95.7%。淋巴细胞减少症是最常见的≥3级不良事件（100%）。一名患者因治疗相关的骨髓抑制死亡。诱导治疗后，健康相关生活质量总体得到改善，尽管身体功能略有下降，但在总体健康状况、情绪功能和部分症状缓解方面有显著改善。本研究表明，诱导免疫化疗继以同步放化疗在不可切除的局部晚期ESCC患者中展现出良好的疗效和可控的安全性，因此有必要开展进一步的随机对照试验。试验编号：ChiCTR2000034304。

### 第二部分 AI 大师评价

本研究旨在探索一种针对不可切除局部晚期食管鳞癌的创新治疗模式，即在标准同步放化疗前，先进行卡瑞利珠单抗联合化疗的诱导治疗。这项II期临床试验的关键发现是，该方案展现出非常优异的疗效，其一年总生存率高达87%，显著超越了预设目标，且安全性总体可控。该研究的价值在于为局部晚期食管癌的治疗策略提供了新的思路，这种将免疫治疗前移至诱导阶段的模式，可能成为未来改善患者预后的重要方向，但其确切疗效仍有待更大规模的III期随机对照试验的验证。

---

## 20. HAT1在肺腺癌中作为乳酰化转移酶介导RPA1乳酰化，从而促进DNA修复与放射抗性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271679](https://pubmed.ncbi.nlm.nih.gov/41271679)
**期刊：** Cell death & disease
**PMID：** 41271679
**DOI：** 10.1038/s41419-025-08113-x

### 第一部分 原文与翻译

**英文原标题：** HAT1 functions as a lactyltransferase and mediates RPA1 lactylation to promote DNA repair and radioresistance in lung adenocarcinoma.

**英文摘要原文：**
Lysine lactylation is a post-translational modification induced by lactate discovered in recent years. Abnormal lysine lactylation contributes to the occurrence and progression of various tumors. However, the mediators and downstream targets of lysine lactylation remain unclear. Here, we report that HAT1 serves as a potential lactyltransferase that can promote homologous recombination and lead to radioresistance by regulating lactylation of RPA1. Lactylation of RPA1 facilitates its binding to single-stranded DNA and MRE11-RAD50-NBS1 (MRN) complexes and promotes homologous recombination. HAT1 knockout inhibits DNA repair in lung adenocarcinoma cells, thereby increasing radiotherapy sensitivity. Interestingly, we also found that K15 auto-lactylation of HAT1 can modulate its lactyltransferase activity. In conclusion, our research reveals that HAT1-regulated RPA1 lactylation plays an important role in homologous recombination and radioresistance, suggesting that HAT1 may become a potential therapeutic target for reversing the radioresistance caused by lactate accumulation in cancer cells.

**中文摘要译文：**
赖氨酸乳酰化是近年来发现的一种由乳酸诱导的翻译后修饰。异常的赖氨酸乳酰化与多种肿瘤的发生和发展有关。然而，赖氨酸乳酰化的介导物及其下游靶点尚不清楚。在此，我们报道了HAT1可作为一种潜在的乳酰化转移酶，通过调控RPA1的乳酰化来促进同源重组并导致放射抗性。RPA1的乳酰化促进了其与单链DNA以及MRE11-RAD50-NBS1（MRN）复合物的结合，并促进同源重组。敲除HAT1会抑制肺腺癌细胞的DNA修复，从而增加其对放射治疗的敏感性。有趣的是，我们还发现HAT1的K15位点自乳酰化可以调节其乳酰化转移酶活性。总之，我们的研究揭示了由HAT1调控的RPA1乳酰化在同源重组和放射抗性中发挥着重要作用，这表明HAT1可能成为一个潜在的治疗靶点，用于逆转癌细胞中因乳酸积累引起的放射抗性。

### 第二部分 AI 大师评价

本研究旨在阐明组蛋白乙酰转移酶1（HAT1）在肺腺癌放射抗性中的新作用。研究通过一系列分子实验，首次揭示了HAT1可作为一种乳酰化转移酶，通过介导复制蛋白A1（RPA1）的乳酰化来增强DNA同源重组修复能力，从而导致肿瘤的放射抗性。这项发现不仅为新兴的蛋白质乳酰化领域提供了关键的酶学证据，更重要的是，它指出了HAT1作为一个潜在的治疗靶点，为克服肿瘤（尤其是富含乳酸的微环境中的肿瘤）的放射抗性提供了新的策略和理论依据，具有重要的临床转化潜力。

---

## 21. SARS-CoV-2通过羊膜腔内感染存在于胎儿器官

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271675](https://pubmed.ncbi.nlm.nih.gov/41271675)
**期刊：** Nature communications
**PMID：** 41271675
**DOI：** 10.1038/s41467-025-65131-1

### 第一部分 原文与翻译

**英文原标题：** Presence of SARS-CoV-2 in fetal organs via intraamniotic infection.

**英文摘要原文：**
The COVID-19 pandemic underlined the need to focus on women's health, particularly during pregnancy. Recent studies have shown that maternal SARS-CoV-2 infection during pregnancy may increase obstetrical risks. However, intraamniotic SARS-CoV-2 infection has been understudied. Here, we conduct inclusive autopsies on 18 fetuses following maternal SARS-CoV-2 infection to determine whether and which fetal organs can be infected by SARS-CoV-2 in utero. We analyze a total of 538 samples from 32 tissue types to comprehensively map and quantify the distribution and replication patterns of SARS-CoV-2 across fetal organs. Our observations reveal that SARS-CoV-2 can be widely distributed in fetal organs through vertical transmission. As the length of time from SARS-CoV-2 infection to termination of pregnancy increases, the prevalence of infection in fetal organs decrease. Further, proteomic profiling reveals DNA damage and immune imbalance in infected organs.

**中文摘要译文：**
COVID-19大流行凸显了关注女性健康，特别是孕期女性健康的必要性。近期的研究表明，孕期母体感染SARS-CoV-2可能会增加产科风险。然而，关于羊膜腔内SARS-CoV-2感染的研究尚不充分。在此，我们对18例母体感染SARS-CoV-2后的胎儿进行了全面尸检，以确定SARS-CoV-2在子宫内是否能够以及能够感染哪些胎儿器官。我们共分析了来自32种组织类型的538份样本，以全面绘制并量化SARS-CoV-2在胎儿各器官的分布和复制模式。我们的观察结果显示，SARS-CoV-2可通过垂直传播广泛分布于胎儿器官中。随着从SARS-CoV-2感染到终止妊娠的时间间隔延长，胎儿器官的感染率下降。此外，蛋白质组学分析揭示了受感染器官中存在DNA损伤和免疫失衡。

### 第二部分 AI 大师评价

本研究通过对母体感染SARS-CoV-2后的胎儿进行全面尸检，旨在系统性地探究病毒在子宫内垂直传播至胎儿器官的情况。研究团队利用多组织样本分析和蛋白质组学技术，关键性地发现SARS-CoV-2可广泛分布于胎儿器官，且感染会引发DNA损伤与免疫失衡，感染率随时间推移而降低。这项研究为理解新冠病毒的母婴垂直传播机制提供了直接且有力的证据，对评估孕期感染的潜在风险和指导临床实践具有重要价值。

---

## 22. LMNA-PRKDC轴增强胶质母细胞瘤的DNA修复并促进其化疗耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271669](https://pubmed.ncbi.nlm.nih.gov/41271669)
**期刊：** Cell death & disease
**PMID：** 41271669
**DOI：** 10.1038/s41419-025-08226-3

### 第一部分 原文与翻译

**英文原标题：** LMNA-PRKDC axis enhances DNA repair and promotes chemoresistance in glioblastoma.

**英文摘要原文：**
Glioblastoma (GBM) remains one of the deadliest primary brain tumors, with rapid recurrence and near-universal resistance to temozolomide (TMZ) limiting long-term survival. In this study, we identify a clinically actionable mechanism of resistance driven by the LMNA-PRKDC axis, which enhances DNA repair and tumor cell survival following TMZ treatment. Using patient-derived xenograft models of recurrent GBM, we demonstrate that resistant tumors exhibit elevated LMNA expression and increased physical interaction with PRKDC, a central regulator of non-homologous end joining (NHEJ). This interaction accelerates the repair of TMZ-induced DNA lesions, contributing to therapeutic failure. Proteomic profiling and targeted immunoprecipitation revealed a distinct LMNA-PRKDC-associated DNA repair complex. Inhibition of PRKDC with the ATP-competitive inhibitor KU57788 reversed resistance, restoring TMZ sensitivity and impairing tumor growth in vivo. Single-cell RNA sequencing of primary and recurrent GBM specimens further identified LMNA-PRKDC co-expression as a hallmark of treatment-resistant, glioma stem-like cell populations. Importantly, high LMNA-PRKDC expression was associated with inferior survival outcomes in GBM patient cohorts. These results establish the LMNA-PRKDC axis as a functional driver of TMZ resistance through enhanced DNA repair capacity in stem-like tumor subpopulations. Our findings support pharmacologic inhibition of PRKDC as a rational strategy to resensitize resistant GBM to standard chemotherapy and offer a foundation for future biomarker-driven clinical trials targeting DNA repair vulnerabilities in recurrent disease.

**中文摘要译文：**
胶质母细胞瘤（GBM）仍然是致死率最高的原发性脑肿瘤之一，其快速复发和对替莫唑胺（TMZ）的普遍耐药性限制了患者的长期生存。在本研究中，我们鉴定出一个由LMNA-PRKDC轴驱动的具有临床可操作性的耐药机制，该机制在TMZ治疗后能增强DNA修复和肿瘤细胞存活。我们利用复发性GBM的患者来源异种移植模型证明，耐药肿瘤表现出LMNA表达升高，并与非同源末端连接（NHEJ）的核心调控因子PRKDC发生更强的物理相互作用。这种相互作用加速了TMZ诱导的DNA损伤修复，从而导致治疗失败。蛋白质组学分析和靶向免疫沉淀技术揭示了一个独特的LMNA-PRKDC相关DNA修复复合物。使用ATP竞争性抑制剂KU57788抑制PRKDC可逆转耐药性，恢复肿瘤对TMZ的敏感性，并在体内抑制肿瘤生长。对原发性和复发性GBM样本进行的单细胞RNA测序进一步发现，LMNA-PRKDC的共表达是具有治疗抵抗性的胶质瘤干细胞样细胞群的一个标志。重要的是，在GBM患者队列中，LMNA-PRKDC的高表达与较差的生存结局相关。这些结果证实，LMNA-PRKDC轴通过增强干细胞样肿瘤亚群的DNA修复能力，是TMZ耐药性的一个功能性驱动因素。我们的研究结果支持将药物抑制PRKDC作为一种合理策略，以使耐药GBM对标准化疗重新敏感，并为未来针对复发性疾病中DNA修复脆弱性的生物标志物驱动的临床试验提供了基础。

### 第二部分 AI 大师评价

该研究精准地揭示了胶质母细胞瘤（GBM）中由LMNA-PRKDC轴介导的替莫唑胺（TMZ）化疗耐药新机制。研究综合运用了患者来源的异种移植模型、蛋白质组学和单细胞测序等前沿技术，不仅阐明了LMNA与PRKDC相互作用如何增强肿瘤干细胞样细胞群的DNA修复能力，还验证了靶向抑制PRKDC能有效逆转耐药性。这项工作不仅为理解GBM的治疗失败提供了新的分子见解，更重要的是提出了一个具有明确靶点（PRKDC）和潜在生物标志物（LMNA-PRKDC共表达）的临床转化策略，为改善复发性GBM患者的预后带来了希望。

---

## 23. 利用多尺度红细胞搭载策略实现靶向性肺部深层组织基因递送

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271662](https://pubmed.ncbi.nlm.nih.gov/41271662)
**期刊：** Nature communications
**PMID：** 41271662
**DOI：** 10.1038/s41467-025-65185-1

### 第一部分 原文与翻译

**英文原标题：** Multiscale red blood cell hitchhiking for targeted deep tissue gene delivery in lungs.

**英文摘要原文：**
The clinical impact of gene therapies is constrained by poor delivery to target tissues beyond the liver after intravenous administration. Current molecular targeting strategies, such as capsid engineering or gene-carrier surface modification, have achieved only limited success due to their inability to overcome the hierarchical barriers from injection to deep tissue transduction. Here, we introduce a Multiscale Approach using RBC-mediated hitchhiking and Vascular Endothelium Leakage (MARVEL), which integrates red blood cell hitchhiking with VEGF-induced vascular permeabilization to enhance accumulation and penetration of cargoes. Using adeno-associated viruses (AAVs) as a model, MARVEL markedly increases AAV localization in the lungs, improves endothelial transcytosis, and enables gene expression in deeper tissue layers while maintaining a favorable safety profile. We further demonstrate that MARVEL can be adopted into an in situ hitchhiking approach, bypassing the need for ex vivo formulation. MARVEL provides a scalable strategy to address long-standing delivery challenges in gene therapy.

**中文摘要译文：**
静脉注射后，基因疗法药物难以递送至肝外靶组织，这限制了其临床应用效果。现有的分子靶向策略，如病毒衣壳工程或基因载体表面修饰，因无法克服从注射到深层组织转导的多重障碍，仅取得了有限的成功。本研究介绍了一种名为MARVEL（利用红细胞介导的搭载和血管内皮渗漏的多尺度方法）的新策略，该策略将红细胞搭载技术与VEGF诱导的血管通透化相结合，以增强载荷的蓄积和穿透。以腺相关病毒（AAVs）为模型，MARVEL策略显著增加了AAV在肺部的定位，改善了内皮细胞的跨细胞转运，并能在更深的组织层中实现基因表达，同时保持了良好的安全性。我们进一步证明，MARVEL可以采用一种原位搭载的方法，从而无需体外制备过程。MARVEL为解决基因治疗中长期存在的递送难题提供了一种可规模化的策略。

### 第二部分 AI 大师评价

该研究旨在解决基因疗法向肝外组织（尤其是肺部）递送效率低下的核心难题，为此独创性地提出了一种名为MARVEL的多尺度递送策略，该策略巧妙地将红细胞“搭便车”技术与VEGF诱导的血管通透化相结合。研究结果表明，以AAV为模型，MARVEL策略能显著提高其在肺部的富集和组织穿透深度，成功实现深层组织的基因表达，且具备良好的安全性。此项工作的创新之处在于它超越了传统的载体修饰思路，通过整合生理机制来系统性地攻克多重递送障碍，为肺部疾病及其他组织的靶向基因治疗提供了极具临床转化潜力的可规模化新平台，特别是其原位搭载方法简化了应用流程。

---

## 24. 癌细胞源性IL-1β可逆转非小细胞肺癌的化学免疫治疗耐药性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271647](https://pubmed.ncbi.nlm.nih.gov/41271647)
**期刊：** Nature communications
**PMID：** 41271647
**DOI：** 10.1038/s41467-025-64839-4

### 第一部分 原文与翻译

**英文原标题：** Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer.

**英文摘要原文：**
Many non-small cell lung cancer (NSCLC) patients remain unresponsive to the current standard of care, which includes chemotherapy and immune checkpoint inhibitors, like anti-PD-1/PD-L1 antibodies. While interleukin (IL)-1β is known to promote lung cancer growth in humans and mice, we show here that IL-1β administration or overexpression overcomes resistance to classical chemo-immunotherapy (cisplatin/pemetrexed/anti-PD-1) in mouse lung cancer models. The antitumor effects of IL-1β rely on cancer cell-derived CXCL10 which mediates CD8 T cell recruitment at the tumor site. In lung cancer cells, Thioredoxin Interacting Protein (TXNIP) induces mitochondrial DNA (mtDNA) release in the cytosol, activating Absence in Melanoma 2 (AIM2) inflammasome, which subsequently triggers IL-1β and CXCL10 secretion, thereby reversing chemo-immunotherapy resistance. The clinical relevance of our findings is supported by the transcriptomic analysis of patient tumors, showing that high expression of IL1B, IL1R1, AIM2 and/or TXNIP is associated with better response to immunotherapy in NSCLC patients. Additionally, drug screening identifies MEK and MDM2 inhibitors as inducers of TXNIP expression capable of reversing resistance to chemo-immunotherapy. This study highlights a positive role of IL-1β in lung cancer treatment and suggests that enhancing IL-1β production at the tumor site can overcome resistance to chemo-immunotherapy.

**中文摘要译文：**
许多非小细胞肺癌（NSCLC）患者对当前的标准治疗方案（包括化疗和以抗PD-1/PD-L1抗体为代表的免疫检查点抑制剂）无应答。尽管已知白细胞介素（IL）-1β在人类和小鼠中会促进肺癌生长，但我们在此项研究中发现，在小鼠肺癌模型中，施用或过表达IL-1β能够克服对经典化学免疫疗法（顺铂/培美曲塞/抗PD-1）的耐药性。IL-1β的抗肿瘤效应依赖于癌细胞源性的CXCL10，后者介导CD8+ T细胞在肿瘤部位的招募。在肺癌细胞中，硫氧还蛋白相互作用蛋白（TXNIP）诱导线粒体DNA（mtDNA）释放到胞质溶胶中，从而激活黑色素瘤缺失蛋白2（AIM2）炎症小体，进而触发IL-1β和CXCL10的分泌，最终逆转化学免疫治疗的耐药性。我们研究结果的临床相关性得到了患者肿瘤转录组分析的支持，该分析表明IL1B、IL1R1、AIM2和/或TXNIP的高表达与NSCLC患者对免疫治疗更好的应答相关。此外，药物筛选发现MEK和MDM2抑制剂作为TXNIP表达的诱导剂，能够逆转化学免疫治疗的耐药性。本研究强调了IL-1β在肺癌治疗中的积极作用，并提出增强肿瘤部位的IL-1β生成可以克服对化学免疫治疗的耐药性。

### 第二部分 AI 大师评价

本研究旨在探讨IL-1β在克服非小细胞肺癌（NSCLC）化学免疫治疗耐药中的作用。研究通过小鼠模型、患者肿瘤转录组分析及药物筛选，关键性地发现了一条由TXNIP诱导线粒体DNA释放、激活AIM2炎症小体，进而分泌IL-1β和CXCL10以招募CD8+ T细胞的信号通路。此项工作的创新之处在于揭示了传统上被认为促癌的IL-1β在特定情境下具有抗肿瘤的积极作用，不仅为理解和逆转治疗耐药性提供了新的分子机制，还指出了MEK和MDM2抑制剂作为潜在的增敏药物，具有重要的临床转化潜力。

---

## 25. 不同种族复发/难治性多发性骨髓瘤患者接受CAR T细胞治疗的疗效：一项多中心真实世界研究。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271645](https://pubmed.ncbi.nlm.nih.gov/41271645)
**期刊：** Blood cancer journal
**PMID：** 41271645
**DOI：** 10.1038/s41408-025-01419-1

### 第一部分 原文与翻译

**英文原标题：** Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究旨在通过一项多中心的真实世界数据，探讨不同种族背景的复发/难治性多发性骨髓瘤患者在接受CAR T细胞治疗后的疗效是否存在差异。其价值在于聚焦于种族因素对这一前沿疗法在真实世界中应用效果的影响，对于揭示潜在的健康不平等问题、优化临床决策具有重要的社会与临床意义。由于暂无摘要，本研究的具体发现和结论尚不明确，但其研究方向为精准医疗和健康公平性领域提供了新的视角。

---

## 26. 美国结外边缘区淋巴瘤患者的部位特异性预后及时间趋势分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271637](https://pubmed.ncbi.nlm.nih.gov/41271637)
**期刊：** Blood cancer journal
**PMID：** 41271637
**DOI：** 10.1038/s41408-025-01424-4

### 第一部分 原文与翻译

**英文原标题：** Site-specific prognosis and temporal trends in extranodal marginal zone lymphoma patients in the United States.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究旨在分析美国结外边缘区淋巴瘤（EMZL）患者的部位特异性预后，并探讨其随时间变化的趋势。研究可能利用了大型流行病学数据库（如SEER），对不同原发部位的患者生存数据和发病趋势进行了回顾性分析。其核心价值在于为临床医生提供了基于真实世界数据的证据，有助于根据肿瘤累及部位对患者进行更精准的风险分层和预后判断，从而指导个体化治疗决策。尽管缺乏摘要信息，但这类研究对于理解EMZL的疾病异质性和优化管理策略具有重要的临床指导意义。

---

## 27. UCHL3耗竭通过ENO1泛素化调节AKT/CCND1信号轴，从而抑制胃癌进展并增强帕博西尼的敏感性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271634](https://pubmed.ncbi.nlm.nih.gov/41271634)
**期刊：** Cell death & disease
**PMID：** 41271634
**DOI：** 10.1038/s41419-025-08153-3

### 第一部分 原文与翻译

**英文原标题：** UCHL3 depletion inhibits gastric cancer progression and enhances palbociclib sensitivity by regulating the AKT/CCND1 signaling axis via ENO1 ubiquitination.

**英文摘要原文：**
Ubiquitin carboxyl-terminal hydrolase L3 (UCHL3) is a deubiquitinating enzyme involved in various cancers, yet its role in gastric cancer (GC) requires further exploration. This study primarily investigates the expression, function, and mechanisms of UCHL3 in GC. Clinical samples and bioinformatics analysis indicated that UCHL3 is overexpressed in GC tissues compared to adjacent normal tissues, with higher expression levels correlating with worse prognosis. Functional assays demonstrated that UCHL3 promotes GC cell proliferation, invasion, and migration, accelerates cell cycle progression, and induces epithelial-mesenchymal transition (EMT). In vivo studies using a cell line-derived xenograft (CDX) model confirmed that UCHL3 enhances GC proliferation, and its therapeutic potential was validated in patient-derived xenografts (PDX). Mechanistically, transcriptomic analysis and validation experiments identified the AKT/CCND1 signaling pathway as a key mediator of UCHL3-driven GC progression. Co-immunoprecipitation (Co-IP) and liquid chromatography-mass spectrometry identified potential UCHL3-binding proteins, notably the AKT activator ENO1. Molecular docking simulations, Co-IP, and GST-pull down assays further confirmed the interaction, mapping the binding regions between UCHL3 (AA 179-230) and ENO1 (AA 140-434). Cycloheximide (CHX) and in vivo ubiquitination assays demonstrated that UCHL3 deubiquitinates and stabilizes ENO1, thus extending its half-life, while UCHL3 inhibition produced the opposite effect. A C95A point mutation significantly impaired UCHL3's deubiquitination function on ENO1. Further studies revealed UCHL3 removes K48-linked polyubiquitin chains from ENO1 at lysine 92, activating the AKT/CCND1 signaling pathway. In addition, the small-molecule inhibitor TCID, specific for UCHL3, inhibited this deubiquitination, counteracting pro-tumorigenic effects. In vitro and in vivo experiments demonstrated that TCID increased the sensitivity of GC cells to CDK4/6 inhibitors palbociclib. These findings suggest that UCHL3 contributes to GC progression and represents a promising therapeutic target for GC treatment.

**中文摘要译文：**
泛素羧基末端水解酶L3（UCHL3）是一种参与多种癌症的去泛素化酶，但其在胃癌（GC）中的作用有待进一步探索。本研究主要探讨UCHL3在胃癌中的表达、功能及其作用机制。临床样本和生物信息学分析表明，与癌旁正常组织相比，UCHL3在胃癌组织中过表达，且其高表达水平与较差的预后相关。功能性实验证明，UCHL3促进胃癌细胞的增殖、侵袭和迁移，加速细胞周期进程，并诱导上皮-间质转化（EMT）。使用细胞源性异种移植（CDX）模型的体内研究证实了UCHL3能增强胃癌的增殖能力，其治疗潜力在患者源性异种移植物（PDX）中也得到了验证。机制上，转录组学分析和验证性实验确定了AKT/CCND1信号通路是UCHL3驱动胃癌进展的关键介导者。免疫共沉淀（Co-IP）和液相色谱-质谱联用技术鉴定出潜在的UCHL3结合蛋白，特别是AKT激活剂ENO1。分子对接模拟、Co-IP和GST pull-down实验进一步证实了二者的相互作用，并确定了UCHL3（氨基酸179-230）与ENO1（氨基酸140-434）之间的结合区域。环己酰亚胺（CHX）实验和体内泛素化实验表明，UCHL3通过去泛素化稳定ENO1，从而延长其半衰期，而抑制UCHL3则产生相反效果。C95A位点突变显著削弱了UCHL3对ENO1的去泛素化功能。进一步研究揭示，UCHL3移除了ENO1上赖氨酸92位点的K48连接的多聚泛素链，从而激活了AKT/CCND1信号通路。此外，针对UCHL3的小分子抑制剂TCID能够抑制这一去泛素化过程，从而抵消其促癌效应。体内外实验证明，TCID能增加胃癌细胞对CDK4/6抑制剂帕博西尼的敏感性。这些发现表明，UCHL3促进了胃癌的进展，并可能成为胃癌治疗的一个有前景的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明去泛素化酶UCHL3在胃癌中的作用及分子机制。研究综合运用了临床样本分析、体内外功能实验及蛋白质组学等方法，关键发现是UCHL3通过去泛素化并稳定ENO1，进而激活AKT/CCND1信号通路，从而促进胃癌进展。此项工作的创新性在于揭示了“UCHL3-ENO1-AKT/CCND1”这一全新的调控轴，不仅为理解胃癌的发病机制提供了新视角，更重要的是，其为靶向UCHL3作为胃癌治疗新策略，特别是与CDK4/6抑制剂（如帕博西尼）联合用药，提供了坚实的实验依据和转化潜力。

---

## 28. 营养胁迫使RRN3从rRNA转录转向调控卵巢癌中自噬相关mRNA的选择性多聚腺苷酸化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271632](https://pubmed.ncbi.nlm.nih.gov/41271632)
**期刊：** Cell death & disease
**PMID：** 41271632
**DOI：** 10.1038/s41419-025-08142-6

### 第一部分 原文与翻译

**英文原标题：** Nutrient stress diverts RRN3 from rRNA transcription to alternative polyadenylation of autophagy mRNAs in ovarian cancer.

**英文摘要原文：**
Stress-induced alternative processing of mRNA is emerging as an essential mechanism to drive almost every hallmark of cancer. Through a genome-wide screening based on an abnormal transcriptional readthrough event favoring the malignant progression of ovarian carcinoma (OC), we identified novel mRNA processing regulators including RRN3, an essential factor for the transcriptional initiation of rRNA. The long-read RNA sequencing and PAR-CLIP analyses revealed that RRN3 was involved in the usage of alternative polyadenylation (APA) sites, resulting in the altered stability of autophagy-related mRNAs. More interestingly, we discovered that nutrient-deprivation-induced phosphorylation of RRN3 at serine 199 was sufficient to divert RRN3 out of the nucleolus to the nuclear plasma, where RRN3 regulated the APA of autophagy mRNAs, such as OPTN, to enhance their stability and eventually promoted autophagy. Further in vivo experiments showed that nutrient-stress-triggered switch of RRN3 from rRNA transcription to APA regulation was essential for the growth and dissemination of OC in mice.

**中文摘要译文：**
应激诱导的mRNA选择性加工正成为驱动几乎所有癌症特征的一个关键机制。通过一次基于异常转录通读事件（该事件促进卵巢癌（OC）恶性进展）的全基因组筛选，我们鉴定出包括RRN3在内的多种新型mRNA加工调控因子，其中RRN3是rRNA转录起始的必需因子。长读长RNA测序和PAR-CLIP分析显示，RRN3参与了选择性多聚腺苷酸化（APA）位点的使用，从而导致自噬相关mRNA稳定性的改变。更有趣的是，我们发现营养剥夺诱导的RRN3丝氨酸199位点磷酸化足以使其从核仁转移至核质，进而在核质中调控如OPTN等自噬相关mRNA的APA过程，以增强其稳定性并最终促进自噬。进一步的体内实验表明，营养胁迫触发的RRN3功能（从rRNA转录到APA调控）转换，对小鼠体内卵巢癌的生长和播散至关重要。

### 第二部分 AI 大师评价

本研究旨在探究RRN3在营养胁迫下对卵巢癌恶性进展的调控机制。研究团队综合运用全基因组筛选、长读长测序及体内外实验，关键性地发现营养胁迫能诱导RRN3磷酸化并发生核内定位转移，使其功能从经典的rRNA转录切换至调控自噬相关mRNA的选择性多聚腺苷酸化（APA），进而促进肿瘤存活。此项工作创新性地揭示了RRN3作为营养感受器和RNA加工调控因子的双重角色，阐明了肿瘤细胞应对微环境压力的全新分子机制，为卵巢癌的治疗提供了RRN3-APA-自噬轴这一潜在新靶点。

---

## 29. 活化的蛋白C通过释放肿瘤细胞外囊泡和转移microRNA-200a促进人肺癌进展。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271627](https://pubmed.ncbi.nlm.nih.gov/41271627)
**期刊：** Cell death & disease
**PMID：** 41271627
**DOI：** 10.1038/s41419-025-08173-z

### 第一部分 原文与翻译

**英文原标题：** Activated protein C promotes human lung cancer progression through the release of tumor extracellular vesicles and transfer of microRNA-200a.

**英文摘要原文：**
Blood coagulation and cancer are intricately related. Hypercoagulation associated with cancer leads to aberrant thrombin generation, which contributes to thrombosis. Thrombin also activates anticoagulant protein C and the activated protein C (aPC), in addition to regulating the coagulation pathway, it also elicits cell signaling by binding to endothelial cell protein C receptor (EPCR) and activating protease-activated receptor 1 (PAR1)-mediated cell signaling. Earlier studies showed that aPC promotes lung adenocarcinoma survival and metastasis. However, the underlying mechanism remains largely unknown. Our present study provides mechanistic insight into how aPC promotes lung adenocarcinoma survival, metastasis, and drug resistance. Our study shows that aPC, through EPCR-PAR1-driven activation of RhoA-ROCKII-JNK1/2-MLC2 signaling, triggers extracellular vesicle (EV) release from lung adenocarcinoma cells. aPC-EVs, via the transfer of microRNA (miR)-200a, promote proliferation, migration, and invasion of normal lung epithelial cells. They also confer resistance to lung cancer against chemotherapeutic agents. Inhibition of miR-200a functions through the incorporation of anti-miR-200a abrogates aPC-EVs-mediated tumorigenic effects. Furthermore, loading miR-200a mimic into control EVs showed similar phenotypic responses to that of aPC-EVs. miR-200a is shown to target SOX17 in the recipient cells, leading to tumorigenesis. miR-200a upregulation and SOX17 downregulation are consistently observed in lung cancer tissues in the UALCAN portal database of clinical specimens. Consistent with these findings, our in vivo studies in BALB/c nude mice showed that aPC-EVs from lung cancer cells promote tumor growth, metastasis, and drug resistance through miR-200a transfer. Targeting EV biogenesis, EV's miR-200a, and/or EV uptake mechanisms may offer novel therapeutic strategies in limiting lung tumorigenesis, thereby increasing patients' survival.

**中文摘要译文：**
血液凝固与癌症密切相关。与癌症相关的高凝状态导致异常的凝血酶生成，从而引发血栓形成。凝血酶除了调节凝血途径外，还激活抗凝血的蛋白C，而活化的蛋白C（aPC）通过与内皮细胞蛋白C受体（EPCR）结合并激活蛋白酶激活受体1（PAR1）介导的细胞信号传导来引发细胞信号效应。早期研究表明，aPC能促进肺腺癌的生存和转移。然而，其潜在机制在很大程度上仍然未知。我们当前的研究为aPC如何促进肺腺癌的生存、转移和耐药性提供了机制性的见解。我们的研究表明，aPC通过EPCR-PAR1驱动的RhoA-ROCKII-JNK1/2-MLC2信号通路激活，触发肺腺癌细胞释放细胞外囊泡（EV）。由aPC诱导的细胞外囊泡（aPC-EVs）通过转移microRNA（miR）-200a，促进正常肺上皮细胞的增殖、迁移和侵袭。它们还赋予肺癌细胞对化疗药物的抗性。通过整合anti-miR-200a来抑制miR-200a的功能，可以消除aPC-EVs介导的致瘤效应。此外，将miR-200a模拟物加载到对照EVs中，也显示出与aPC-EVs相似的表型反应。研究表明，miR-200a在受体细胞中靶向SOX17，从而导致肿瘤发生。在UALCAN门户网站的临床标本数据库中，肺癌组织中一致性地观察到miR-200a的上调和SOX17的下调。与这些发现一致，我们在BALB/c裸鼠中的体内研究表明，来自肺癌细胞的aPC-EVs通过转移miR-200a促进肿瘤生长、转移和耐药性。靶向EV的生物发生、EV中的miR-200a和/或EV的摄取机制，可能为限制肺部肿瘤发生、从而提高患者生存率提供新的治疗策略。

### 第二部分 AI 大师评价

本研究旨在揭示活化的蛋白C（aPC）促进肺腺癌进展的具体分子机制。研究综合运用了细胞实验、裸鼠体内模型及临床数据库分析，发现aPC通过EPCR-PAR1信号通路促使肺癌细胞释放富含miR-200a的细胞外囊泡（EVs）。这些EVs能将miR-200a转移至受体细胞，通过靶向抑制SOX17，从而增强肿瘤的增殖、转移及耐药性。该研究的创新之处在于阐明了凝血系统通过细胞外囊泡介导的miRNA转移来调控肿瘤微环境的新途径，不仅深化了对肺癌进展机制的理解，也为开发针对EVs或miR-200a的抗癌疗法提供了重要的理论依据和潜在靶点。

---

## 30. 一种基于质谱的策略实现了对糖尿病性白内障患者泪液中特征代谢物的鉴定

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271624](https://pubmed.ncbi.nlm.nih.gov/41271624)
**期刊：** Nature communications
**PMID：** 41271624
**DOI：** 10.1038/s41467-025-65082-7

### 第一部分 原文与翻译

**英文原标题：** A mass spectrometry-based strategy allows signature metabolite identification in tear fluid from people with diabetic cataracts.

**英文摘要原文：**
Metabolic biomarker discovery in trace body fluids remains a significant challenge, toward molecular diagnosis and pathology studies in many diseases. Especially for eye-related diseases, such an approach based on non-invasive tear fluids remains an unsatisfied urgent need in ophthalmology. Here we construct a metabolic biomarker panel from 10 nL of tear fluids in seconds using nanoparticle-enhanced laser desorption/ionization -mass spectrometry (MS), which achieves an area under the curve of 0.923 for discriminating diabetic cataracts from alone age-related cataracts. Importantly, we integrate liquid chromatography -MS into the above analysis process to construct an integrated strategy, allowing reliable metabolite annotation by nanoliter sample volume without compromising high throughput. Further, using matched aqueous humors, we identify 1,5-anhydroglucitol as a biomarker of diabetic cataracts, revealing its protective effect against high glucose-induced lens oxidative stress and opacification, as a demonstration of the metabolic reprogramming. Our approach can be universally applied to uncover biomarkers using trace body fluid, promising next-generation metabolic reprogramming identification.

**中文摘要译文：**
在痕量体液中发现代谢生物标志物，对于许多疾病的分子诊断和病理学研究而言，仍然是一个重大挑战。特别是在眼科疾病领域，基于无创性泪液的此类方法仍是眼科一个未被满足的迫切需求。本研究中，我们利用纳米颗粒增强激光解吸/电离质谱（MS）技术，在数秒内从10纳升的泪液中构建了一个代谢生物标志物组合，其在区分糖尿病性白内障与单纯年龄相关性白内障方面的曲线下面积达到了0.923。重要的是，我们将液相色谱-质谱联用技术整合到上述分析流程中，构建了一套集成策略，从而能够在不牺牲高通量的前提下，利用纳升级样本量实现可靠的代谢物注释。此外，通过使用匹配的房水样本，我们鉴定出1,5-脱水葡糖醇是糖尿病性白内障的一个生物标志物，并揭示了其在高糖诱导的晶状体氧化应激和浑浊过程中的保护作用，以此证明了代谢重编程的存在。我们的方法具有普适性，可应用于利用痕量体液发现生物标志物，为下一代代谢重编程的鉴定提供了前景。

### 第二部分 AI 大师评价

本研究旨在利用极微量泪液，开发一种快速、无创的糖尿病性白内障代谢生物标志物鉴定新方法。研究团队创新性地结合了纳米颗粒增强激光解吸/电离质谱与液相色谱-质谱技术，成功从仅10纳升的泪液中构建了能高效区分糖尿病性与年龄相关性白内障的标志物组合。该研究不仅鉴定出关键保护性代谢物1,5-脱水葡糖醇，更重要的是，其建立的超灵敏分析策略为眼科疾病的早期诊断和利用痕量体液进行生物标志物研究开辟了新途径，具有巨大的临床转化潜力。

---

## 31. 拓扑异构酶IIb的结合描绘了癌症基因组中的局部突变过程和驱动突变

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271620](https://pubmed.ncbi.nlm.nih.gov/41271620)
**期刊：** Nature communications
**PMID：** 41271620
**DOI：** 10.1038/s41467-025-65005-6

### 第一部分 原文与翻译

**英文原标题：** Topoisomerase IIb binding delineates localized mutational processes and driver mutations in cancer genomes.

**英文摘要原文：**
Type-II topoisomerases resolve topological stress in DNA through double-strand breaks. While topoisomerases are chemotherapy targets linked to therapy-related genotoxicity, TOP2B is uniquely positioned to influence mutagenesis through its activity in non-dividing cells and sensitivity to topoisomerase poisons. To investigate this, we generated DNA-binding maps of TOP2B, CTCF, and RAD21 in human cancer samples and analyzed these for driver mutations and mutational processes across 6500 whole cancer genomes. TOP2B-CTCF-RAD21 and TOP2B-RAD21 sites are enriched in somatic mutations and structural variants, particularly at sites with evolutionary conservation, high transcription and long-range chromatin interactions. TOP2B binds driver genes such as TP53, MYC, FOXA1, and VHL, and many frequently mutated non-coding regions. We show that one non-coding TOP2B-bound element at the non-coding RNA gene RMRP drives tumor initiation and growth in vivo. Our study highlights TOP2B as a safeguard of genome integrity and a marker of mutational processes and hotspots in cancer, underscoring implications for cancer genomics research.

**中文摘要译文：**
II型拓扑异构酶通过产生双链断裂来解决DNA的拓扑应力。虽然拓扑异构酶是与治疗相关的遗传毒性有关的化疗靶点，但TOP2B因其在非分裂细胞中的活性以及对拓扑异构酶毒物的敏感性，在影响诱变方面具有独特定位。为探究这一点，我们在人类癌症样本中生成了TOP2B、CTCF和RAD21的DNA结合图谱，并在6500个全癌症基因组中分析了这些图谱中的驱动突变和突变过程。TOP2B-CTCF-RAD21和TOP2B-RAD21位点富集了体细胞突变和结构变异，尤其是在具有进化保守性、高转录水平和长程染色质相互作用的位点。TOP2B结合了TP53、MYC、FOXA1和VHL等驱动基因，以及许多频繁突变的非编码区。我们证明，位于非编码RNA基因RMRP处的一个与TOP2B结合的非编码元件可在体内驱动肿瘤的发生和生长。我们的研究强调，TOP2B是基因组完整性的守护者，也是癌症中突变过程和突变热点的标志，这突显了其对癌症基因组学研究的意义。

### 第二部分 AI 大师评价

本研究旨在阐明拓扑异构酶IIb（TOP2B）在癌症基因组突变过程及驱动突变形成中的作用。研究团队通过绘制TOP2B、CTCF和RAD21在癌症样本中的DNA结合图谱，并结合对6500个全基因组的分析，创新性地揭示了TOP2B结合位点是体细胞突变和结构变异的热点区域，尤其与关键驱动基因（如TP53、MYC）和功能性非编码区紧密相关。此项工作不仅深化了我们对突变起源机制的理解，还将TOP2B定位为基因组完整性的守护者和突变过程的标志物，为癌症基因组学研究和潜在治疗靶点的发现提供了重要的新视角。

---

## 32. 解析多发性骨髓瘤与意义未明单克隆丙种球蛋白血症患者的骨髓血浆蛋白质组

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271617](https://pubmed.ncbi.nlm.nih.gov/41271617)
**期刊：** Blood cancer journal
**PMID：** 41271617
**DOI：** 10.1038/s41408-025-01417-3

### 第一部分 原文与翻译

**英文原标题：** Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究旨在通过蛋白质组学技术，系统性地解析并定义多发性骨髓瘤（MM）及其癌前病变——意义未明的单克隆丙种球蛋白血症（MGUS）患者骨髓微环境中的血浆蛋白质全貌。研究的核心价值在于，通过直接检测病变发生的局部环境（骨髓血浆），有望发现与疾病发生、发展及恶性转化直接相关的关键蛋白标志物。这些发现可能为区分MGUS与早期MM、预测MGUS的进展风险以及开发新的治疗靶点提供重要的分子生物学基础。由于摘要缺失，本研究的具体方法学、样本量及关键发现尚不明确，但其研究方向对于深化理解骨髓瘤发病机制具有重要意义。

---

## 33. HIV-1包膜三聚体疫苗诱导的抗体应答存在性别差异：一项1期临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271616](https://pubmed.ncbi.nlm.nih.gov/41271616)
**期刊：** Nature communications
**PMID：** 41271616
**DOI：** 10.1038/s41467-025-65101-7

### 第一部分 原文与翻译

**英文原标题：** HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial.

**英文摘要原文：**
A protective vaccine will be the most powerful instrument to reduce HIV-1 infections worldwide and help bring about a lasting end to the AIDS epidemic. The single centre, randomised, open-label, uncontrolled, phase 1 ACTHIVE-001 clinical trial (NCT03961438) aims to assess the safety and immunogenicity of the ConM SOSIP.v7 native-like trimer protein vaccine, based on an HIV-1 group M consensus sequence, in HIV-negative adults. Twenty-four individuals were enrolled to receive three dosages of ConM SOSIP.v7 protein vaccine in a liposome formulation containing a high dose of the TLR4-agonist MPLA. The primary outcome is vaccine reactogenicity, whereas the main secondary outcome is binding and neutralising antibody responses. Overall, the vaccine is safe and well-tolerated. Furthermore, the vaccine elicits robust strain-specific binding and neutralising antibody responses in nearly all vaccinees. Post-hoc exploratory analyses demonstrate that female-born participants have 22- and 6-fold higher neutralisation titres after the second and third vaccination, respectively. The vaccine adjuvant induces higher levels of IL-6 secretion from in vitro cultured monocytes from female compared to male participants, providing a possible mechanistic explanation for the sex-based differences. Our study highlights the need to take sex-based differences into consideration when assessing HIV-1 vaccine candidates and adjuvants.

**中文摘要译文：**
预防性疫苗将是减少全球HIV-1感染、助力最终终结艾滋病流行的最有力工具。这项单中心、随机、开放标签、无对照的1期ACTHIVE-001临床试验（NCT03961438）旨在评估基于HIV-1 M组共识序列的ConM SOSIP.v7天然样三聚体蛋白疫苗在HIV阴性成年人中的安全性和免疫原性。共24名受试者入组，接受了三剂ConM SOSIP.v7蛋白疫苗，该疫苗采用含有高剂量TLR4激动剂MPLA的脂质体制剂。主要结局是疫苗的反应原性，而主要次要结局是结合抗体和中和抗体的应答水平。总体而言，该疫苗安全且耐受性良好。此外，该疫苗在几乎所有接种者中都诱导了强有力的病毒株特异性结合抗体和中和抗体应答。事后探索性分析表明，在第二次和第三次疫苗接种后，生理性别为女性的参与者的中和抗体滴度分别高出22倍和6倍。该疫苗佐剂能诱导来自女性参与者的体外培养单核细胞分泌更高水平的IL-6，这为性别差异提供了一种可能的机制解释。我们的研究强调，在评估HIV-1候选疫苗和佐剂时，需要考虑性别差异。

### 第二部分 AI 大师评价

本研究通过一项1期临床试验，评估了新型HIV-1候选疫苗ConM SOSIP.v7的安全性和免疫原性。研究的关键发现不仅在于证实了该疫苗安全且能诱导强大的抗体应答，更在于其通过事后分析揭示了显著的性别差异——女性接种者的中和抗体水平远高于男性，并初步探讨了IL-6介导的潜在免疫机制。此项发现极具临床和科研价值，它强调了在未来疫苗研发与评估中必须将性别作为关键生物学变量，对优化疫苗免疫策略具有重要的指导意义。

---

## 34. HNRNPA2B1通过靶向乳酸/铁死亡赋予非小细胞肺癌免疫逃逸能力

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271615](https://pubmed.ncbi.nlm.nih.gov/41271615)
**期刊：** Cell death & disease
**PMID：** 41271615
**DOI：** 10.1038/s41419-025-08232-5

### 第一部分 原文与翻译

**英文原标题：** HNRNPA2B1 confers immune escape of non-small cell lung cancer through targeting lactate/ferroptosis.

**英文摘要原文：**
Immune escape and ferroptosis resistance contribute to non-small cell lung cancer (NSCLC) carcinogenesis. This study aimed to investigate the role of N-methyladenosine (mA) reader heterogeneous nuclear ribonucleoprotein A2B1 (HNRNPA2B1) in NSCLC immune escape and ferroptosis resistance. HNRNPA2B1 expression was clinically elevated both in the NSCLC samples and single-cell transcriptome sequencing (scRNA-Seq). In vitro co-culture with activated CD8 T cells, HNRNPA2B1 high-expression hampered the CD8 T cell-mediated killing effect and accelerated the immune escape. Besides, the enforced HNRNPA2B1 high-expression alleviated the ferroptosis. Furthermore, HNRNPA2B1 targeted the LDHA mRNA mA modified site to enhance LDHA mRNA stability and lactate accumulation, thereby assisted NSCLC cells to evade CD8 T antitumor immunity and reduced IFN-γ secretion by CD8 T. Furthermore, IFN-γ could stimulate ferroptosis of NSCLC cells. Taken together, these findings revealed an important role for HNRNPA2B1 on NSCLC immune escape and ferroptosis resistance, which provided novel insight into mA modification in NSCLC.

**中文摘要译文：**
免疫逃逸和铁死亡抵抗促进了非小细胞肺癌（NSCLC）的发生发展。本研究旨在探讨N-甲基腺苷（mA）阅读蛋白异质性核糖核蛋白A2B1（HNRNPA2B1）在NSCLC免疫逃逸和铁死亡抵抗中的作用。在NSCLC样本和单细胞转录组测序（scRNA-Seq）中，HNRNPA2B1的表达在临床上均呈升高趋势。在与活化的CD8+ T细胞进行的体外共培养实验中，HNRNPA2B1的高表达抑制了CD8+ T细胞介导的杀伤效应，并加速了免疫逃逸。此外，强制高表达HNRNPA2B1减轻了铁死亡。进一步研究发现，HNRNPA2B1靶向LDHA mRNA的mA修饰位点，以增强LDHA mRNA的稳定性并促进乳酸积累，从而帮助NSCLC细胞逃避CD8+ T细胞的抗肿瘤免疫，并减少CD8+ T细胞分泌IFN-γ。此外，IFN-γ可刺激NSCLC细胞的铁死亡。综上所述，这些发现揭示了HNRNPA2B1在NSCLC免疫逃逸和铁死亡抵抗中的重要作用，为理解mA修饰在NSCLC中的机制提供了新的见解。

### 第二部分 AI 大师评价

本研究聚焦于非小细胞肺癌（NSCLC）领域，旨在揭示RNA N-甲基腺苷（mA）阅读蛋白HNRNPA2B1在介导肿瘤免疫逃逸和铁死亡抵抗中的关键作用。研究综合运用临床样本分析、单细胞测序及体外功能实验，发现HNRNPA2B1通过稳定LDHA mRNA并促进乳酸积累，进而抑制CD8+ T细胞的抗肿瘤功能，并降低细胞对铁死亡的敏感性。该研究的创新之处在于，它清晰地将mA修饰、肿瘤代谢（乳酸）与免疫微环境（免疫逃逸与铁死亡）三者联系起来，阐明了一条全新的调控通路，为NSCLC的治疗提供了潜在的新靶点和理论依据。

---

## 35. 基于模拟氧化还原酶的层状双金属氢氧化物（LDHs）的先进治疗方法

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271593](https://pubmed.ncbi.nlm.nih.gov/41271593)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41271593
**DOI：** 10.1002/advs.202519115

### 第一部分 原文与翻译

**英文原标题：** Advanced Therapeutic Approach Based on LDHs-Mimetic Oxidoreductase.

**英文摘要原文：**
Redox dysregulation is recognized as a key driver in the pathophysiology of numerous refractory diseases, contributing significantly to the progression and poor prognosis. The precise targeting and sophisticated modulation of redox processes within pathological microenvironments thus offer a promising avenue for innovative therapeutic strategies. Layered double hydroxides (LDHs)-based nanozyme lies in the programmable multi-active site architecture, which enables unprecedented functional integration for precise pathological microenvironment remodeling. In this review, the redox modulating mechanisms of LDHs-based nanozyme in these critical disease contexts are systematically explored, with special emphasis on intrinsic enzyme-like activities and structure-activity relationships. At the same time, it highlights how designing LDHs-based nanozyme can manipulate redox homeostasis to precisely reprogram the pathological microenvironment for stimulating effective, context-dependent pro- and anti-inflammatory therapeutic outcomes, which is a crucial requirement in conditions such as tumors and tissue injury. Finally, building upon recent advances, a forward-looking perspective is provided on the current challenges and future research directions in this rapidly progressing field.

**中文摘要译文：**
氧化还原失调被认为是多种难治性疾病病理生理学中的关键驱动因素，并显著影响疾病的进展和不良预后。因此，对病理微环境中的氧化还原过程进行精确靶向和精细调控，为创新性治疗策略提供了一条有前景的途径。基于层状双金属氢氧化物（LDHs）的纳米酶的优势在于其可编程的多活性位点结构，该结构能够实现前所未有的功能整合，从而精确重塑病理微环境。本综述系统探讨了基于LDHs的纳米酶在这些关键疾病背景下的氧化还原调节机制，并特别强调了其固有的类酶活性和构效关系。同时，本综述还重点阐述了如何通过设计基于LDHs的纳米酶来操控氧化还原稳态，以精确重编程病理微环境，从而在肿瘤和组织损伤等情况下，根据具体情境激发有效的促炎或抗炎治疗效果，而这正是此类疾病治疗的关键需求。最后，基于最新研究进展，本文对这一快速发展领域当前面临的挑战和未来的研究方向提出了前瞻性展望。

### 第二部分 AI 大师评价

该综述系统阐述了基于层状双金属氢氧化物（LDHs）的纳米酶作为一种先进治疗策略的潜力。文章核心聚焦于这类材料如何模拟天然氧化还原酶，通过其可编程的多活性位点结构来精确调控疾病的氧化还原微环境。作者不仅总结了其在肿瘤、组织损伤等难治性疾病中的应用前景，还深入探讨了其构效关系，为开发新型、精准的氧化还原调节疗法提供了重要的理论依据和方向，对于推动纳米医学与材料科学的交叉融合具有显著的参考价值。

---

## 36. 一种用于癌症疫苗的合理设计的靶向脾脏的单组分脂质-mRNA复合物 (OncoLRC)

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271591](https://pubmed.ncbi.nlm.nih.gov/41271591)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41271591
**DOI：** 10.1002/advs.202512535

### 第一部分 原文与翻译

**英文原标题：** A Rationally Engineered Spleen-Tropic One-Component Lipid-mRNA Complex (OncoLRC) for Cancer Vaccines.

**英文摘要原文：**
mRNA vaccines offer great potential for cancer immunotherapy, yet efficient delivery of antigen-encoding mRNA to antigen-presenting cells (APCs) in lymphoid organs remains a significant challenge. Here, OncoLRC is introduced, a rationally engineered, spleen-tropic, one-component lipid-mRNA complex that selectively delivers mRNA to splenic APCs following systemic administration. Through a systemic screening and optimization process, a dimethylamino (DMA)-lipidoid-based OncoLRC formulation that achieves nearly exclusive spleen-targeting mRNA delivery, outperforming its conventional four-component lipid nanoparticle (LNP) formulation counterpart has been developed. Notably, OncoLRC requires a reduced lipid-to-mRNA weight ratio of 1.5:1 compared to the typical 10:1 ratio in standard LNPs. OncoLRC formulated with ovalbumin (OVA) mRNA (OncoLRC) promotes dendritic cell (DC) maturation and activation, eliciting robust antigen-specific immune responses. Mechanistic studies suggest that splenic delivery is mediated primarily via macropinocytosis. Moreover, OncoLRC enhances the secretion of endogenous cytokines such as IL-12, further stimulating T cell activation and cytotoxic activity. In the B16F10-OVA cold tumor model, OncoLRC demonstrates strong prophylactic antitumor efficacy and exhibits a profound synergistic effect when combined with immune checkpoint blockade therapy, leading to significant tumor growth inhibition. Collectively, our findings establish OncoLRC as a simple yet effective APC-targeted mRNA delivery platform, highlighting its potential as a next-generation mRNA cancer vaccine system.

**中文摘要译文：**
mRNA疫苗在癌症免疫治疗中展现出巨大潜力，然而，将编码抗原的mRNA高效递送至淋巴器官中的抗原呈递细胞（APC）仍然是一个重大挑战。在此，我们介绍了一种名为OncoLRC的合理设计的、具有脾脏趋向性的单组分脂质-mRNA复合物，该复合物在全身给药后能选择性地将mRNA递送至脾脏APC。通过系统的筛选和优化过程，我们开发出一种基于二甲氨基（DMA）类脂的OncoLRC制剂，该制剂实现了几乎专一的脾脏靶向mRNA递送，其性能优于传统的四组分脂质纳米颗粒（LNP）制剂。值得注意的是，与标准LNP中典型的10:1的脂质与mRNA重量比相比，OncoLRC所需的比例降低至1.5:1。用卵清蛋白（OVA）mRNA配制的OncoLRC能够促进树突状细胞（DC）的成熟与激活，引发强有力的抗原特异性免疫应答。机制研究表明，其脾脏递送主要通过巨胞饮作用介导。此外，OncoLRC还能增强内源性细胞因子（如IL-12）的分泌，进一步刺激T细胞的活化和细胞毒性活性。在B16F10-OVA冷肿瘤模型中，OncoLRC显示出强大的预防性抗肿瘤功效，并在与免疫检查点阻断疗法联合使用时表现出显著的协同效应，导致肿瘤生长受到明显抑制。总而言之，我们的研究结果确立了OncoLRC作为一个简单而有效的靶向APC的mRNA递送平台，凸显了其作为下一代mRNA癌症疫苗系统的潜力。

### 第二部分 AI 大师评价

本研究旨在开发一种新型mRNA癌症疫苗递送系统，以解决将mRNA高效、特异性地递送至脾脏抗原呈递细胞（APC）的难题。研究团队通过合理设计和系统筛选，成功构建了一种名为OncoLRC的单组分脂质-mRNA复合物。其关键发现是，OncoLRC不仅实现了对脾脏的高度靶向性，远超传统LNP，而且显著降低了所需的脂质剂量，从而提升了潜在的安全性。该平台在动物模型中展现出强大的抗肿瘤免疫激活能力和协同治疗效果，为开发更简单、高效的下一代mRNA癌症疫苗提供了极具前景的新策略。

---

## 37. 靶向实体瘤治疗中肿瘤相关巨噬细胞与CAR-T细胞间的动态相互作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271577](https://pubmed.ncbi.nlm.nih.gov/41271577)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41271577
**DOI：** 10.1002/advs.202515700

### 第一部分 原文与翻译

**英文原标题：** Targeting the Dynamics Between TAMs and CAR-T Cells in Solid Tumor Therapies.

**英文摘要原文：**
Although CAR T-cell therapy has transformed treatment outcomes for patients with haematological malignancies, the existing barriers in solid tumors treatment remain due to TAM immunosuppression. This review explores the work of others on the interplay between M2-like immunosuppressive TAMs and CAR-T cells in the tumor microenvironment. The ways TAMs impair the effector functions of CAR-T cells are described mediated by secretion of cytokines, immune checkpoints, metabolites, and detrimental post-translational modification. New concept therapeutic approaches are designed to these interactions for improving the efficacy of CAR-T cells in solid tumors. With an emphasis on novel strategies to counteract TAM immunosuppression, this review aims to reshape the perspective on the utility and effectiveness of CAR-T therapy in solid tumors and, consequently, extend the reach of a highly promising therapeutic approach.

**中文摘要译文：**
尽管CAR T细胞疗法已经改变了血液系统恶性肿瘤患者的治疗结局，但由于肿瘤相关巨噬细胞（TAM）的免疫抑制作用，实体瘤治疗中仍然存在障碍。这篇综述探讨了其他研究者关于肿瘤微环境中M2型免疫抑制性TAM与CAR-T细胞相互作用的研究工作。文章描述了TAM通过分泌细胞因子、免疫检查点、代谢物以及有害的翻译后修饰等方式损害CAR-T细胞效应功能的机制。针对这些相互作用，设计了新的概念性治疗方法，以提高CAR-T细胞在实体瘤中的疗效。本综述重点关注对抗TAM免疫抑制的新型策略，旨在重塑对CAR-T疗法在实体瘤中功用与效果的看法，从而扩展这一极具前景的治疗方法的应用范围。

### 第二部分 AI 大师评价

本篇综述精准聚焦于实体瘤治疗的一大核心挑战——肿瘤相关巨噬细胞（TAMs）对CAR-T细胞疗效的抑制作用。文章系统性地总结了M2型TAMs通过分泌细胞因子、免疫检查点、代谢物和翻译后修饰等多种机制削弱CAR-T细胞功能的现有研究，并梳理了旨在克服这种抑制的新兴治疗策略。其核心价值在于为研究人员提供了一个关于该领域关键问题和前沿解决方案的全景视图，为开发更有效的实体瘤CAR-T联合疗法指明了方向，对未来的临床转化研究具有重要的指导意义。

---

## 38. 靶向Notch1-YY1-ICAM1信号轴通过激活CD8+ T细胞驱动的癌细胞焦亡以增强免疫治疗在肝细胞癌中的疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271562](https://pubmed.ncbi.nlm.nih.gov/41271562)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41271562
**DOI：** 10.1002/advs.202512845

### 第一部分 原文与翻译

**英文原标题：** Targeting the Notch1-YY1-ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8 T-Cell-Driven Cancer Cell Pyroptosis.

**英文摘要原文：**
Immunotherapy has shown a modest clinical benefit in advanced hepatocellular carcinoma (HCC), probably due to tumor immunosuppressive functions. Although Notch1 signaling has been implicated in tumor immune escape, its underlying mechanism is unclear. Here, Notch1 signaling is established as a determinant of immunotherapy efficacy in HCC. Studies showed that high Notch1 expression correlates with poor progression-free survival and worse immunotherapeutic response in recurrent HCC patients, while Notch1 overexpression promotes cancer cell escape by inhibiting CD8 T cell activation. Mechanistically, Notch1 overexpression upregulates the expression of transcriptional factor YY1 (Yin-Yang 1), which in turn represses ICAM1 expression to prohibit CD8 T cell-derived granzyme-driven cancer cell pyroptosis and cytotoxicity. Finally, co-administration of a PD-L1 antibody with PEI-siYY1 represses HCC tumor growth without causing severe adverse effects, as observed with the Notch1 inhibitor DAPT. The results establish that targeting Notch1-YY1-ICAM1 signaling axis may enhance immunotherapy efficacy by activating CD8 T cell-driven cancer cell pyroptosis, providing a safe and effective treatment strategy for HCC patients.

**中文摘要译文：**
免疫治疗在晚期肝细胞癌（HCC）中显示出有限的临床益处，这可能归因于肿瘤的免疫抑制功能。尽管Notch1信号传导被认为与肿瘤免疫逃逸有关，但其潜在机制尚不清楚。本研究确定了Notch1信号传导是肝细胞癌免疫治疗疗效的一个决定因素。研究表明，在复发性肝细胞癌患者中，Notch1的高表达与较差的无进展生存期和更糟糕的免疫治疗反应相关，同时Notch1的过表达通过抑制CD8+ T细胞活化来促进癌细胞逃逸。从机制上讲，Notch1的过表达会上调转录因子YY1（阴阳因子1）的表达，而YY1则会抑制ICAM1的表达，从而阻止CD8+ T细胞来源的颗粒酶驱动的癌细胞焦亡和细胞毒性作用。最后，PD-L1抗体与PEI-siYY1的联合给药能够抑制肝细胞癌肿瘤的生长，且不会引起像Notch1抑制剂DAPT那样的严重不良反应。研究结果证实，靶向Notch1-YY1-ICAM1信号轴可能通过激活CD8+ T细胞驱动的癌细胞焦亡来增强免疫治疗的疗效，为肝细胞癌患者提供了一种安全有效的治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明Notch1信号通路在肝细胞癌（HCC）免疫逃逸中的具体机制，并探索其作为增敏免疫治疗新靶点的可行性。研究综合运用临床数据分析、分子机制探究和动物模型实验，精准定位了“Notch1-YY1-ICAM1”这一关键信号轴，并发现其通过抑制CD8+ T细胞驱动的癌细胞焦亡来削弱免疫疗效。这项工作不仅揭示了HCC免疫治疗抵抗的一个全新机制，更提出了一种靶向YY1联合PD-L1抗体的创新治疗策略，为解决当前HCC免疫治疗瓶颈提供了坚实的理论基础和具潜力的临床转化方案。

---

## 39. 巨噬细胞中胞葬作用驱动的多胺代谢促进卵巢癌化疗后癌症干细胞的富集

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41271556](https://pubmed.ncbi.nlm.nih.gov/41271556)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41271556
**DOI：** 10.1002/advs.202512508

### 第一部分 原文与翻译

**英文原标题：** Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer.

**英文摘要原文：**
Chemotherapy-induced enrichment of cancer stem cells (CSCs) is a key mechanism underlying acquired chemoresistance and recurrence of epithelial ovarian cancer (OC). Although chemotherapy may enrich CSCs through selection or by inducing dedifferentiation, the dynamic changes in the tumor niche and their impact on CSCs during chemotherapy remain unclear. In this study, single-cell sequencing and multiplex immunohistochemical analysis are used to define microenvironmental changes, and a post-chemotherapy increase in efferocytotic macrophages that phagocytosed chemotherapy-induced apoptotic tumor cells is identified. Efferocytotic macrophages are associated with poor prognosis and CSCs in OC. Their conditioned medium facilitates OC stemness in vitro. Meanwhile, targeting efferocytosis suppresses CSC enrichment, chemoresistance, and regrowth in vivo. Mechanistically, it is demonstrated that enhanced expression of ODC1 driven by efferocytosis increases polyamine flux, particularly putrescine, by integrating metabolomics and transcriptomics. The increase in putrescine content leads to the SPP1 and OPN overexpression in macrophages, conferring cancer stemness to OC cells through the OPN-CD44 axis. Treatment with an ODC1 selector inhibitor mitigates CSC enrichment, sensitizes tumors to cisplatin, and restricts tumor regrowth. Together, the study shows that efferocytosis and associated polyamine metabolic reprogramming support the chemotherapy-induced enrichment of CSCs, providing new targets for addressing chemoresistance and recurrence of OC.

**中文摘要译文：**
化疗诱导的癌症干细胞（CSCs）富集是上皮性卵巢癌（OC）获得性化疗耐药和复发的关键机制。尽管化疗可通过筛选或诱导去分化来富集CSC，但化疗期间肿瘤微环境的动态变化及其对CSC的影响尚不清楚。本研究利用单细胞测序和多重免疫组化分析来明确微环境的变化，并发现化疗后吞噬了化疗诱导的凋亡肿瘤细胞的胞葬巨噬细胞有所增加。在卵巢癌中，胞葬巨噬细胞与不良预后和CSC相关。在体外实验中，其条件培养基可促进卵巢癌细胞的干性特征。同时，在体内实验中，靶向胞葬作用可抑制CSC的富集、化疗耐药性和肿瘤再生长。从机制上讲，通过整合代谢组学和转录组学研究证明，胞葬作用驱动的ODC1表达增强，增加了多胺流，特别是腐胺的水平。腐胺含量的增加导致巨噬细胞中SPP1和OPN的过表达，并通过OPN-CD44轴赋予卵巢癌细胞癌症干性。使用ODC1选择性抑制剂治疗可减轻CSC的富集，使肿瘤对顺铂敏感，并限制肿瘤的再生长。总之，该研究表明，胞葬作用及相关的多胺代谢重编程支持化疗诱导的CSC富集，为解决卵巢癌的化疗耐药和复发问题提供了新的靶点。

### 第二部分 AI 大师评价

本研究聚焦于卵巢癌化疗后癌症干细胞（CSC）富集这一临床难题，通过单细胞测序等前沿技术，创新性地揭示了化疗诱导的巨噬细胞胞葬作用是关键驱动因素。研究的核心发现是，胞葬作用通过重编程巨噬细胞的多胺代谢（ODC1-腐胺通路），上调OPN分泌，进而通过OPN-CD44轴增强肿瘤细胞的干性。这项工作不仅深刻阐明了化疗耐药的新机制，更指出了靶向ODC1作为增敏化疗、抑制复发的潜力治疗策略，具有重要的临床转化价值。

---

## 40. 单细胞ATAC-seq的计算分析与挑战

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270791](https://pubmed.ncbi.nlm.nih.gov/41270791)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41270791
**DOI：** 10.1093/gpbjnl/qzaf115

### 第一部分 原文与翻译

**英文原标题：** Computational Analyses and Challenges of Single-cell ATAC-seq.

**英文摘要原文：**
Single-cell Assay for Transposase-Accessible Chromatin using sequencing (scATAC-seq) has emerged as a powerful technique to study cell-specific epigenetic landscapes and to provide a multidimensional portrait of gene regulation. However, low genomic coverage per cell results in intrinsic data sparsity and missing-data issues, presenting unique methodological challenges. Consequently, numerous computational methods and techniques have been developed to address these challenges. This review provides a concise overview of published workflows for scATAC-seq analysis, covering preprocessing through downstream analysis including quality control, alignment, peak calling, dimension reduction, clustering, gene regulation score calculation, cell-type annotation, and multiomics integration. Additionally, we survey key scATAC-seq databases that offer curated, accessible resources; discuss emerging deep-learning methods and Artificial Intelligence (AI) foundation models tailored to scATAC-seq data; and highlight recent advances in spatial ATAC-seq technologies and associated computational approaches. Our objective is to equip readers with a clear understanding of current scATAC-seq methodologies so they can select appropriate tools and construct customized workflows for exploring gene regulation and cellular diversity.

**中文摘要译文：**
单细胞转座酶可及性染色质测序技术（scATAC-seq）已成为研究细胞特异性表观遗传图谱和提供基因调控多维视图的一项强大技术。然而，单个细胞的基因组覆盖率较低，导致了固有的数据稀疏性和数据缺失问题，从而带来了独特的方法学挑战。因此，为应对这些挑战，学术界已开发出众多的计算方法和技术。本综述简要概述了已发表的scATAC-seq分析工作流程，涵盖了从预处理到下游分析的全过程，包括质量控制、比对、峰值检出、降维、聚类、基因调控评分计算、细胞类型注释以及多组学整合。此外，我们调研了提供精心整理且易于获取资源的关键scATAC-seq数据库；讨论了针对scATAC-seq数据新兴的深度学习方法和人工智能（AI）基础模型；并重点介绍了空间ATAC-seq技术的最新进展及相关的计算方法。我们的目标是使读者能够清晰地理解当前的scATAC-seq方法学，从而能够选择合适的工具并构建定制化的工作流程，以探索基因调控和细胞多样性。

### 第二部分 AI 大师评价

该综述全面梳理了单细胞ATAC-seq（scATAC-seq）数据分析的计算挑战与解决方案。文章系统性地总结了从数据预处理到下游多组学整合的全套分析流程，并重点介绍了深度学习、AI基础模型及新兴的空间ATAC-seq技术的应用。此文为研究人员选择分析工具和构建工作流程提供了清晰的路线图，其价值在于前瞻性地指出了人工智能与空间技术将如何重塑未来的表观遗传学研究，对该领域的初学者和资深专家均有重要的参考意义。

---

## 41. 回复：优化慢性淋巴细胞白血病临床试验的对照组：BRUIN-CLL-321试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270260](https://pubmed.ncbi.nlm.nih.gov/41270260)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41270260
**DOI：** 10.1200/JCO-25-02231

### 第一部分 原文与翻译

**英文原标题：** Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文并非一项原创性研究，而是一篇针对特定临床试验（BRUIN-CLL-321）设计的回应性文章。从标题推断，该文的核心在于探讨慢性淋巴细胞白血病（CLL）临床试验中对照组的优化选择问题，这对于确保试验的科学性、伦理性和结果的可靠性至关重要。此类学术讨论有助于推动CLL治疗领域研究方法的完善，并为未来临床试验设计提供重要参考，但由于缺乏摘要，无法深入了解其具体论点和证据。

---

## 42. 如果运动是粒药，我们都会将其开给癌症患者——但它并不是。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270257](https://pubmed.ncbi.nlm.nih.gov/41270257)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41270257
**DOI：** 10.1200/JCO-25-01649

### 第一部分 原文与翻译

**英文原标题：** If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本文献的标题极具启发性，通过一个巧妙的比喻，强调了运动对于癌症患者的巨大价值，其重要性不亚于一种特效药。此文很可能是一篇社论或观点性文章，而非原创性研究，其核心目的在于呼吁临床医生重视并积极推广运动干预在肿瘤治疗与康复中的应用。该文的价值在于引发思考，探讨了为何如此明确有效的“疗法”在临床实践中的推广却面临重重困难，并可能就如何克服这些障碍提出了见解，对推动运动肿瘤学的临床转化具有重要的倡导意义。

---

## 43. 优化慢性淋巴细胞白血病临床试验中的对照组：BRUIN-CLL-321试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270246](https://pubmed.ncbi.nlm.nih.gov/41270246)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41270246
**DOI：** 10.1200/JCO-25-01695

### 第一部分 原文与翻译

**英文原标题：** Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

由于本文献无摘要，仅从标题分析，本研究（或评述）聚焦于慢性淋巴细胞白血病（CLL）临床试验设计的关键方法学问题——对照组的优化。文章以BRUIN-CLL-321试验为例，可能深入探讨了在当前CLL治疗快速发展的背景下，如何选择更合理、更具临床代表性的标准治疗作为对照，以确保试验结果的科学性、伦理性和临床指导价值。此类研究对于指导未来新型CLL药物的临床开发、加速有效疗法上市具有重要的实践意义和方法学参考价值。

---

## 44. 卡铂用于绝经前三阴性乳腺癌：是时候重新思考新辅助治疗标准了吗？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270244](https://pubmed.ncbi.nlm.nih.gov/41270244)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41270244
**DOI：** 10.1200/JCO-25-02336

### 第一部分 原文与翻译

**英文原标题：** Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard?

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该文献标题揭示了其核心议题：探讨将卡铂纳入绝经前三阴性乳腺癌（TNBC）新辅助治疗方案的必要性。由于缺乏摘要，可推断本文可能是一篇社论或评论性文章，旨在通过评述现有证据，挑战当前的治疗常规。文章的核心价值在于引发学界对优化这一特定、预后较差患者群体治疗策略的深入思考，并可能推动相关临床实践指南的更新。此讨论对于提高TNBC患者的病理完全缓解率和改善长期生存具有重要的临床意义。

---

## 45. DNA纳米结构模板化的多价性实现广谱病毒抑制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270218](https://pubmed.ncbi.nlm.nih.gov/41270218)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41270218
**DOI：** 10.1002/advs.202513710

### 第一部分 原文与翻译

**英文原标题：** DNA Nanostructure-Templated Multivalency Enables Broad-Spectrum Virus Inhibition.

**英文摘要原文：**
The rapid evolution and antigenic diversity of influenza A viruses (IAVs) continue to challenge antiviral strategies, highlighting the need for broadly effective and modular therapeutic platforms. While single-domain nanobodies and DNA aptamer-based inhibitors have emerged as promising candidates, their efficacy is limited by monomeric binding to the hemagglutinin (HA) proteins populating the viral envelope. A programmable antiviral platform based on a honeycomb-shaped designer DNA nanostructure (HC-DDN) engineered to multivalently display HA-targeting ligands with nanometer precision is presented. Two constructs are synthesized, HC-Nanobody and HC-Aptamer, organized in trimeric clusters to match the native HA trimer geometry. Using murine-adapted H1N1 and H3N2 models, it is shown that both constructs outperform their free counterparts in viral neutralization and cytoprotection. HC-Nanobody construct achieves >99% inhibition of viral entry and improves cell viability by 35-45% at nanomolar concentrations. To assess translational relevance, the HC-Nanobody construct in a porcine IAV infection model is further evaluated, where it maintains high antiviral efficacy (>97% inhibition) and confers a 30-55% increase in cell viability relative to free nanobodies, confirming robust cross-species performance. Overall, this work demonstrates the power of geometry-matched multivalency to enhance viral neutralization and provides a rational blueprint for designing broad-spectrum antivirals against rapidly evolving respiratory pathogens.

**中文摘要译文：**
甲型流感病毒（IAVs）的快速进化和抗原多样性持续对现有抗病毒策略构成挑战，这凸显了开发广谱有效且模块化的治疗平台的必要性。尽管单域纳米抗体和基于DNA适配体的抑制剂已成为有前景的候选方案，但它们的功效受限于其与病毒包膜上血凝素（HA）蛋白的单价结合模式。本研究展示了一种可编程的抗病毒平台，该平台基于一种蜂窝状的设计师DNA纳米结构（HC-DDN），该结构经过工程化改造，能够以纳米级的精度多价展示靶向HA的配体。研究人员合成了两种构建体，即HC-纳米抗体和HC-适配体，并将它们组织成三聚体簇，以匹配天然HA三聚体的几何构型。通过使用适应小鼠的H1N1和H3N2模型，研究表明这两种构建体在病毒中和及细胞保护方面的效果均优于其游离的对应物。在纳摩尔浓度下，HC-纳米抗体构建体实现了超过99%的病毒进入抑制，并将细胞存活率提高了35-45%。为评估其转化应用价值，研究团队在猪流感病毒感染模型中进一步评估了HC-纳米抗体构建体，结果显示其在该模型中同样保持了高效的抗病毒活性（抑制率>97%），并使细胞存活率相对于游离纳米抗体提高了30-55%，证实了其强大的跨物种有效性。总而言之，这项工作展示了利用几何匹配的多价策略增强病毒中和能力的巨大潜力，并为设计针对快速进化的呼吸道病原体的广谱抗病毒药物提供了合理的蓝图。

### 第二部分 AI 大师评价

该研究巧妙地利用DNA纳米技术，构建了一种蜂窝状纳米结构作为模板，以多价形式精确展示靶向流感病毒血凝素（HA）的纳米抗体或适配体。其核心创新在于，通过模拟HA三聚体的天然几何构型，显著增强了抑制剂与病毒的结合亲和力，从而实现了卓越的病毒中和效果。研究结果表明，这种多价构建体在小鼠和猪模型中均表现出远超单体抑制剂的广谱抗病毒活性和细胞保护能力。此项工作不仅为抗击快速变异的流感病毒提供了高效、可编程的治疗新策略，也为针对其他病原体的多价药物设计提供了极具价值的蓝图，展示了巨大的临床转化潜力。

---

## 46. 靶向SOX9/TIMP1轴的iRGD偶联纳米平台增强胃癌中的树突状细胞功能与光动力免疫疗法

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270217](https://pubmed.ncbi.nlm.nih.gov/41270217)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41270217
**DOI：** 10.1002/advs.202510500

### 第一部分 原文与翻译

**英文原标题：** Targeting the SOX9/TIMP1 Axis with iRGD-Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer.

**英文摘要原文：**
Gastric cancer (GC) remains a therapeutic challenge due to its immunosuppressive microenvironment. This study reveals that the SOX9/TIMP1/FAK/PI3K axis impedes dendritic cell (DC) maturation and antitumor immunity in GC, using integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST-seq) analysis. Irgd-conjugated poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) co-loaded with small interfering RNA targeting SOX9 (si-SOX9), the photosensitizer chlorin e6 (Ce6), and L-arginine (L-Arg) (termed iRGD NPs@si-SOX9/CL) are developed to simultaneously disrupt this immunosuppressive axis and amplify photodynamic therapy (PDT). In vitro, these NPs enhance cellular uptake and lysosomal escape, suppressing SOX9 expression and generating reactive oxygen species (ROS) and nitric oxide (NO) upon near-infrared (NIR) irradiation. This dual action significantly inhibits GC cell proliferation, migration, and invasion while promoting DC maturation (evidenced by elevated CD80/CD86 expression) and CD8⁺ T-cell activation. In vivo, iRGD modification boosts tumor accumulation of NPs, and NP-mediated PDT synergized with SOX9 silencing to suppress tumor growth in GC xenografts. Mechanistically, NPs@si-SOX9/CL blocks SOX9-driven transcriptional activation of TIMP1, reversing FAK/PI3K signaling and restoring DC function. Consequently, tumor-infiltrating mature DCs and cytotoxic T lymphocytes increase significantly, reshaping the immunosuppressive niche. This nanoplatform offers a promising strategy to augment GC immunotherapy by precisely targeting tumor-intrinsic immunosuppression and potentiating PDT efficacy.

**中文摘要译文：**
由于其免疫抑制微环境，胃癌（GC）仍然是一个治疗挑战。本研究利用单细胞RNA测序（scRNA-seq）和空间转录组学（ST-seq）的整合分析，揭示了SOX9/TIMP1/FAK/PI3K轴在胃癌中阻碍树突状细胞（DC）成熟和抗肿瘤免疫。研究人员开发了一种共载靶向SOX9的小干扰RNA（si-SOX9）、光敏剂二氢卟吩e6（Ce6）和L-精氨酸（L-Arg）的iRGD偶联聚乳酸-羟基乙酸共聚物（PLGA）纳米颗粒（NPs）（命名为iRGD NPs@si-SOX9/CL），旨在同时破坏此免疫抑制轴并增强光动力疗法（PDT）的效果。在体外实验中，这些纳米颗粒增强了细胞摄取和溶酶体逃逸，在近红外（NIR）照射下能抑制SOX9表达并产生活性氧（ROS）和一氧化氮（NO）。这种双重作用显著抑制了胃癌细胞的增殖、迁移和侵袭，同时促进了DC的成熟（表现为CD80/CD86表达升高）和CD8⁺ T细胞的活化。在体内实验中，iRGD修饰提升了纳米颗粒在肿瘤部位的富集，并且纳米颗粒介导的PDT与SOX9沉默协同作用，抑制了胃癌异种移植瘤的生长。从机制上讲，NPs@si-SOX9/CL阻断了SOX9驱动的TIMP1转录激活，从而逆转了FAK/PI3K信号通路并恢复了DC功能。因此，肿瘤浸润的成熟DC和细胞毒性T淋巴细胞显著增加，重塑了免疫抑制微环境。该纳米平台通过精确靶向肿瘤内在的免疫抑制机制并增强PDT疗效，为加强胃癌免疫治疗提供了一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在解决胃癌的免疫抑制微环境难题，通过构建一种多功能纳米平台，协同增强光动力免疫疗法的抗肿瘤效果。研究创新性地利用iRGD偶联的纳米粒，共递送SOX9干扰RNA、光敏剂和L-精氨酸，实现了对SOX9/TIMP1免疫抑制轴的精确靶向阻断与光动力治疗的有效结合。其关键发现是该策略不仅能直接抑制肿瘤细胞，还能通过恢复树突状细胞功能、激活T细胞来重塑肿瘤微环境，为胃癌治疗提供了极具潜力的“一石二鸟”新思路。该研究将纳米技术、基因沉默和免疫疗法精妙融合，展现了重要的临床转化价值。

---

## 47. 脂质驱动的OLR1/FOXM1/FGF19轴通过调控上皮-成纤维细胞正反馈串扰促进子宫内膜癌的孕激素抵抗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270216](https://pubmed.ncbi.nlm.nih.gov/41270216)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41270216
**DOI：** 10.1002/advs.202511943

### 第一部分 原文与翻译

**英文原标题：** Lipid-Driven OLR1/FOXM1/FGF19 Axis Orchestrates Crosstalk in an Epithelial-Fibroblast Positive Feedback Promoting Progesterone Resistance in Endometrial Cancer.

**英文摘要原文：**
Progesterone resistance (ProR) remains a major obstacle in the conservative management of endometrial cancer (EC). Here, a metabolic-stromal signaling loop centered on the OLR1/FOXM1/FGF19 axis is identified that drives progesterone resistance in EC. Single-cell transcriptomic profiling first revealed a striking correlation between epithelial cells and fibroblasts in EC tissues with ProR. Tumor epithelial cells display profound alterations in lipid metabolism, whereas fibroblasts exhibited enhanced oxidative stress signatures. Clinical samples analyses indicated that oxidized low density lipoprotein (oxLDL), a product of LDL oxidation, is associated with adverse outcomes. The binding of oxLDL to its receptor OLR1 promoted the expression of FOXM1, a transcription factor that directly upregulates fibroblast growth factor 19 (FGF19). Immunofluorescence confirmed not only the spatial co-localization of epithelial cells and fibroblasts but also the enrichment of OLR1 within epithelial compartments. Furthermore, treatment with the antioxidant resveratrol (RSV) and its nanoformulation (RSV-NPs) markedly inhibited tumor growth in mice with lipid metabolic disorders, highlighting their potential to counteract progesterone resistance by disrupting this OLR1/FOXM1/FGF19 axis. This work highlights the therapeutic potential of targeting the tumor-stroma metabolic axis to increase progesterone sensitivity and improve outcomes in EC patients with fertility-preserving demands.

**中文摘要译文：**
孕激素抵抗（ProR）仍然是子宫内膜癌（EC）保守治疗中的一个主要障碍。本研究发现了一个以OLR1/FOXM1/FGF19轴为中心的代谢-基质信号环，该信号环驱动了EC中的孕激素抵抗。单细胞转录组分析首先揭示了在伴有ProR的EC组织中，上皮细胞与成纤维细胞之间存在显著的关联。肿瘤上皮细胞表现出显著的脂质代谢改变，而成纤维细胞则呈现出增强的氧化应激特征。临床样本分析表明，作为低密度脂蛋白（LDL）氧化产物的氧化低密度脂蛋白（oxLDL）与不良预后相关。oxLDL与其受体OLR1的结合促进了FOXM1的表达，而FOXM1作为一个转录因子，能直接上调成纤维细胞生长因子19（FGF19）。免疫荧光技术不仅证实了上皮细胞和成纤维细胞在空间上的共定位，还证实了OLR1在上皮区域内的富集。此外，使用抗氧化剂白藜芦醇（RSV）及其纳米制剂（RSV-NPs）进行治疗，显著抑制了脂质代谢紊乱小鼠的肿瘤生长，这凸显了它们通过破坏OLR1/FOXM1/FGF19轴来对抗孕激素抵抗的潜力。这项工作强调了靶向肿瘤-基质代谢轴的治疗潜力，有望为有生育保留需求的EC患者提高孕激素敏感性并改善其预后。

### 第二部分 AI 大师评价

本研究旨在揭示子宫内膜癌（EC）中孕激素抵抗的核心机制。研究综合运用单细胞转录组学、临床样本分析及动物模型，创新性地发现了一条由脂质代谢驱动的OLR1/FOXM1/FGF19信号轴，该信号轴通过介导上皮细胞与成纤维细胞间的正反馈串扰，促进了孕激素抵抗。此发现不仅深刻揭示了肿瘤-基质代谢互作在EC耐药中的关键作用，还为有保留生育需求的患者提供了靶向该信号轴（如使用白藜芦醇）的潜在治疗新策略，具有重要的临床转化价值。

---

## 48. 亮氨酸依赖性的SLC7A5-PGAM5相互作用通过抑制巨噬细胞线粒体功能促进晚期动脉粥样硬化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270215](https://pubmed.ncbi.nlm.nih.gov/41270215)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41270215
**DOI：** 10.1002/advs.202518359

### 第一部分 原文与翻译

**英文原标题：** Leucine-Dependent SLC7A5-PGAM5 Interaction Promotes Advanced Atherosclerosis Through Hindering Mitochondrial Function of Macrophages.

**英文摘要原文：**
The residual risks of advanced atherosclerosis remain substantial despite current preventive strategies and pharmacotherapy. Circulating branched-chain amino acids are biomarkers of cardiovascular disease risk. However, the mechanism of leucine in atherosclerosis progression remains unclear. Leucine transporter-SLC7A5-mediated leucine intake that promotes advanced atherosclerosis in mice, increasing apoptotic macrophages and lipids accumulation within plaques. Multi-omics analyses showed that leucine deprivation enhanced macrophage mitochondrial function and increased plaque CD5L macrophages, under SLC7A5-deficiency-mediated leucine deprivation, these cells exhibited stronger oxidative phosphorylation and lipid metabolism. Mechanistically, leucine deficiency reduced SLC7A5-PGAM5 binding in macrophages, promoting PGAM5-NDUFV1 interaction and enhancing mitochondrial function, which attenuates atherosclerosis progression. Collectively, these findings elucidate the function and mechanism of SLC7A5 in Cd5l macrophages, highlighting it as a potential therapeutic target. Strategies aimed at improving mitochondrial function also offer a promising approach for advanced atherosclerosis treatment.

**中文摘要译文：**
尽管现有预防策略和药物治疗已取得进展，但晚期动脉粥样硬化的残余风险仍然显著。循环中的支链氨基酸是心血管疾病风险的生物标志物。然而，亮氨酸在动脉粥样硬化进展中的具体机制仍不明确。亮氨酸转运蛋白SLC7A5介导的亮氨酸摄取促进了小鼠的晚期动脉粥样硬化，增加了斑块内的凋亡巨噬细胞和脂质积累。多组学分析显示，亮氨酸缺乏增强了巨噬细胞的线粒体功能，并增加了斑块中CD5L+巨噬细胞的数量；在SLC7A5缺陷介导的亮氨酸缺乏条件下，这些细胞表现出更强的氧化磷酸化和脂质代谢能力。从机制上讲，亮氨酸缺乏减少了巨噬细胞中SLC7A5与PGAM5的结合，从而促进了PGAM5与NDUFV1的相互作用并增强了线粒体功能，进而减缓了动脉粥样硬化的进展。总而言之，这些发现阐明了SLC7A5在CD5L+巨噬细胞中的功能和作用机制，突显了其作为一个潜在的治疗靶点。旨在改善线粒体功能的策略也为治疗晚期动脉粥样硬化提供了一种有前景的方法。

### 第二部分 AI 大师评价

本研究旨在阐明支链氨基酸中的亮氨酸在晚期动脉粥样硬化进展中的具体作用机制。研究通过多组学分析和小鼠模型发现，亮氨酸通过其转运蛋白SLC7A5进入巨噬细胞后，促进了SLC7A5与PGAM5的结合，这抑制了巨噬细胞的线粒体功能，从而加剧了动脉粥样硬化。该研究创新性地揭示了“亮氨酸-SLC7A5-PGAM5”这一调控巨噬细胞线粒体功能的信号轴，不仅深化了对动脉粥样硬化病理生理的理解，也为晚期动脉粥样硬化的治疗提供了新的潜在靶点（如SLC7A5）和策略（如改善线粒体功能）。

---

## 49. 基于上转换杂化纳米系统的时空可控肿瘤光动力/免疫联合治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270206](https://pubmed.ncbi.nlm.nih.gov/41270206)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41270206
**DOI：** 10.1002/advs.202515052

### 第一部分 原文与翻译

**英文原标题：** Spatiotemporally Controlled Tumor Photodynamic/Immunotherapy Therapy Based on Upconversion Hybrid Nanosystem.

**英文摘要原文：**
Immunotherapy holds great promise for cancer treatment, but its clinical application is hindered by the immunosuppressive tumor microenvironment (TME) and the systematic toxicity. Herein, a spatiotemporally controllable smart nanodevice based on upconversion nanoparticles (UCNPs) that can be activated by dual near - infrared (NIR) light for tumor immunotherapy, namely PURH, is developed. PURH is constructed by a five-layer UCNPs surface coated with mesoporous silica, which encapsulates the photosensitizer rose bengal (RB) within the mesoporous channels. Additionally, CpG oligonucleotides (CpG ODN) is linked to the surface, followed by the surface functionalization of hyaluronic acid (HA) to achieve tumor targeting. PURH allows for dual NIR light activation, where 980 nm NIR light irradiation activates photodynamic therapy (PDT), inducing apoptosis and immunogenic cell death (ICD), while 808 nm NIR light irradiation triggers the release of CpG for tumor immunotherapy. The study offers a powerful tool and strategy for spatiotemporal controlled tumor immunotherapy.

**中文摘要译文：**
免疫疗法在癌症治疗中展现出巨大潜力，但其临床应用受到免疫抑制性肿瘤微环境（TME）和全身性毒性的阻碍。在此，我们开发了一种名为PURH的、基于上转换纳米颗粒（UCNPs）的时空可控智能纳米器件，该器件可通过双近红外（NIR）光激活以用于肿瘤免疫治疗。PURH由一个五层结构的上转换纳米颗粒构成，其表面包覆介孔二氧化硅，并将光敏剂玫瑰红（RB）封装于介孔通道内。此外，CpG寡核苷酸（CpG ODN）被连接到其表面，随后通过透明质酸（HA）进行表面功能化以实现肿瘤靶向。PURH可由双近红外光激活：980 nm近红外光照射可激活光动力疗法（PDT），诱导细胞凋亡和免疫原性细胞死亡（ICD）；而808 nm近红外光照射则触发CpG的释放，用于肿瘤免疫治疗。该研究为时空可控的肿瘤免疫治疗提供了一种强有力的工具和策略。

### 第二部分 AI 大师评价

本研究旨在开发一种时空可控的纳米系统（PURH），用于联合肿瘤光动力疗法与免疫疗法。该系统巧妙地利用上转换纳米颗粒，通过两种不同波长的近红外光（980 nm 和 808 nm）分别、精准地触发光敏剂介导的免疫原性细胞死亡和免疫佐剂CpG的释放。其核心创新在于双波长近红外光响应的“正交”激活机制，实现了在时间与空间上对两种治疗模式的精确调控，有望在增强抗肿瘤效果的同时，降低传统联合疗法的全身毒副作用。这项工作为开发下一代智能纳米药物、实现精准可控的癌症联合免疫治疗提供了富有前景的新策略。

---

## 50. 基于深度学习的无标记亚细胞分辨率光声组织学用于快速癌症诊断

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270177](https://pubmed.ncbi.nlm.nih.gov/41270177)
**期刊：** Science advances
**PMID：** 41270177
**DOI：** 10.1126/sciadv.adz1820

### 第一部分 原文与翻译

**英文原标题：** Rapid cancer diagnosis using deep learning-powered label-free subcellular-resolution photoacoustic histology.

**英文摘要原文：**
Traditional hematoxylin and eosin staining in formalin-fixed paraffin-embedded sections, while essential for diagnostic pathology, is time-consuming, labor intensive, and prone to artifacts that can obscure critical histological details. Label-free ultraviolet photoacoustic microscopy (UV-PAM) has emerged as a promising alternative, offering fast histology-like images without the need for traditional staining and excessive tissue preparation. However, current UV-PAM systems face challenges in achieving the high spatial resolution required for detailed histological analysis and diagnosis. To address this, we developed a subcellular-resolution UV-PAM (SRUV-PAM) system with a 240-nanometer resolution, enabled by the integration of a high numerical aperture (NA) objective lens (NA = 0.64) and the precise piezo actuators for fine scanning control. This configuration allows visualization of detailed nuclear structures. In addition, we demonstrated virtual staining of SRUV-PAM images via cycle-consistent generative adversarial networks and diagnosis of malignant and benign tumors in liver tissues via densely connected convolutional networks DenseNet-121, achieving an area under the receiver operating characteristic curve of 0.902.

**中文摘要译文：**
传统的福尔马林固定石蜡包埋切片的苏木精和伊红染色法，虽然对诊断病理学至关重要，但其过程耗时、费力，且易产生伪影，可能掩盖关键的组织学细节。无标记紫外光声显微镜（UV-PAM）作为一种有前景的替代技术应运而生，它无需传统染色和过多的组织制备即可提供快速的类组织学图像。然而，现有的UV-PAM系统在达到详细组织学分析和诊断所需的高空间分辨率方面面临挑战。为解决这一问题，我们开发了一种亚细胞分辨率的UV-PAM（SRUV-PAM）系统，该系统通过集成高数值孔径（NA=0.64）物镜和用于精确扫描控制的精密压电驱动器，实现了240纳米的分辨率。这种配置使得观察精细的细胞核结构成为可能。此外，我们通过循环一致性生成对抗网络对SRUV-PAM图像进行了虚拟染色，并利用密集连接卷积网络DenseNet-121对肝组织中的恶性与良性肿瘤进行诊断，其受试者工作特征曲线下面积达到了0.902。

### 第二部分 AI 大师评价

本研究旨在解决传统病理诊断耗时费力且易产生伪影的痛点，创新性地开发了一种亚细胞分辨率的无标记紫外光声显微镜（SRUV-PAM）系统。该技术通过集成高数值孔径物镜，实现了240纳米的高分辨率，能够清晰展示细胞核等精细结构。更进一步，研究团队将该成像技术与深度学习模型相结合，不仅实现了对光声图像的虚拟染色，还成功构建了对肝脏肿瘤良恶性的高效诊断模型，展现出优异的诊断性能。这项工作为实现快速、自动化的数字病理诊断提供了全新思路，在术中快速诊断和癌症研究领域具有巨大的应用潜力。

---

## 51. 用于动态核极化代谢成像的稳定的电子辐照[1-C]丙氨酸自由基

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270160](https://pubmed.ncbi.nlm.nih.gov/41270160)
**期刊：** Science advances
**PMID：** 41270160
**DOI：** 10.1126/sciadv.adz4334

### 第一部分 原文与翻译

**英文原标题：** Stable electron-irradiated [1-C]alanine radicals for metabolic imaging with dynamic nuclear polarization.

**英文摘要原文：**
Dissolution dynamic nuclear polarization (dDNP) increases the sensitivity of magnetic resonance experiments by >10-fold, permitting isotopically labeled molecules to be transiently visible in magnetic resonance imaging scans. dDNP mechanistically takes place at ~1 K and requires unpaired electrons and microwaves. These electrons are usually chemical radicals, requiring removal by filtration prior to injection into humans. Alternative sources, such as ultraviolet irradiation, generate lower polarization and require cryogenic transport. We present ultrahigh-dose rate electron irradiation as an alternative for generating nonpersistent radicals in alanine/glycerol mixtures. These are stable for months at room temperature, quench spontaneously upon dissolution, are present in dose-dependent concentrations, and generate comparable nuclear polarization (17%) to trityl radicals used clinically (19%) through a previously unknown mechanism we believe to involve partial ordering and electron-electron interactions. Owing to the large radiation doses required, this process is sterilizing, permits imaging of alanine metabolism in vivo in the rat kidney, and may aid clinically translating dDNP.

**中文摘要译文：**
溶解动态核极化（dDNP）技术可将磁共振实验的灵敏度提高超过10倍，使得同位素标记的分子能够在磁共振成像扫描中短暂可见。dDNP的机理是在约1开尔文的温度下发生，并且需要未配对电子和微波。这些电子通常是化学自由基，在注入人体前需要通过过滤去除。其他替代来源，如紫外线辐照，产生的极化程度较低，并且需要低温运输。我们提出采用超高剂量率的电子辐照作为一种在丙氨酸/甘油混合物中生成非持久性自由基的替代方法。这些自由基在室温下可稳定数月，溶解时会自发猝灭，其浓度呈剂量依赖性，并且通过一种我们认为涉及部分有序化和电子-电子相互作用的未知新机制，产生了与临床使用的三苯甲基自由基（19%）相当的核极化率（17%）。由于所需辐射剂量大，该过程本身具有灭菌效果，能够实现大鼠肾脏内丙氨酸代謝的在体成像，并可能有助于dDNP技术的临床转化。

### 第二部分 AI 大师评价

本研究旨在为动态核极化（dDNP）代谢成像开发一种新型、更稳定的自由基生成方法。研究团队创新性地采用超高剂量率电子辐照丙氨酸/甘油混合物，成功生成了可在室温下长期稳定、溶解后自发猝灭的自由基。这些自由基产生了与临床标准相当的高核极化率，且该制备过程兼具灭菌效果，成功应用于大鼠在体代谢成像。此项技术无需低温运输和注入前过滤，极大地简化了探体制备流程，为推动dDNP技术更广泛的临床转化提供了重要实践途径，具有很高的应用价值。

---

## 52. 靶向线粒体DNA突变的可经肾脏清除的CRISPR纳米传感器用于无创监测肿瘤进展与转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270157](https://pubmed.ncbi.nlm.nih.gov/41270157)
**期刊：** Science advances
**PMID：** 41270157
**DOI：** 10.1126/sciadv.adz4594

### 第一部分 原文与翻译

**英文原标题：** Renal clearable CRISPR nanosensor targeting mitochondrial DNA mutation for noninvasive monitoring of tumor progression and metastasis.

**英文摘要原文：**
Mitochondrial DNA (mtDNA) mutations are emerging as important molecular features of tumorigenesis. Liquid biopsies, involving analysis of cell-free mtDNA, enable early cancer detection but suffer from low sensitivity due to scarce analytes. Here, we developed a CRISPR/Cas12a-mediated urinary biomarker, termed CasUber, for in vivo monitoring of tumor progression and metastasis. Our results demonstrate that CasUber can deliver a CRISPR detection system into tumor cell mitochondria, leverage the single-nucleotide variant recognition ability and trans-cleavage activity of Cas12a to convert tumor-specific mtDNA mutations into renal-clearable fluorescent biomarkers, and exocytosed along with the natural efflux pathway of damaged mtDNA. As a result, CasUber enables discrimination of ultrasmall tumor lesions (~1 cubic millimeter) and detection of lung tumor nodules earlier than bioluminescence imaging in a blood-lung metastasis model. This renal clearable nanosensor allows in situ recognition of specific gene mutation to generate amplified signals, overcoming the limitation of low mtDNA abundance and enabling noninvasive and ultrasensitive monitoring of tumor progression and metastasis via a simple urine test.

**中文摘要译文：**
线粒体DNA（mtDNA）突变正逐渐成为肿瘤发生的重要分子特征。液体活检通过分析无细胞mtDNA实现癌症的早期检测，但因分析物稀少而灵敏度较低。本研究中，我们开发了一种由CRISPR/Cas12a介导的尿液生物标志物，命名为CasUber，用于在体内监测肿瘤的进展和转移。我们的结果表明，CasUber能够将CRISPR检测系统递送至肿瘤细胞线粒体，利用Cas12a的单核苷酸变异识别能力和反式切割活性，将肿瘤特异性的mtDNA突变转化为可经肾脏清除的荧光生物标志物，并随受损mtDNA的自然外排途径被胞吐出来。因此，在血行-肺转移模型中，CasUber能够区分极小的肿瘤病灶（约1立方毫米），并且比生物发光成像更早地检测到肺部肿瘤结节。这种肾脏可清除的纳米传感器能够原位识别特定基因突变以产生放大信号，克服了mtDNA丰度低的限制，通过简单的尿液检测即可实现对肿瘤进展和转移的无创、超灵敏监测。

### 第二部分 AI 大师评价

本研究旨在开发一种无创监测肿瘤进展与转移的新方法。研究团队创新性地构建了一种名为CasUber的CRISPR纳米传感器，该传感器能进入肿瘤细胞线粒体，特异性识别mtDNA突变，并通过酶切活性将此信号转化为可经尿液排出的荧光标志物。关键发现是，该技术在动物模型中实现了对极微小肿瘤（~1mm³）的检测，并能比传统成像更早地发现转移灶。这项技术巧妙地将基因编辑工具的精准识别能力与纳米探针相结合，实现了信号的体内转换与放大，为通过简单的尿检进行超灵敏肿瘤动态监测提供了全新策略，具有巨大的临床转化潜力。

---

## 53. 单细胞谱系示踪技术揭示急性髓系白血病对FLT3抑制剂的耐药特征及增敏策略

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270153](https://pubmed.ncbi.nlm.nih.gov/41270153)
**期刊：** Cancer research
**PMID：** 41270153
**DOI：** 10.1158/0008-5472.CAN-24-3753

### 第一部分 原文与翻译

**英文原标题：** Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia.

**英文摘要原文：**
While FLT3 inhibitors have significantly improved the treatment of aggressive FLT3-mutated acute myeloid leukemia (AML), the emergence of resistance remains as a major challenge. Here, we applied our recently developed single-cell lineage tracing method ReSisTrace to identify cells that are intrinsically resistant or sensitive to the FLT3 inhibitors midostaurin and quizartinib in AML with FLT3-ITD mutations. Comparison of the gene expression profiles of these cells revealed transcriptional resistance signatures, including upregulation of GSPT1. Depletion of GSPT1 with CRISPR-Cas9-mediated knockout resulted in increased sensitivity of AML cells to quizartinib treatment. Further, targeting GSPT1 with the small molecule CC-90009 exhibited strong synergistic effects when combined with FLT3 inhibitors in the FLT3-ITD cell lines and primary AML patient samples. In addition, in an FLT3-ITD-positive AML patient-derived xenograft (PDX) mouse model, the CC-90009 and quizartinib combination showed significantly higher anti-tumor efficacy and prolonged overall survival compared to either treatment alone. Furthermore, compounds that induced transcriptomic changes opposite to the resistance signatures prompted cells to acquire FLT3 inhibitor-sensitive states. Vistusertib (mTOR inhibitor), linsitinib (IGF1R and insulin receptor inhibitor), and meisoindigo (IGF1R and Src family kinase inhibitor), all inhibiting pathways parallel to or downstream of oncogenic FLT3 signaling, were predicted and validated to sensitize FLT3-mutated cell lines and primary cells to FLT3 inhibitors. Collectively, these findings demonstrate the ability of ReSisTrace to unveil pre-existing transcriptional features of treatment vulnerability in hematological cancers and elucidate strategies for enhancing FLT3 inhibitor treatment efficacy in FLT3-ITD-mutated AML.

**中文摘要译文：**
尽管FLT3抑制剂显著改善了侵袭性FLT3突变型急性髓系白血病（AML）的治疗效果，但耐药性的出现仍是一项重大挑战。本研究中，我们应用了最新开发的单细胞谱系示踪方法ReSisTrace，以识别在FLT3-ITD突变的AML中对FLT3抑制剂米哚妥林和奎扎atinib具有内在耐药性或敏感性的细胞。对这些细胞的基因表达谱进行比较，揭示了转录水平的耐药特征，包括GSPT1的上调。通过CRISPR-Cas9介导的基因敲除耗尽GSPT1，导致AML细胞对奎扎atinib治疗的敏感性增加。此外，在FLT3-ITD细胞系和原代AML患者样本中，使用小分子药物CC-90009靶向GSPT1，当与FLT3抑制剂联合使用时，表现出强大的协同效应。另外，在一个FLT3-ITD阳性的AML患者来源的异种移植（PDX）小鼠模型中，与单一治疗相比，CC-90009和奎扎atinib的联合用药显示出显著更高的抗肿瘤疗效并延长了总生存期。再者，能够诱导与耐药特征相反的转录组学变化的化合物，可促使细胞获得对FLT3抑制剂的敏感状态。Vistusertib（mTOR抑制剂）、linsitinib（IGF1R和胰岛素受体抑制剂）以及meisoindigo（IGF1R和Src家族激酶抑制剂），这些药物均能抑制致癌性FLT3信号通路的平行或下游通路，经预测和验证，它们能够使FLT3突变的细胞系和原代细胞对FLT3抑制剂敏感。总而言之，这些发现证明了ReSisTrace技术能够揭示血液系统恶性肿瘤中预先存在的治疗脆弱性转录特征，并阐明了提高FLT3抑制剂在FLT3-ITD突变AML中治疗效果的策略。

### 第二部分 AI 大师评价

本研究运用其创新的单细胞谱系示踪技术ReSisTrace，旨在揭示FLT3突变型急性髓系白血病（AML）对FLT3抑制剂产生内在耐药性的分子机制。研究的关键发现是，GSPT1基因的上调是导致耐药的核心转录特征，并且通过药物（如CC-90009）靶向GSPT1能与FLT3抑制剂产生强大的协同抗癌效应。此项工作的创新性在于前瞻性地识别出了预先存在的耐药细胞亚群，不仅为克服AML治疗耐药提供了精准的靶点和联合用药策略，也为开发更有效的个性化治疗方案提供了重要的临床前证据和新思路。

---

## 54. 雄激素受体驱动多胺合成，为前列腺癌创造了一个治疗弱点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270152](https://pubmed.ncbi.nlm.nih.gov/41270152)
**期刊：** Cancer research
**PMID：** 41270152
**DOI：** 10.1158/0008-5472.CAN-25-1532

### 第一部分 原文与翻译

**英文原标题：** Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer.

**英文摘要原文：**
Supraphysiological androgen (SPA) treatment can paradoxically restrict growth of castration-resistant prostate cancer with high androgen receptor (AR) activity, which is the basis for use of Bipolar Androgen Therapy (BAT) for patients with this disease. While androgens are widely appreciated to enhance anabolic metabolism, how SPA-mediated metabolic changes alter prostate cancer progression and therapy response is unknown. Here, we report that SPA markedly increased intracellular and secreted polyamines in prostate cancer models. AR binding at enhancer sites upstream of the ODC1 promoter increased the abundance of ornithine decarboxylase (ODC), a rate-limiting enzyme of polyamine synthesis, and de novo synthesis of polyamines from arginine. SPA-stimulated polyamines enhanced prostate cancer fitness, as dCas9-KRAB-mediated inhibition of AR regulation of ODC1 or direct ODC inhibition by difluoromethylornithine (DFMO) increased efficacy of SPA. Mechanistically, AR activation combined with loss of negative feedback by polyamines increased the activity of S-adenosylmethionine decarboxylase 1 (AMD1), leading to depletion of its substrate S-adenosylmethionine and global protein methylation. These data provided the rationale for a clinical trial testing the safety and efficacy of BAT in combination with DFMO for patients with metastatic castration-resistant prostate cancer. Pharmacodynamic studies of this therapeutic combination in the first five patients on trial indicated that this approach effectively depleted polyamines in plasma. Thus, the AR potently stimulates polyamine synthesis, which constitutes a vulnerability in prostate cancer treated with SPA that can be targeted therapeutically.

**中文摘要译文：**
超生理剂量雄激素（SPA）治疗可以出乎意料地抑制高雄激素受体（AR）活性的去势抵抗性前列腺癌的生长，这是对该病患者使用双相雄激素疗法（BAT）的基础。虽然雄激素被广泛认为能增强合成代谢，但SPA介导的代谢变化如何改变前列腺癌的进展和治疗反应尚不清楚。在此，我们报告SPA显著增加了前列腺癌模型中细胞内和分泌的多胺水平。AR在ODC1启动子上游的增强子位点结合，增加了多胺合成的限速酶——鸟氨酸脱羧酶（ODC）的丰度，并促进了从精氨酸从头合成多胺。SPA刺激产生的多胺增强了前列腺癌的适应性，因为通过dCas9-KRAB介导的对AR调控ODC1的抑制或通过二氟甲基鸟氨酸（DFMO）直接抑制ODC，均能增加SPA的疗效。从机制上讲，AR的激活与多胺负反馈的缺失相结合，增加了S-腺苷甲硫氨酸脱羧酶1（AMD1）的活性，从而导致其底物S-腺苷甲硫氨酸的耗竭和全局蛋白质甲基化。这些数据为一项旨在检验BAT联合DFMO治疗转移性去势抵抗性前列腺癌患者的安全性和有效性的临床试验提供了理论依据。该试验中前五名患者的药效学研究表明，这种联合治疗方法能有效耗竭血浆中的多胺。因此，AR能强效刺激多胺合成，这构成了经SPA治疗的前列腺癌中的一个可被治疗性靶向的弱点。

### 第二部分 AI 大师评价

本研究旨在揭示超生理剂量雄激素（SPA）疗法在治疗去势抵抗性前列腺癌（CRPC）中的一个关键代谢机制。研究通过细胞模型和机制分析发现，雄激素受体（AR）通过激活ODC1强力驱动多胺合成，而这种对多胺的依赖性反而成为肿瘤的一个可攻击的“弱点”。基于此，研究提出了将双相雄激素疗法（BAT）与多胺合成抑制剂（DFMO）联合应用的创新策略，并初步在临床试验中验证了其药效学效果。这项工作不仅深化了对SPA疗法作用机理的理解，也为晚期前列腺癌的治疗提供了极具转化价值的新靶点和联合用药方案。

---

## 55. 癌症相关成纤维细胞通过PGK1介导的代谢重编程促进胃肠道间质瘤的伊马替尼耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270149](https://pubmed.ncbi.nlm.nih.gov/41270149)
**期刊：** Cancer research
**PMID：** 41270149
**DOI：** 10.1158/0008-5472.CAN-25-1404

### 第一部分 原文与翻译

**英文原标题：** Cancer-Associated Fibroblasts Promote Imatinib Resistance in Gastrointestinal Stromal Tumors through PGK1-Mediated Metabolic Reprogramming.

**英文摘要原文：**
Gastrointestinal stromal tumors (GISTs), the most common sarcomas of the gastrointestinal tract, are primarily driven by c-KIT or PDGFRA mutations that activate downstream signaling pathways, including PI3K/AKT/mTOR. While imatinib, a first-line tyrosine kinase inhibitor (TKI), is initially effective, resistance develops in ~50% of patients within 20 months. Second- and third-line TKIs, such as sunitinib and regorafenib, provide limited benefits, highlighting the urgent need to address resistance mechanisms. Previous research has predominantly focused on genetic drivers of resistance and overlooked the role of the tumor microenvironment (TME). Here, we identified a role for cancer-associated fibroblasts (CAFs) in driving imatinib resistance. Specifically, TGF-β1 secreted by CAFs amplified CCN2/Rack1 signaling. The CCN2/Rack1 axis activated PI3K/AKT signaling to induce phosphorylation and mitochondrial translation of PGK1, promoting metabolic reprogramming that supported tumor survival and drug resistance. Co-culture models and single-cell RNA sequencing revealed distinct CAF subtypes and showed that CAF-secreted TGF-β1 enhanced glycolysis and inhibited the tricarboxylic acid (TCA) cycle, fueling GIST progression and secondary resistance. Inversely, CCN2 secreted by GIST cells promoted TGF-β1 production in CAFs. These findings uncover a TGF-β1/CCN2/Rack1/PGK1 mechanism linking CAF-mediated metabolic reprogramming to imatinib resistance in GISTs. Targeting CAF-GIST interactions and key metabolic pathways presents a promising therapeutic strategy.

**中文摘要译文：**
胃肠道间质瘤（GISTs）是胃肠道最常见的肉瘤，主要由激活下游信号通路（包括PI3K/AKT/mTOR）的c-KIT或PDGFRA突变驱动。尽管一线酪氨酸激酶抑制剂（TKI）伊马替尼在初期有效，但约50%的患者在20个月内会产生耐药性。二线和三线TKI，如舒尼替尼和瑞戈非尼，带来的获益有限，这凸显了解决耐药机制的迫切需求。以往的研究主要集中在耐药的遗传驱动因素上，而忽略了肿瘤微环境（TME）的作用。在本研究中，我们明确了癌症相关成纤维细胞（CAFs）在驱动伊马替尼耐药中的作用。具体而言，CAFs分泌的TGF-β1放大了CCN2/Rack1信号。CCN2/Rack1轴激活PI3K/AKT信号，诱导PGK1的磷酸化和线粒体翻译，从而促进了支持肿瘤存活和耐药的代谢重编程。共培养模型和单细胞RNA测序揭示了不同的CAF亚型，并表明CAF分泌的TGF-β1增强了糖酵解并抑制了三羧酸（TCA）循环，从而助长了GIST的进展和继发性耐药。反之，GIST细胞分泌的CCN2则促进了CAFs中TGF-β1的产生。这些发现揭示了一个将CAF介导的代谢重编程与GIST伊马替尼耐药联系起来的TGF-β1/CCN2/Rack1/PGK1机制。靶向CAF-GIST相互作用和关键代谢通路提出了一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究聚焦于胃肠道间质瘤（GIST）的伊马替尼耐药问题，创新性地从肿瘤微环境（TME）而非传统的基因突变角度进行探究。研究通过共培养模型和单细胞测序等方法，首次揭示了癌症相关成纤维细胞（CAFs）通过分泌TGF-β1，激活一个全新的TGF-β1/CCN2/Rack1/PGK1信号轴，进而诱导GIST细胞发生代谢重编程，最终导致耐药。此项发现不仅深刻阐明了TME在GIST耐药中的关键作用机制，更为开发针对CAF-GIST互作或代谢通路的新型联合治疗策略以克服耐药提供了坚实的理论基础和潜在靶点。

---

## 56. 癌症中长非编码RNA的功能、药物基因组学及免疫图景

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41270088](https://pubmed.ncbi.nlm.nih.gov/41270088)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41270088
**DOI：** 10.1002/advs.202513414

### 第一部分 原文与翻译

**英文原标题：** Functional, Pharmacogenomic, and Immune Landscapes of Long Non-Coding RNAs in Cancer.

**英文摘要原文：**
Long non-coding RNAs (lncRNAs) are emerging as key regulators in cancer, with significant potential as diagnostic, prognostic, and therapeutic targets. Here, this work systematically analyzes lncRNA associations with targeted therapies and immunotherapies across 33 cancer types using The Cancer Genome Atlas (TCGA) and real-world datasets. This work identifies 53,173 lncRNA-pathway associations, millions of lncRNA-drug response associations (via CancerRxTissue and VAEN), and extensive correlations with immune checkpoints and infiltration. This work further identifies 69 lncRNAs associated with immunotherapy response and 2,611 differentially expressed lncRNAs between low and high objective response rate (ORR) groups. Additionally, two lncRNAs are correlated with immune-related adverse events (irAEs), and 1,376 lncRNAs exhibited expression differences between cancers with low and high irAE risk. To facilitate further research, this work develops PILNC (https://hanlaboratory.com/PILNC), a comprehensive web portal enabling exploration of lncRNA associations with cancer pathways, drug responses, immune features, and immunotherapy outcomes.

**中文摘要译文：**
长非编码RNA（lncRNA）正成为癌症中的关键调控因子，具有作为诊断、预后和治疗靶点的巨大潜力。本研究利用癌症基因组图谱（TCGA）和真实世界数据集，系统性地分析了33种癌症类型中lncRNA与靶向治疗和免疫治疗的关联。本研究识别了53,173个lncRNA-通路关联、数百万个lncRNA-药物反应关联（通过CancerRxTissue和VAEN），以及与免疫检查点和免疫浸润的广泛相关性。本研究进一步确定了69个与免疫治疗反应相关的lncRNA，以及在低和高客观缓解率（ORR）组之间存在差异表达的2,611个lncRNA。此外，有两个lncRNA与免疫相关不良事件（irAEs）相关，并且有1,376个lncRNA在低和高irAE风险的癌症之间表现出表达差异。为方便后续研究，本工作开发了一个全面的网络门户——PILNC（https://hanlaboratory.com/PILNC），用于探索lncRNA与癌症通路、药物反应、免疫特征和免疫治疗结果的关联。

### 第二部分 AI 大师评价

该研究通过对33种癌症类型的大规模生物信息学分析，系统揭示了长非编码RNA（lncRNA）在癌症靶向治疗和免疫治疗中的功能、药物基因组学及免疫调控全景。其核心创新在于不仅识别了数万计的lncRNA与药物反应、免疫应答及不良事件的潜在关联，更开发了PILNC数据库，为全球研究者提供了一个极其宝贵的交互式探索平台。这项工作为发现新的癌症生物标志物和治疗靶点奠定了坚实的数据基础，对推动精准肿瘤学研究具有重要意义。

---

## 57. TNFR2的上调早于耗竭性T细胞中TOX的表达，并限制抗肿瘤与抗病毒免疫

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41269210](https://pubmed.ncbi.nlm.nih.gov/41269210)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41269210
**DOI：** 10.1158/1078-0432.CCR-24-3455

### 第一部分 原文与翻译

**英文原标题：** Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity.

**英文摘要原文：**
PURPOSE: Exhaustion represents a collection of programmed T cell differentiation states and an important mode of T cell dysfunction. T cell progression from progenitor to terminal exhaustion is associated with upregulation of the transcription factor TOX. Our understanding of factors regulating TOX expression and the transition from progenitor to terminal exhaustion, however, remains incomplete.

EXPERIMENTAL DESIGN: Single-cell RNA sequencing was used to evaluate expression of TNF receptors on human and murine tumor-infiltrating CD8+ T cells. Flow cytometry was utilized to assess exhaustion markers and TNF receptors on CD8+ T cells. Bulk RNA sequencing was used to demonstrate the role of TNFR2 on the overall exhaustion profile. Finally, the effect of TNFR2 on the overall anti-tumor response was established using TNFR2 KO mice and an antagonist.

RESULTS: We reveal that upregulation of TNFR2 coincides with the gain of phenotypic markers and functions reflective of terminal exhaustion. Loss of TNFR2 affords a novel population of T cells that express TIM3 but possess diminished TOX levels and contain functional characteristics of both progenitor and terminally exhausted cells. TIM3+ TNFR2 KO T cells exhibit reduced exhaustion transcriptional programs and enhanced AP1 pathway signatures. Finally, TNFR2 KO mice demonstrate improved T cell-dependent control of tumor and chronic lymphocytic choriomeningitis (cLCMV) infection, while pharmacologic antagonism of TNFR2 licenses responses to checkpoint blockade in multiple subcutaneous and intracranial tumor models.

CONCLUSIONS: Our data place TNFR2 signaling as a potential upstream regulator of TOX expression in T cells and propose TNFR2 antagonism as a novel immunotherapeutic strategy.

**中文摘要译文：**
目的：耗竭是一系列程序化的T细胞分化状态的集合，也是T细胞功能障碍的一种重要模式。T细胞从祖细胞向终末耗竭的演进与转录因子TOX的上调有关。然而，我们对调控TOX表达以及从祖细胞向终末耗竭过渡的因素的理解仍不完整。

实验设计：采用单细胞RNA测序技术评估人与鼠肿瘤浸润CD8+ T细胞上TNF受体的表达。利用流式细胞术评估CD8+ T细胞上的耗竭标志物和TNF受体。使用批量RNA测序证明TNFR2在整体耗竭图谱中的作用。最后，通过使用TNFR2基因敲除（KO）小鼠和拮抗剂，确定了TNFR2对整体抗肿瘤反应的影响。

结果：我们揭示，TNFR2的上调与反映终末耗竭的表型标志物和功能的获得相一致。TNFR2的缺失产生了一群新的T细胞群体，它们表达TIM3但TOX水平降低，并同时具有祖细胞和终末耗竭细胞的功能特征。TIM3+的TNFR2 KO T细胞表现出耗竭相关转录程序的减弱和AP1通路信号的增强。最后，TNFR2 KO小鼠在肿瘤和慢性淋巴细胞性脉络丛脑膜炎（cLCMV）感染中表现出更强的T细胞依赖性控制能力，而TNFR2的药物拮抗则能在多种皮下和颅内肿瘤模型中增强对免疫检查点阻断的响应。

结论：我们的数据表明TNFR2信号是T细胞中TOX表达的一个潜在上游调控因子，并提出TNFR2拮抗可作为一种新的免疫治疗策略。

### 第二部分 AI 大师评价

本研究旨在探究肿瘤坏死因子受体2（TNFR2）在T细胞耗竭过程中的作用及其与关键转录因子TOX的关系。研究综合运用单细胞测序、基因敲除小鼠模型及药物拮抗等方法，关键性地发现TNFR2的上调是驱动T细胞终末耗竭并诱导TOX表达的上游事件。该研究的创新之处在于揭示了TNFR2在T细胞耗竭调控网络中的新地位，为开发以TNFR2为靶点、旨在逆转T细胞耗竭的新型免疫疗法提供了强有力的实验依据和新颖的治疗策略。

---

## 58. 头颈癌中的HPV整合：与不良预后相关的下游剪接事件和表达比率。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41269209](https://pubmed.ncbi.nlm.nih.gov/41269209)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41269209
**DOI：** 10.1158/1078-0432.CCR-25-0645

### 第一部分 原文与翻译

**英文原标题：** HPV integration in head and neck cancer: downstream splicing events and expression ratios linked with poor outcomes.

**英文摘要原文：**
PURPOSE: HPV integration (HPVint) is associated with carcinogenesis and tumor progression in HPV-associated cancers, including head and neck squamous cell carcinomas (HNSCC). While its impact on human DNA has been well characterized, its relationship with clinical outcomes remains unconfirmed.

EXPERIMENTAL DESIGN: We analyzed HPVint events from 261 HPV-associated HNSCC bulk and single-cell RNA-seq samples from five cohorts, including 62 from a new University of Michigan cohort, and DNA HPVint events from 102 HPV(+) HNSCC participants in two of the cohorts. We investigated the consequences of HPVint both with respect to human and HPV gene expression and clinical outcomes (recurrence and overall survival).

RESULTS: By leveraging this large meta-cohort of HNSCC, we first reveal an oncogenic gene network based on the recurrent HPV integration locations in the human genome and gene expression alterations, highlighting key recurrent and overexpressed genes including NR4A2, CD274, CCER1 and genes from the CAMK and KLF families. We then stratify HPVint-positive participants by risk using HPV RNA features, specifically spliced HPV-human fusion transcripts (E1* integration) and HPV gene expression ratios (HGER), showing that subsets of participants have worse clinical outcomes based on these two candidate biomarkers.

CONCLUSIONS: By focusing on RNA instead of DNA, we expand our understanding of the carcinogenic mechanisms of HPVint, in part addressing the conflicting findings of whether HPVint is associated with aggressive phenotypes and worse clinical consequences and provide potential biomarkers to advance precision oncology in HPV-associated HNSCC. Newly identified genes with recurrent integration events may serve as candidates for targeted therapy.

**中文摘要译文：**
目的：HPV整合（HPVint）与HPV相关癌症（包括头颈部鳞状细胞癌，HNSCC）的癌变和肿瘤进展有关。尽管其对人类DNA的影响已得到充分表征，但其与临床结局的关系仍未确定。

实验设计：我们分析了来自五个队列的261例HPV相关HNSCC的批量和单细胞RNA测序样本中的HPVint事件，其中包括来自密歇根大学一个新队列的62例样本，以及其中两个队列中102例HPV阳性HNSCC参与者的DNA HPVint事件。我们研究了HPVint在人类和HPV基因表达以及临床结局（复发和总生存期）方面的影响。

结果：通过利用这个大型的HNSCC荟萃队列，我们首先基于人类基因组中反复出现的HPV整合位点和基因表达改变，揭示了一个致癌基因网络，并突出了关键的复发性和过表达基因，包括NR4A2、CD274、CCER1以及CAMK和KLF家族的基因。然后，我们使用HPV RNA特征，特别是剪接型HPV-人类融合转录本（E1*整合）和HPV基因表达比率（HGER），对HPVint阳性参与者进行风险分层，结果表明，基于这两种候选生物标志物，部分参与者亚群的临床结局更差。

结论：通过关注RNA而非DNA，我们拓展了对HPVint致癌机制的理解，部分解决了关于HPVint是否与侵袭性表型和更差临床后果相关的矛盾发现，并为推进HPV相关HNSCC的精准肿瘤学提供了潜在的生物标志物。新发现的具有复发性整合事件的基因可能成为靶向治疗的候选靶点。

### 第二部分 AI 大师评价

本研究聚焦于HPV整合在头颈癌中的临床意义，创新性地从RNA层面而非传统的DNA层面进行分析。通过对大规模多队列样本的RNA测序数据进行深度挖掘，研究不仅揭示了由HPV整合驱动的关键致癌基因网络，更重要的是，首次提出了两种与不良预后显著相关的RNA生物标志物——HPV-人源融合剪接本和HPV基因表达比率。这项发现解决了既往研究中关于HPV整合与预后关系不一致的争议，为HPV相关头颈癌患者的精准风险分层和靶向治疗开发提供了极具价值的新思路和候选靶点。

---

## 59. 造血干细胞完整异质性受损是原发性血小板增多症的发生基础

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41268701](https://pubmed.ncbi.nlm.nih.gov/41268701)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41268701
**DOI：** 10.1002/advs.202505249

### 第一部分 原文与翻译

**英文原标题：** Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development.

**英文摘要原文：**
Essential thrombocythemia (ET) includes the JAK2 -, CALR-, and MPL-mutated subtypes, and a triple-negative (TN) ET subtype, which lacks these canonical drivers. How specific driver mutations affect hematopoietic stem cell (HSC) heterogeneity and their relation to ET pathogenesis remain unclear. Here, by using single-cell RNA sequencing (scRNA-seq) combined with driver mutation detection across ET patients, it is found that MPL-mutated HSCs exhibited aberrant metabolism, CALR-mutated HSCs displayed active cell cycling, while JAK2 -mutated HSCs demonstrated enhanced megakaryocyte (Mk) priming capacity and interferon (IFN) response. An HSC subset is identified in TN ET that transcriptionally resembled driver-mutated HSCs, exhibiting enhanced megakaryocytic priming and proliferative activity. Notably, the frequency of a CXCR4 HSC subset is reduced across the ET spectrum. Loss of CXCR4 HSCs skewed lineage differentiation of HSCs toward the myeloid lineage, whereas restoring this subset delayed the onset of ET. Altogether, this study reveals both the shared and distinct molecular features of mutant HSCs in ET and provides novel insights into the pathogenesis and potential therapeutic strategies of ET.

**中文摘要译文：**
原发性血小板增多症（ET）包括JAK2、CALR和MPL突变亚型，以及一个缺乏这些典型驱动基因的三阴性（TN）ET亚型。特定的驱动基因突变如何影响造血干细胞（HSC）的异质性及其与ET发病机制的关系尚不清楚。本研究通过对ET患者进行单细胞RNA测序（scRNA-seq）并结合驱动基因突变检测发现，MPL突变的HSC表现出代谢异常，CALR突变的HSC细胞周期活跃，而JAK2突变的HSC则表现出增强的巨核细胞（Mk）启动能力和干扰素（IFN）应答。在三阴性ET中，本研究鉴定出一个HSC亚群，其在转录水平上与驱动基因突变的HSC相似，表现出增强的巨核细胞启动和增殖活性。值得注意的是，在所有ET亚型中，一个CXCR4+ HSC亚群的频率均有所降低。CXCR4+ HSC的缺失使HSC的谱系分化偏向髓系，而恢复该亚群则延缓了ET的发生。总而言之，本研究揭示了ET中突变HSC的共同和特异性分子特征，并为ET的发病机制和潜在治疗策略提供了新的见解。

### 第二部分 AI 大师评价

该研究利用前沿的单细胞测序技术，系统揭示了不同驱动基因突变（JAK2, CALR, MPL）及三阴性原发性血小板增多症（ET）中造血干细胞（HSC）的异质性特征。研究的核心发现是，不同突变亚型HSC具有独特的分子表型，但所有ET亚型均表现出CXCR4+ HSC亚群的共同减少，且该亚群的缺失与髓系偏向分化及疾病发生直接相关。这项工作的创新之处在于，它不仅深化了对ET各亚型发病机制异同的理解，更重要的是识别出一个跨越所有亚型的共同细胞缺陷和潜在治疗靶点，为开发更精准的ET干预策略提供了重要科学依据。

---

## 60. 靶向氧化低密度脂蛋白（OxLDL）的嵌合抗原受体调节性T细胞可减少动脉粥样硬化斑块的形成

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41268661](https://pubmed.ncbi.nlm.nih.gov/41268661)
**期刊：** Circulation
**PMID：** 41268661
**DOI：** 10.1161/CIRCULATIONAHA.125.073987

### 第一部分 原文与翻译

**英文原标题：** OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development.

**英文摘要原文：**
BACKGROUND: Cardiovascular disease caused by atherosclerosis is responsible for 18 million deaths annually, highlighting a significant need for new medical therapies, especially for patients who are not eligible for percutaneous interventions. Atherosclerosis is driven by the accumulation of low-density lipoprotein (LDL) and the formation of foam cells, accompanied by oxidative stress and the accumulation of oxidized LDL (OxLDL), a pro-inflammatory molecule. Lowering LDL is the mainstay of current treatment along with blood pressure control and lifestyle changes, but to date, it has not been feasible to specifically target inflammatory pathways contributing to plaque development without significant systemic side effects. Over the past decade, chimeric antigen receptor (CAR) T cells have been used to treat cancer, resolve cardiac fibrosis, and restore immune balance in autoimmune diseases. In some instances, T regulatory cells endowed with CAR (CAR Tregs) have been developed to treat autoimmunity through antigen-specific immunosuppression.

METHODS: Using an inducible Treg platform, we created an anti-OxLDL-specific CAR Treg therapy and evaluated cell- and cytokine-mediated immunosuppression to reduce macrophage foam-cell formation in vitro. We then tested murine anti-OxLDL CAR Tregs in immunocompetent mouse models of hyperlipidemia and atherosclerosis.

RESULTS: Anti-OxLDL CAR Tregs reduced macrophage foam-cell formation in vitro and significantly inhibited atherosclerotic plaque formation in vivo in immunocompetent mouse models.

CONCLUSIONS: Anti-OxLDL CAR Tregs mitigate inflammation and plaque deposition associated with oxidized LDL and may offer a new therapeutic option for atherosclerosis.

**中文摘要译文：**
背景：由动脉粥样硬化引起的心血管疾病每年导致1800万人死亡，这凸显了对新疗法的巨大需求，特别是对于不适合经皮介入治疗的患者。动脉粥样硬化的驱动因素是低密度脂蛋白（LDL）的积聚和泡沫细胞的形成，并伴有氧化应激和促炎分子——氧化低密度脂蛋白（OxLDL）的累积。降低LDL是当前治疗的基石，辅以血压控制和生活方式的改变，但迄今为止，尚无法在不产生显著全身性副作用的情况下，特异性地靶向参与斑块形成的炎症通路。在过去十年中，嵌合抗原受体（CAR）T细胞已被用于治疗癌症、解决心脏纤维化以及在自身免疫性疾病中恢复免疫平衡。在某些情况下，研究人员开发了被赋予CAR的T调节细胞（CAR-Treg），以通过抗原特异性的免疫抑制来治疗自身免疫。

方法：我们利用一个可诱导的Treg平台，创建了一种抗OxLDL特异性的CAR-Treg疗法，并在体外评估了其通过细胞和细胞因子介导的免疫抑制作用，以减少巨噬细胞泡沫细胞的形成。接着，我们在免疫功能正常的高脂血症和动脉粥样硬化小鼠模型中测试了鼠源抗OxLDL CAR-Treg细胞的功效。

结果：抗OxLDL CAR-Treg细胞在体外减少了巨噬细胞泡沫细胞的形成，并在免疫功能正常的小鼠模型中显著抑制了体内动脉粥样硬化斑块的形成。

结论：抗OxLDL CAR-Treg细胞能够减轻与氧化低密度脂蛋白相关的炎症和斑块沉积，可能为动脉粥样硬化提供一种新的治疗选择。

### 第二部分 AI 大师评价

本研究旨在探索一种创新的细胞疗法以治疗动脉粥样硬化。研究团队巧妙地将已在肿瘤和自身免疫病领域取得成功的CAR-T技术进行转化，构建了能特异性靶向动脉粥样硬化关键分子——氧化低密度脂蛋白（OxLDL）的CAR-Treg细胞。研究发现，这种细胞疗法不仅在体外有效抑制了泡沫细胞的形成，更在小鼠模型中显著减少了动脉粥样硬化斑块。这项工作开创性地提出了一种精准靶向斑块内炎症的免疫新策略，为心血管疾病治疗提供了极具潜力的未来方向，但其向临床转化的安全性和有效性仍需进一步验证。

---

## 61. 饿死肿瘤，助长转移：对癌症治疗中低碳水化合物饮食的警示

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41266319](https://pubmed.ncbi.nlm.nih.gov/41266319)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41266319
**DOI：** 10.1038/s41392-025-02469-4

### 第一部分 原文与翻译

**英文原标题：** Starving tumor, feeding metastasis: a warning about low-carbohydrate diets in cancer therapy.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文献标题揭示了一个极具警示意义的观点，挑战了当前流行的低碳水化合物饮食抗癌策略。其核心论点在于，此类饮食在可能“饿死”原发肿瘤的同时，或将意外改变机体代谢环境，从而为癌细胞的转移扩散创造了有利条件，即“助长转移”。尽管无摘要信息使我们无法得知其具体研究方法，但该标题提出的悖论性发现，对探索癌症代谢疗法的临床医生和科研人员提出了一个至关重要的安全考量，具有重要的临床警示价值。

---

## 62. 循环miR-18b-3p是预测头颈癌放化疗所致口腔黏膜炎的新型生物标志物。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41266308](https://pubmed.ncbi.nlm.nih.gov/41266308)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41266308
**DOI：** 10.1038/s41392-025-02478-3

### 第一部分 原文与翻译

**英文原标题：** Circulating miR-18b-3p is a novel biomarker predicting chemo-radiotherapy induced oral mucositis in head and neck cancer.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该研究的核心目的在于鉴定并验证一种新型的、可用于预测头颈癌患者放化疗后口腔黏膜炎风险的生物标志物。研究发现，血液循环中的miR-18b-3p水平可以作为有效的预测指标。这一发现具有显著的临床应用前景，通过简单的血液检测便能筛选出高风险人群，从而为个体化的预防和治疗策略提供依据，改善患者的治疗体验和生活质量。由于摘要缺失，该研究的样本规模和具体方法的细节尚不明确。

---

## 63. 晚期胰腺癌患者接受NK细胞疗法联合吉西他滨加S-1治疗后的动态转录免疫图谱：一项1b/2期临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41266303](https://pubmed.ncbi.nlm.nih.gov/41266303)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41266303
**DOI：** 10.1038/s41392-025-02488-1

### 第一部分 原文与翻译

**英文原标题：** Dynamic transcriptional immune landscape in response to NK-cell therapy combined with gemcitabine plus S-1 in advanced pancreatic cancer: a phase 1b/2 trial.

**英文摘要原文：**
Despite advancements in several malignancies, the treatment atlas of natural killer (NK) cell therapy for pancreatic cancer remains inadequate, and the dynamic immune landscape underlying the various responses is still incompletely understood. This phase 1b/2 trial evaluated the safety and efficacy of allogeneic NK cell therapy combined with gemcitabine and S-1 as a first-line treatment for advanced pancreatic cancer (APC) and explored the dynamic responsive immune landscape (ChiCTR1900021764). The administration of 1 × 10 to 8 × 10 NK cells to 24 patients was well tolerated, with no graft-versus-host disease or dose-limiting toxicity. Among the 19 evaluable patients, the objective response rate was 31.6%, and the disease control rate was 73.7%. The median progression-free survival was 6.6 months, and the overall survival was 10.8 months. Further longitudinal single-cell RNA sequencing (scRNA-seq) of 19 paired-blood samples revealed an increased proportion of certain NK cell subsets (c4-ZEB2, c5-IL7, c6-IL15, c10-NCR3, and c11-TNFSF8) and T-cell subsets (CD8 Teff and CD4 Tem) in responders, characterized by increased expression of proinflammatory and effector molecules. Bulk T-cell receptor (TCR) Vβ repertoire sequencing of responders indicated potential T-cell clonal expansion, manifested as a greater abundance of large and hyperexpanded clonotypes. Our first-in-human trial demonstrated its safety and potentially preliminary efficacy, warranting further clinical evaluation. Multiomic profiling identified specific circulating NK and T-cell subsets potentially associated with clinical outcomes, providing novel insights into the dynamic transcriptional underpinnings of the immune landscape in response to NK cell-based therapy.

**中文摘要译文：**
尽管在多种恶性肿瘤的治疗上取得了进展，但自然杀伤（NK）细胞疗法在胰腺癌中的治疗图谱仍不完善，且不同治疗反应背后的动态免疫机制仍未被完全阐明。本项1b/2期临床试验旨在评估同种异体NK细胞疗法联合吉西他滨和S-1作为晚期胰腺癌（APC）一线治疗的安全性与有效性，并探索其动态免疫应答图谱（ChiCTR1900021764）。24名患者接受了1×10⁷至8×10⁷个NK细胞的输注，耐受性良好，未发生移植物抗宿主病或剂量限制性毒性。在19名可评估患者中，客观缓解率为31.6%，疾病控制率为73.7%。中位无进展生存期为6.6个月，中位总生存期为10.8个月。对19对配对血样的纵向单细胞RNA测序（scRNA-seq）进一步揭示，治疗有效者的特定NK细胞亚群（c4-ZEB2, c5-IL7, c6-IL15, c10-NCR3, 和 c11-TNFSF8）与T细胞亚群（CD8 Teff 和 CD4 Tem）比例增加，其特征是促炎分子和效应分子的表达上调。对治疗有效者进行的大量T细胞受体（TCR）Vβ谱系测序表明，其可能存在T细胞克隆扩增，表现为大型和超扩增克隆型的丰度更高。我们的首次人体试验证明了该疗法的安全性与初步疗效，值得进一步的临床评估。多组学分析识别出与临床结局可能相关的特定循环NK细胞和T细胞亚群，为理解NK细胞疗法应答过程中的动态转录免疫机制提供了新的见解。

### 第二部分 AI 大师评价

本研究是一项创新的1b/2期临床试验，首次探索了同种异体NK细胞疗法联合吉西他滨和S-1一线治疗晚期胰腺癌的安全性与有效性。研究不仅展示了该联合方案良好的耐受性和初步的临床获益，更具价值的是，它通过单细胞测序等多组学技术，纵向揭示了治疗有效患者体内NK细胞和T细胞亚群的动态变化及克隆扩增特征。这些发现为理解胰腺癌的免疫治疗应答机制提供了宝贵线索，并为筛选潜在的疗效预测生物标志物指明了方向，具有重要的临床转化潜力。

---

## 64. 利用喷涂式荧光探针靶向癌症相关成纤维细胞以实现术中实时肿瘤识别

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41259533](https://pubmed.ncbi.nlm.nih.gov/41259533)
**期刊：** Science advances
**PMID：** 41259533
**DOI：** 10.1126/sciadv.aeb5810

### 第一部分 原文与翻译

**英文原标题：** Targeting cancer-associated fibroblasts for real-time intraoperative tumor identification with a spray-on fluorescent probe.

**英文摘要原文：**
Surgical tumor resection is often the only curative option for the nearly 20 million newly diagnosed patients with cancer every year. Fluorescence-guided surgery techniques are being developed in an effort to improve margin detection and surgical resection outcomes, with several systemically administered imaging agents having gained clinical approval. However, it has been challenging to overcome limited margin contrast with current approaches and to navigate procedural complexities of intravenous contrast delivery. We hypothesized that "spray-on probes" with specificity for fibroblast activation protein alpha in peritumoral fibroblasts could improve fluorescence-guided surgery, detect smaller tumors, improve imaging accuracy, and reduce the amount of times a patient is hospitalized. We show that this strategy increases achievable tumor margin contrast by 5- to 10-fold and detects even microscopic cancer deposits. These improvements have the potential to transform patient outcomes by enabling more accurate cancer surgeries, reducing the number of follow-up surgeries, and leading to personalized treatment plans.

**中文摘要译文：**
对于每年近2000万新诊断的癌症患者而言，手术切除肿瘤往往是唯一的根治性治疗选择。为了改善切缘检测和手术切除效果，荧光引导手术技术应运而生，其中几种全身给药的显像剂已获得临床批准。然而，现有方法在克服切缘对比度有限以及应对静脉注射造影剂的程序复杂性方面仍面临挑战。我们假设，一种对瘤周成纤维细胞中的成纤维细胞激活蛋白α具有特异性的“喷涂式探针”，能够改进荧光引导手术、检测更小的肿瘤、提高成像准确性，并减少患者的住院次数。我们证明，该策略可将肿瘤切缘对比度提高5至10倍，甚至能够检测到微小的癌沉积。这些改进有望通过实现更精准的癌症手术、减少二次手术次数以及促进个性化治疗方案的制定，从而改变患者的预后。

### 第二部分 AI 大师评价

本研究旨在解决荧光引导手术中肿瘤切缘对比度不足的难题。研究团队创新性地开发了一种靶向癌周成纤维细胞激活蛋白α的“喷涂式”荧光探针。关键发现表明，该探针能将肿瘤切缘对比度提升5-10倍，并能识别微小癌灶。此项技术突破了传统全身给药显像剂的局限，为实现更精准的肿瘤切除、减少二次手术提供了极具潜力的临床工具，有望革新癌症外科治疗模式。

---

## 65. 口服递送适体修饰的SICTERS拉曼探针用于结肠镜引导的微小肿瘤切除与光热免疫治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41259525](https://pubmed.ncbi.nlm.nih.gov/41259525)
**期刊：** Science advances
**PMID：** 41259525
**DOI：** 10.1126/sciadv.adx5246

### 第一部分 原文与翻译

**英文原标题：** Oral delivery of aptamer-decorated SICTERS Raman probes for colonoscopy-guided resection and photothermal immunization of microtumors.

**英文摘要原文：**
Endoscopic resection of colon cancer represents an advanced technique in early intervention, but faces the challenges in identifying tumor margins and removing residual lesions. Here, we developed orally administered Raman probes (i.e., BBT-Apt@CS NPs) that enable precise tumor imaging and photothermal ablation. Protected by an enteric coating for colon-targeted release, the inner nanoparticles use a stacking-induced charge transfer-enhanced Raman scattering (SICTERS) mechanism and are functionalized with tumor-targeting aptamers. In a proof-of-concept study using the endoscopic optical fiber, we achieved in situ precise detection of microtumors and effective photothermal ablation of residual lesions at the resection margins, with simultaneous induction of immune memory. In a rechallenge model, mice treated with photothermal therapy on residual lesions exhibited no tumor recurrence. We have optimized endoscopic resection strategies through theranostic Raman probes, thus providing an innovative solution for the minimally invasive precision intervention in colorectal cancer.

**中文摘要译文：**
结肠癌的内镜下切除是早期干预的一项先进技术，但面临着识别肿瘤边缘和清除残留病灶的挑战。在此，我们开发了一种可口服的拉曼探针（即BBT-Apt@CS NPs），该探针能够实现精确的肿瘤成像和光热消融。该探针由肠溶衣保护以实现结肠靶向释放，其内部纳米颗粒利用堆积诱导电荷转移增强拉曼散射（SICTERS）机制，并用肿瘤靶向适体进行了功能化。在一项使用内镜光纤的概念验证研究中，我们实现了对微小肿瘤的原位精确检测以及对切除边缘残留病灶的有效光热消融，并同时诱导了免疫记忆。在再次攻击模型中，接受残留病灶光热治疗的小鼠未表现出肿瘤复发。我们通过这种诊疗一体化的拉曼探针优化了内镜下切除策略，从而为结直肠癌的微创精准干预提供了一种创新解决方案。

### 第二部分 AI 大师评价

本研究旨在解决结肠镜下切除术中微小肿瘤及残留病灶难以识别和清除的挑战。研究团队创新性地开发了一种可口服的、由肠溶衣包裹的适体修饰拉曼探针，它利用SICTERS机制实现高灵敏度的肿瘤成像，并能进行光热消融。关键发现表明，该探针能在结肠内精准靶向并检测到微小肿瘤，有效清除切缘残留病灶，并诱导了防止肿瘤复发的免疫记忆效应。这项工作将先进的纳米探针技术与临床内镜手术相结合，为结直肠癌的精准诊疗一体化提供了极具前景的微创解决方案。

---

## 66. 选择性AMPKβ1激活通过非经典NRF2通路在人红系细胞和镰状细胞小鼠中诱导胎儿血红蛋白

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41259521](https://pubmed.ncbi.nlm.nih.gov/41259521)
**期刊：** Science advances
**PMID：** 41259521
**DOI：** 10.1126/sciadv.adx1144

### 第一部分 原文与翻译

**英文原标题：** Selective AMPKβ1 activation induces fetal hemoglobin in human erythroid cells and sickle cell mice via the noncanonical NRF2 pathway.

**英文摘要原文：**
Sickle cell disease (SCD), an inherited blood disorder caused by mutation of the β-globin gene, results in sickle-shaped erythrocytes, organ damage, and increased mortality. Current therapeutic options are limited, and innovative treatments to induce fetal hemoglobin (HbF) are needed. Adenosine monophosphate-activated protein kinase (AMPK) comprises a family of 12 isoforms. In the present study, single-cell RNA sequencing of bone marrow cells revealed that AMPKβ1 isoform (AMPKα1β1γ1) predominates in the erythroid lineage. AMPKβ1 activators increased the expression of HbF in erythroid cells from SCD donors and decreased sickling in vitro through activation of nuclear factor erythroid 2-related factor 2 (NRF2) but independently from direct Kelch-like ECH-associated protein 1 (KEAP1) inhibition, by way of a noncanonical NRF2 pathway, as shown by phosphorylation of Unc-51-like autophagy-activating kinase 1 (ULK1) and sequestosome 1/p62 (SQSTM1). In vivo studies in Townes SCD mice treated with the selective AMPKβ1 activator PF-06409577 confirmed increased HbF in circulating erythrocytes, associated with decreased reactive oxygen species and reduced chronic inflammation markers. Collectively, these findings establish selective AMPKβ1 activation as a promising therapeutic approach to induce HbF in hemoglobinopathies.

**中文摘要译文：**
镰状细胞病（SCD）是一种由β-珠蛋白基因突变引起的遗传性血液病，可导致红细胞呈镰刀状、器官损伤和死亡率增加。目前的治疗选择有限，亟需创新疗法来诱导胎儿血红蛋白（HbF）。单磷酸腺苷激活的蛋白激酶（AMPK）是一个包含12种亚型的家族。在本研究中，对骨髓细胞的单细胞RNA测序显示，AMPKβ1亚型（AMPKα1β1γ1）在红系细胞中占主导地位。AMPKβ1激活剂通过激活核因子红系2相关因子2（NRF2），增加了来自SCD供体的红系细胞中HbF的表达，并在体外减少了细胞镰变，但此作用独立于对Kelch样ECH相关蛋白1（KEAP1）的直接抑制，而是通过一条非经典的NRF2通路，这一点已由Unc-51样自噬激活激酶1（ULK1）和隔离体1/p62（SQSTM1）的磷酸化所证实。在Townes SCD小鼠中进行的体内研究证实，使用选择性AMPKβ1激活剂PF-06409577治疗后，循环红细胞中的HbF增加，并伴有活性氧水平的下降和慢性炎症标志物的减少。总而言之，这些发现确立了选择性激活AMPKβ1作为一种在血红蛋白病中诱导HbF的有前景的治疗方法。

### 第二部分 AI 大师评价

本研究旨在探索选择性激活AMPKβ1作为一种治疗镰状细胞病（SCD）的新策略。研究者通过单细胞测序、体外细胞实验及SCD小鼠模型，发现AMPKβ1的选择性激活剂能显著提升胎儿血红蛋白（HbF）水平。其核心创新在于揭示了一条不依赖于经典KEAP1-NRF2轴的非经典NRF2信号通路，为SCD及其他血红蛋白病的药物研发开辟了全新视角。这项研究不仅为开发靶向AMPKβ1的药物提供了坚实的临床前证据，也深化了对HbF表达调控机制的理解。

---

## 67. 3D坏死打印：利用生物材料作为3D打印喷嘴

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41259509](https://pubmed.ncbi.nlm.nih.gov/41259509)
**期刊：** Science advances
**PMID：** 41259509
**DOI：** 10.1126/sciadv.adw9953

### 第一部分 原文与翻译

**英文原标题：** 3D necroprinting: Leveraging biotic material as the nozzle for 3D printing.

**英文摘要原文：**
Nature has long inspired engineering innovations. Recent advances in biohybrid research have taken this inspiration further by directly integrating biotic materials into engineered systems. Here we report "3D necroprinting," a biohybrid manufacturing technique that repurposes female mosquito proboscides as high-resolution 3D printing nozzles. The mosquito proboscis, with its unique geometry, structure, and mechanics, enables printed line widths as fine as 20 μm, surpassing commercially available 36-gauge dispense tips by ~100%. The mosquito proboscis dispense tip can withstand internal pressures of approximately 60 kPa, enabling effective fluid extrusion. Demonstrated applications include high-resolution printing of complex structures such as a honeycomb structure, a maple leaf, and bioscaffolds encapsulating cancer cells and red blood cells, showcasing the versatility and capacity of 3D necroprinting. By introducing biotic materials as viable substitutes to complex engineered components, this work paves the way for sustainable and innovative solutions in advanced manufacturing and microengineering.

**中文摘要译文：**
长期以来，大自然一直是工程创新的灵感来源。生物混合研究的最新进展通过将生物材料直接集成到工程系统中，进一步深化了这一灵感。在此，我们报告了一种名为“3D坏死打印”的生物混合制造技术，该技术将雌性蚊子的口器改造用作高分辨率3D打印喷嘴。蚊子口器以其独特的几何形状、结构和力学特性，能够实现细至20微米的打印线宽，其性能超越了市售的36号点胶针头约100%。该蚊子口器点胶针头可承受约60千帕的内部压力，从而实现有效的流体挤出。其应用示例包括高分辨率打印蜂窝结构、枫叶等复杂结构，以及封装癌细胞和红细胞的生物支架，展示了3D坏死打印技术的多功能性和强大能力。通过引入生物材料作为复杂工程组件的可行替代品，这项工作为先进制造和微工程领域的可持续创新解决方案铺平了道路。

### 第二部分 AI 大师评价

本研究开创性地提出了一种名为“3D坏死打印”的生物混合制造技术，其核心是将雌性蚊子的口器巧妙地改造为高精度的3D打印喷嘴。研究发现，这种生物喷嘴能够打印出仅20微米宽的精细线条，性能远超商用微型针头，并成功用于构建复杂的微结构和封装细胞的生物支架。该工作的创新性在于颠覆性地利用“坏死”生物材料作为功能性工程部件，不仅为高分辨率3D打印和微工程领域提供了可持续的新思路，也为开发新型生物混合系统开辟了全新的道路。

---

## 68. 人工智能驱动发现兼具抗衰老与抗阿尔茨海默病双重功效的疗法：通过PROTAC靶点解析一个超级增强子调控轴

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41259504](https://pubmed.ncbi.nlm.nih.gov/41259504)
**期刊：** Science advances
**PMID：** 41259504
**DOI：** 10.1126/sciadv.adz9283

### 第一部分 原文与翻译

**英文原标题：** AI-driven discovery of dual antiaging and anti-AD therapeutics via PROTAC target deconvolution of a super-enhancer-regulated axis.

**英文摘要原文：**
The lack of safe, durable therapeutics that act against both biological aging and Alzheimer's disease is an unmet clinical need. To bridge this gap, we devised an artificial intelligence (AI)-enabled approach that pairs rapid compound triage with mechanistic target deconvolution. Our AI-driven screening highlighted melatonin (MLT) as a promising candidate. Serum profiling of 161 human individuals confirmed an age-related fall in circulating MLT level, while subsequent in vivo and in vitro experiments showed that MLT rescues cognition, suppresses neuroinflammation, and alleviates senescence phenotypes. Proteolysis targeting chimera (PROTAC)-guided chemoproteomic deconvolution next pinpointed the histone acetyltransferase p300 as MLT's target. Integrated Cleavage Under Targets and Tagmentation, single-cell RNA sequencing, and spatial transcriptomics revealed that MLT-bound p300 cooperates with specificity protein 1 (SP1) at a brain and muscle ARNT-like protein 1 super-enhancer, elevating histone H3 lysine-27 acetylation and reengaging a circadian-epigenetic program that links redox resilience to neuroprotection. By combining AI-driven discovery with PROTAC-based target mapping and super-enhancer-centric mechanistic resolution, our study identifies MLT as a dual-action candidate and sets out a reproducible "AI-to-clinic" paradigm for multitarget drug innovation in aging-related neurodegeneration.

**中文摘要译文：**
缺乏能够同时对抗生物衰老和阿尔茨海默病的安全、长效疗法，是一项尚未被满足的临床需求。为填补这一空白，我们设计了一种基于人工智能（AI）的方法，该方法将快速化合物筛选与靶点机制解析相结合。我们通过AI驱动的筛选，发现褪黑素（MLT）是一个有潜力的候选药物。对161名人类个体的血清分析证实，循环褪黑素水平随年龄增长而下降；随后的体内和体外实验表明，褪黑素能够挽救认知功能、抑制神经炎症并减轻衰老表型。接下来，利用蛋白降解靶向嵌合体（PROTAC）引导的化学蛋白质组学解析，我们精确锁定了组蛋白乙酰转移酶p300为褪黑素的靶点。整合运用CUT&Tag、单细胞RNA测序和空间转录组学技术揭示，与褪黑素结合的p300在脑和肌肉ARNT样蛋白1的超级增强子区域与特异性蛋白1（SP1）协同作用，从而提高组蛋白H3赖氨酸27的乙酰化水平，并重新激活一个将氧化还原韧性与神经保护联系起来的昼夜节律-表观遗传程序。通过将AI驱动的发现、基于PROTAC的靶点定位以及以超级增强子为中心的机制解析相结合，本研究不仅确定了褪黑素是一种具有双重作用的候选药物，还为衰老相关神经退行性疾病领域的多靶点药物创新建立了一个可复制的“从AI到临床”的研究范式。

### 第二部分 AI 大师评价

本研究巧妙运用人工智能（AI）筛选策略，旨在发现能同时延缓衰老并治疗阿尔茨海默病的双效药物。研究团队不仅成功筛选出褪黑素作为潜力候选物，还创新性地采用PROTAC引导的化学蛋白质组学技术，精确锁定了其作用靶点为p300。更进一步，通过多组学联合分析，研究揭示了褪黑素通过调控超级增强子相关的表观遗传程序发挥神经保护作用的精细分子机制。这项工作为复杂疾病的多靶点药物研发提供了一个从AI发现到机制验证再到临床转化的全新范例，具有极高的科研价值和潜在的临床应用前景。

---

速递结束，祝您工作愉快！